var title_f36_27_37296="Hidradenitis suppurativa sinus tract";
var content_f36_27_37296=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hidradenitis suppurativa sinus tract",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 370px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFyAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArc8LeGdQ8SXvkWCARrzJM/CoP6n2HNb3hHwFd6ikd9qsckGn5BCfdeQHofZffr6V7ZZaN9nsoraytrO0iQYCoG/P6+/WspVLaLc6KdBy1lojH8JeGdO8O2e2zt3mnYYkuWHMn0PYew/HNdOl6wUA2/yHhWB6+2KpC0vkYqswk/vIowc0pE4iWRZC2e6rjJFYc0tzuUIpWRYa4VWyrRBemCSCpqSW5dUCyIjA+hP5ioRceag81Vf3K1UKP5pC5WMc5U/Lk+x/pTciku5sx3S+TmYtheVPfPse9TQ5SV1kCgvhuOn0rJs5iJAsy5jwSm0ZBHqR1rUth85IOV42kHgUJkSVgurMZMigEdGBHao7UNFN5f3oXGUJ557qffuDWrEQ2QevcVQv7chSYhhgdy+zChrqhKV9GJKAsuH+aIjkn+Hn+VQLZCSJtvySAkZqyJFmVZV+6ylWHpTrM5jBPIbjP0qbJju0Q2z7x5E3yzgf99e4pZVLRtj7684/rU88KyJx94cqR2NRAsQN/Ei9/X2qWrBe+pWlQSxiSPqRkj1/wDr1W4ZBkVfChXIX7rfMPr3qCSMJIePlb9DSZaZkSv9nkLZ+XFS6ZCbyYzScr/DTdUhAhfitfw6qCwRgOg49zS5uhbsveNO3tgsf90enrU6xqFwRj3ojcD7x5pZJlAxVRjcwldlO7s42YEYVj0I71n3KXcKnYQ4/I1pPMNwzTlkBiAfGSOPehwEm0Ya6iitsmUxH/aHH51agnjfBRgfoaddW6TfeUEGsmfTPKJa3doz6L0pLmRpaL8jdSQE1Yjc461yyXl7anEqCZPVeDVy31u2LbZGMbHs4xVxmiZUn0OiByOcU5D+nSs6K9jI4cEe1SpcDPUYq0zJxZeZ+OTxURkBPHaofOHr+NCsN3Bz6GqItYc5yclSMmnM5Bxg/hUfBwSe/rSAA9x+dNIV0fGlFFFbnGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFb/hbwtqHiKci0jKWyHElww+VfYep9qTaSuxqLk7Ix7K0nvblLe0ieWZzhUUZJr2HwZ4Ds9IWK91d47jUAcrGRmOM9hj+Jvf/wDXW/4Z8LWuhWZjsod8rj95PIMOf/rVrC2cSbmaSTJxgrnB9c9q5p176I9GjhVHWW5aVrm4LArGFK7ScnJH0qzb+fAgZ5HwvXAyOKhsgEchGzg4YMcEGrkT7mUMrYX5m49+Ki63Ohq2g2F5DcdcSuu4gqR0NSs7wSSgAMjnePY9/wBasFUILSJhic7SDwB0H+e9APmPsY7oScLnr+NMybKahVT51BA9+R9KjVFPmYyqliTkdfr/APWq8tuFIz82317j0NMNvhw6dOnHp7+9JotNFaOIM3HD53KAe49DVy3B83zBgCTn/ZJ9/Q9aHtmkUtEwBUZGaS1IUsp+rJ3BovbchmkF8yMFDtcdD6H0NJv3oyuNrrywz+o9qZE3IAPX7rdj7VFqA3Imz7wJ4PpjkfQ1V+pCRT8tuXU7Y93Oejf59ansJAFeFxsZZOAemTzjNTug8gg8nP8AhUKRnz7hTjOEP+8MEc/lU2sVe6LoHBI59ajZFJO4ZBGKLWXLMG6g4x3pz/KRx8h/nT3ROzM9i0UpDZ2qdwJ7jvTpow6kkZB6D0qy6CTK/if6VXiJ2fN9D9RUWLTKVzH5kTIw5I61LozCCxjiJ5XNTSx5Gax7h3s5xKMmInDD096iSNY6qxvCfGcmk83f0NZvnq2GU8GpomGOtbQKlFWLZ5HNRkMwD7hhfkA70gcdDTlBXOT8rGrmvdMtmIG/OkkPHNSyR45pjLurNbDdiIxB+2aq3FjDKvKBvwq+isOAc0piJ7daOVMV7HONpRjYtbSSRH0B4/Ko/O1K0J3BZl9vlNdM0IGRjpWffBVHGPpS5LD9pfRmWniOBDtuA8T/AO2MfrUp8RwJl/NXYvJO7gVi3LNf6kum6Zb/AGy/f/lmPuRj+857CtO4s/DXgsqfEUv9r64MMljAo2Rnt8vRfq2T7VtCEpHNVq046JXZYstY1LVXI0fTZ7odBKfkj/M9fwrVHh3xS4DS3OnWrEf6shmx+NcveeKfFmsLttDHodiR8sdsv70r6Fjz+WK52XRLmWQvMJ7hz1kmuGLGrbhHRsxSqz1SseJUUUVqcwUUUUAFFFFABRRRQAUUUUAFFFFABS1b0vTrvVb2O00+B57h+iqP1J7D3r2jwV8N4NKZLrUilzfqw+X+CInpj1+p/ConNRNadJ1Hpscj4G+Hkt+0V7rqtDZ5BFvkh5B/tY5A/U+1e1WoitY4bSzggjt0BRYo0Kqo+n1rQtbcLzCqpIvBXGD9P8DQy5uIzIRtAOc9v84rlnOUjup04x0SIG3KCdq7ccgE8fgadaoTmQKGJGGXPUeo96uMC0I8slkI49qqWygcqDGRkfQ/1FRqma20JnhV9rggr/ePcGoIImSfJO8YB25xk+n171chYbmR1wW5IH8xTLdo3BJTeQBkjgjjmnuFyUK7IojfhjwGHPvSSwyAMpiVsDghsHHapHiMbIUYNHnPzDp7cfzqdS0iqHcAjgHb69j/AI1XkzNuxQIcq4AbdkcMP61Ziw0mGXax+8p4/Gp2jZ4d2MOoyrD2qKdEceYRt9ecbT6ijYTY2aMxpM8fOVwRUFzGI2jlK5Cja/09fwpxecKqIjShmCksNoPPr/8AWp8zSbW3+UpbquST+lDd0C0GtCE+ZWYRnr3H1qO5WVNu7a69Q3Qn2+tPt3lMPlOU3JwNwIyP8/zqXZIYCskRZRwcEH8cUt0GxEk8bhlOdxIwuOTSHDXLlAQ6xj5SMZGeaiHlgbJeGBx8wx/+qnhjHiRnyhyQx6gcY+tNPuDQq7XAGSD1VhUoYspR+GH+ciquJS4xiNSehGSreh+tSyLMqhsK+ORjg0xkkLfKWOM5wfwojRS88bcfxKffFRQSK0zgHOQDj0qZBuuJB1ygNIT0IiPyPeqd3b7lORwa0NuMqfwpjrwQRRa41KxyVyJrEFo1MkIP3e4+lOsdVguOI5BuHVTwRW5cwK6niuW1bRlaQzwfJIO4qV7pvGd0b8dx8w5rRZi4iKAkHgY9a4a1vZoGEc+Qw457/SuoR4hFEy3Jdx91V4x7mqc7qwWTaNs8jHcVERyKS3fcnHXrS7snPTmgjZlq3iBIyPrU0SDYX7k4H+NRW0hV1I496Uvs28/d4qkzOSKVyfKQnPWuG8Ralcz6hFpGkgvqE5AJH8APb6/yrqNWvktra6uJOVhQkD1Pb9a5nwlK+g+H9V8X3AV9TnkNppwYZzM/V/oo5/CrppSd3sjGtN042W7J9RvR4Pg/4Rnwrtl8QzAHUb8DLRE/wKf73/oP1qHw74aitHEshNxeOdzzP8xyevJ6n3NS+FtH+x25lnLSXtwd8sj8sSeTk+p6mu1sbURxgY9zVOfM7LYiFNQXM9ynDYooGVyfWnGxU9q1EixkkcVJ5Yo5UPnZ8VUUUVscYUUUUAFFFFABRRRQAUUUqgsQFBJPAAoASup8F+C9R8UT7oV8ixU4kuZBx9FH8R/ycV0Pg34czXBjvNeRooM5W1zh27/N/dHt1r2nR4obeJoYo1hiTCJGBgKAOg9uaxlVS0R008O2uaRQ8L+GtL8OxJb2MO0fxyvy8jerH+Q6VutCjNINzBuqkDGB/wDrFOgKGdwwBOzGeucmrGChBPQD9K52+bVnbFcuiKpZgeW+ZekicfmKSOVXRZZlG1jneD+HPpVhFUzbHHyMxP0//XUs1qiyboxlH4IHQn/Gp1L0QIixJ8vKgdulNeB0AwA24dDSRoIZFWMhFc7guflI9ParKzMS0GELSfKobOR9f50XuS7orNGXjTGd/GCOo+tR2g8m7mRiBIQHYMOG7GtMwv5Ql3ky/ckwoGe2P5VUureMyR3IZnMfDqx/hPX8qGJO+gsd3C9ugZlXI2t8wyKilvYWAeNZCxG1gF+U+oqSCMbFdCo25XdjPGeBVqNyrlGBzIO54JHv9P5UKV9GDjYp2l1cTQ7REAV7qQxPp1NOVUjYq0NwzqOrLuyvpn1HSrM8cIvo2ZUAfg9jnqMVaK7sLvyf4HPXPoapIzk7GelxHNGqhssrDOeDx9atRxAAqQMfz+tVJwoeTzEVSQSwJ4zjr/8AXFJbzea4VnVowAev38/4d6al3E46aDp4kRg8e4D/AGeh/DoadEWhYpINqnoff0qac+YrKo5XBz1BFOuELQEgfODvX6ij0J9Su8YZip+6y5CjviqRh3T/ALptoTnHVWbHQj2/rV6c+XCJ4gCBzt7c/wD6+aQwiOMLnJXqw7k9T+dD1GnYrPGWjIHDrx161IssZhBZgM9R3z9KjkEkxDxsVgzgsOGf6egz3psSCGRjCoRG5LP1PuPWkpFEflpJKskbYYZAYd6faSlp5S+OMICOhx1xSSwM7FxISe4XjcKmREEaqFAXsKa1G3oLKufmpoOe1OO5RzyvrT9oJyOlVYm5WkTPSs+5gDVrkYb0qCZMggjPvSaKjKxzF7YpICHSs1BNYP3eH17j611joCCGHFZ9zabicdKmxqpj9Pv1dBtPBq+swZutcrJaT2bmW25XOSn+FX7K+WXHOGHVT1BpXsaWUtUdRGwxkVWvZsAkHHNV4rn5faqt3PuPWnfQz5Xc5zxnOz20NnHzJPLyB3A6fqa1fE9sqa5oPh5QBa6RaLNKB0MsnJP1wAPxqlBD/aPjvSLdhlQ6nH45q1cStd+LvEt4/JN2YgfQLxj9K2j7tO6OSfv17PobGnrvuCeveuhhAwc9eK5zSTmQk10ERAxUw2NKu5bIHl+2aGXBwuOBTAR3GalJ3HJPPetTCx8P0UUVqcoUUUUAFFFFABRRXV+DPBd94jlWVs22ng/NOw+97IO59+g/Sk5KKuyoxcnaJh6NpN7rN8lpptu88zc4Xoo9Sewr2/wL4Bs9BdLi8C3Wobc+YR8sZ/2Ae/uf0rc0DQdP0O1W301BF0zk5eQ/3mP+fauht0WRX+8COMA9DXLOq56LY9ClhlDWWrIJIVEyhd6k+vNWLGEshIdWLEllbsaRo2ZBuPPbA/X61NaI8YXA2tjqejCsep08uhNEwjuBvjI3DAxyOKvbEdNyEM45HpVRvLMYcOQVYHPoRUyhnkDW6CJifvE4z+FUmQ0BTYNowd3K/wCFWAjGPGeW6GmLBLKGikdFYDOAp59xSxC4V/L+Uuw6EY/Gi4riGEOz/Lhm+6P7p7/40kUAw24nKnAbup7n6dKnjLQxuZl2tktu6gn39KnXaFSQfdYc554pOwrke8tHIsx2O2M47n1qg582NGIwhO089+lWZJo1utmRhk+XH15qSVY5IWUFdrDBwal6lL3StYtjfb4MZjY7eOoIq08I8kAZZl5Abk5rPtLhpfOE6hDFJtDA5yR3/H0q1JNOB93aT0LH73+FQqkVuOUXewjx28gEkiK6rghj1Q9v/wBdIfMbeqjryuOOPX2+pqnFvtHk+2lASdyjPyjP+H9akhlUsUckofmRSDz/AL3v6CnFqWrE4tEM9pPNEHZ98wz+8XjGfQnqKpWsaQWURkjgdUH32bBb3ya6JbmNvkY8njJBqlILeNRGpVBnK4/h+npTcVumEZN6NGezQLsKRuIyw6IRjNXEu7hX/crLIo42TYBP0Of51TltrhZlkjCfZRxKijJc568nikt2P251Dtt2YAzjHPGf8aSbLdOJfs7hJVWNkkjETMWDpggg8D9f0olnikgSNJVDt8ueRgdzz7UnzW0gm4ZwBvP94f56VPHOjEsxJREwO/LdT+WK0v0ZzuNndDsI9pmPHl4CgKc4HSpVQNEMgGozaxFd0ahDkENHwf0p4EsOesseewww/DvTTtuZvyKckXkykoSqt+QP09KCzKfnXHuOlWZijxLIpBTPP06Gmwr8uG5I4z600x30IwmSDT0GODjHal27CcD5fSmlj6cVYr3FkXjj/wDVUJHGO9PHqDQwB5HSmNFOSMtzxVd0YN0BFaWCD8tRuoJ6YqbFXMt7dWyWHTtWNfafl/NgOyUdx3+tdSyZHSoGgBByKGuhUZ21Obtr0oRFcjY/r2NPmlDMcHg1oX2mpMjBlBrlLuK5tZCqNvUdA3WspRaOinNSN7waob4lWHsmR/3zUFsPL1DX0PUahJn/AL6NQeC7wp440iaVdhcmM5+hFXddj+weMvEFu3SWYTr9GAP+NdH/AC6Rw/8AMQy5pcmJDnnNdCkg2jPrXH2VxslTkda6WObcoxjFTB6GlVamgJM/jU6ycVnCTGKlE3HFaJmNj4yooorc4wooooAKciNI6oilnY4CgZJNX9E0e+1q8Ftp8DSP1Zv4UHqx7CvbPBvge00FBNIEnvcZNw44X2Qdvr1/lWc6ih6m9HDyq+SOX8EfDjcqX3iBSR1S0B/9DP8AT8/SvV4o0iiSKOJI40GMDouPQCkRtpUxsQBwMDrTTIA5GOOhI9K5Jycndnq0qMaasiVkyV3LHlujEnH406O/VXdIVlTaMbsg7vwohXa6lJGVgOQwyMd/wqe2toQ5MKqFzkAip9DV8uzLEF7lViKMH9cYB/PvVrcNrMTkDjkcn0wKikjZ49p2+Wf4WPWmwptYLJI0irwoAySfSi7M3boPS3kBWQMRJnllHT2q9AoZQH3cc9aYoKqPLhOenzN1pwLpJh4SCTwFYHn2PaktCJO5ae38zY8aAFTy2eoqY2ylG8gMk8eGAVjz7fjTYrlRjflX7kjn8f8A61Wo3BkEm8E4x8p7e9XoYNsakRuIEcHzI2H+61V9iwq6ocR90Ycp7gelXI5VguWiCkJJ849A3cfj1pbiESoSy9Oh9PepevqOLtvsY00UcjwucGYK2CO3P9acyDG1EDStyM9uxP0qErNayhZfu/MVYdSD6+9SZaMNIT8/Uk/yrhqSsdLuQxWH2e5MkTF2c5cnjaemR/hVoNmNi25Y/c9vWqkN1K0rRsMBif3hPCge1Szf6RtidSA7c/Nn5Pw9en51zOTlsEr9SrbB53E7hWjB+RSMEjsx/pVqWQKyF0dfmB56fnUskKhiVGCemOMVXV5OuMuMg5P3fp61rSlKGlyW0y156AAk8HjOajkmRjuEfmY4BA6fnVZCjNmRELjkNIefwxwKldhIhTcy5GCc5P4HvXRCu5OzJ5UJNa5izjaBztjPzfn61SWGOKYPEScjb179gw7/AFrTSVYkjgZt0xGFVjknHU/41Wu7RZYwZXJkzwegFdO+wJ2ZCXV4WXjJGNhOfwFJbkQKI+ka5JJ4xUF0vlOmY12E8kL0rOup8ylYiwjXhgvOT2qJOxpGFzoIpyqH7MhaHOORgD6Z7VfDyuuQqfiTWRp7Ca1G2Eq3QszfMD61oWssmwKVXOP73WtInJUjZjbiGU7nURgt94An5v8A6/vTIzNt+VY/fJ71cdyB86kD1zxUYUK544bkVaWpHNoQ7Jn+86IP9kZ/nURtUB+bc4/2mzV8p3HSo5VPUce1VYXMUfKUHCAr9DSbypw1WmxjJqBkDdBRbsNS7ig8cHFKVyKbtOcYp6qT1qkDGAdvSgp7U7GGzxinbge1Mm5TlQ4rntWgHmbj3rq5VB4P51jatBuhOBx1pSjoVCVmclI/2DVdKvFyBFcLk/iK6r4tWONcsNSQlYrqP7O7Dj5l5X9D+lcrrMJksJlHVRuU+4r06ezXxZ8OrXy/muHgWSM+kqf/AKsfjV09YNGdb3aikeQXFxd2Djcvnxg/Rh/jW1o/iO1uCsRk2S/3H+U1BKBdWg8xds8Z2SIRyGHFc9f6ekg+ZAfT1FZ2XQ6Oa61PSorxGxk8VaFwMcYIryazvdS0/CxTefEP4JeSPoa2YfFqqmJoZo37gDP61SZLSPAaKKkhiknlSKFGkkc4VFGST6AV0nnEddh4L8EXevlbm6Y2mmA8ykfNIPRB3+vT69K6vwV8OVg2X3iBFklHzJadVX/f9fp09c9K7e7doEL26AN0GOgH06VhOt0idtHC396Zc0rS9P0WwitdOiSCIfeB+8xxyzH1qaWdcYLYUfLu9q5tZ55Btbe23uOvXvSG4lhtpbhw5iiUswA3N9QPWs/ZvdncpKKsdG8qlSMFF6Ekcn/Ae1Nt5HZsRgEdeTxWVpl/cXVtG8eQjjIZwRgdMEdq2Y4nEEaybQ33ty43H8f6UONtUXGonoWrfzG6mPJ9QeK1bO33r+9jQnAJYDOKzLZhH8wzzyOnNa0F0+MBeG7E9azdglfoSywxJMu0qS3UdvpmpkAT7+VOSWJIAHtntVUylFkzESMjHtWratHcOWYqx6ELgY9sdqS3M5PuZt1LKXUxRkqPu44H1xVm1gnIT7WHDMMmPpt+tafkbQJIcKAcgN0+ue39amikgVhLIXYsM/OOR7VVl1JdTSyRSWAxsdpAUjmMncD747VU1jUrLStNuLy/WREgG4tChcsM4wB681sLKDI5UAlupPb6/wCFRy+VLG0cqpNGRgqy5H4juKh2I9SrZXMkRT7WU8iU/uZAc8EZGT6n9K0XdnT5flB55FUbq1E8bKVWIkcc9fw6VVjuZoj9nmkLtnAxgHGP19azba0ZXLfVBqUMkk1uxDFUc8k9eDxVRsNEFWQOnZgd/I6j3q5M6gBmmlJ5GMc59cY6Vj3Pzyr+9l2KDiPO1cn2x1rGdNSNYNk0twIwyqoZsdM/z9KjS8WBPndSxO7J4HsPoK4bxJ4lEe6y09183kSNGfu/59a4ia/dOZbl2G7hjkA0Kmuh1RoXV5Ox7s2poQBvTcRz838qRbuM9MfUV4cNV3x4llAB/hVic1YtPEEkDNDBdfOBkBj0q/ZeRDw8Okj2vzIn5B68Y7VMYopV569Pl4rynTPE1yTumUsuMlwcD9a6Sz8QiXASZRnt3H4VPskmRLDzWzOtEwgkcsR8oAyx605bkzHKKQp/icf0rn4L1TMZA4cnrvPIx/Kry36HnIrRcyMJRsXbiDKlpWLgDJzwPyrPtEzDGONzHe2cdTzmo7y/RYXy4bjAGelV01PyWIctNCOhRclfqO/1FUpRbKjzWOghGwhiuCOGx3FWDJgkKORzmsa01RJhiIofQlsfnVsPKV+UJj/Zbj9a0TT2MZR11NVJxIgOOO4oYY+7nHYelZdrdKsjJLujbryetaCyMoyGDDr71S1MpRtsThuOeuMjFRvknNQNKWYhcjuM/qKVZcDDZz2zVLUzasB5Yg8CnYx0pGOeAKcBjrTC4nGMYoHNLjuKCMDimK41wB1qIDmpGOcg1AxwcHrVIVyRiMelU7kBkYdjUhcZ5qKVsA81SFc5a9QfvF9iK7b4NXPn+F5ICc/Z5mAHsa4zUZFRJpH4Cgk12fwLtpB4cu7krgTTfKfUCiktWFd3SKfxG8NPa3D63p8W6N/+PyJP/RgH864KdFlTfEQynvX0ZMilGEi59c9MV5b4y8EvavJfaHGWhY7pbTuD6p/hSnGzugpVdOVnmksQBPA96ia1UnJFaDgNu25yDhlIwQfcVXK+pxUnQeO+G/D+oeIr8Wumw7j/AByMcJGPVj/Tqa9v8IeB7Hw7CJcedeEEPcPx+CjsP510+kaXZaNZpa6dbJDCnRVGST6k9z71NJG7SBmOR6ZrKpWc9FsaUMOqer3Ks0UhUCBSwPY8YFElq/l/MuAfXvVyM+WcHGCe9XBHvIycn35rOL1OiRzs2nnYTggHoD0Bp8OmKyjLFTnjFdL5e1Nrcg8cd6T7Cu7hvLBHpmuhVbGL1MiLTrSNRJFE0k56+YSFB9eOtTmBJwqiMNL0wo+UD2rQ8gKcOqyepVqmi8rkElPqvA/Kh1L6BFW1M6Cz2vgKcAZJHQVLOxDASOVROQc8Z/pV4iLzMCRWOc+uaa1qk8rCRsrHjBA7+9YNm6kt2QxSoYxg7TuBweoHv71qJEiXJmCguRycVnxWojLBUQ7s4PpV5Wl2ROVBVhgnPekRO3QuPOMEE+4p0VxxkyMuRyR6egqtMrBRzwByKpedsbGT7j0p3dyOVNF25YSkAIY+4KcE/wCfenRXKgiKZcZOBk4DVjS34Vyz9M9z1qvcanG6EKFcHqp7f407aXDl6HStcRiM/MAVwAM5GKqzhp97KmT2APIP1rl4dQnM+1yuCcpx19vrWl9rmUIQRnOMVjzqRfs+U03YSBPNUu4GOTgr+PauH8capPZQyeWTvPViPUdj34rpjc5gZpA6HOTx1+lea+PtUjubhYnyNnLZ+lN7G2Hj7+pxsN15snmg7jg54680soZvndeCcgEHFQWVzC77FkVWPRSMVqyK6Idygsw49KHo9jqjK+7M9o4CrNIku48gKB83tTls48BwEVehUoWYe+egqexQMh3xg5bk571cl2KuQoyTyvcUuZp2KlGPU57UYJ7YI8l1IpOduELfhnOM1Fb6nd4kHnZC9ZJMBV+v+A5qzrmYBEgRnkn5SJepBOBnvyeMd65298xJminBV4iVMZUrsPcbexB4rqgrrVHBVnyv3Wdtb+LoTgF2dgMAOD/k/jWzYeI9wDuW2D+7z+GK800iJpp2EaeY4Unb0GO5zWhult4281SjDG0Bl5z6jORTlRvsZRxNtJI9Wj1S3nVN7MQ5+YKw6dcfyq5a3Kb28vAUY2nPX8O1eVy3F/HsdIt8LKMMTyTjn3rS0zWJeU2Sq4OcuDz9O1ZezsbxqU5abHq0V5FJxLEC3QnHJq1GsDsDE7xn0VyK4Oy10MyCQmNQMtkcE+mKuL4itxn5in+yxz+Ro5GZzUV1O0kic4Mc8u4dAxDA+1Oikuo1ypUkdcLx+I61x6+K7eP7s4PrkGp4/GtmM794b+8qls1XIzFyj3R2cd6kkeJTt985U/jT0nZm2plkI4bGfyrhn8Z6cZNwhuS397Zyfxpy+OraP/V21yR1HygU1GXYynKHc75fMP3GXI52tzxTkdzn5QD3ANefv8QE4Menz7h0JcY9wfaopfiBKzBotNI+sn/1q05GYOS7npImI6oD/wACpTMCO+fSvL5PHeovwmnwj6sxqJvGGtyjAggX/gJP9arlZHMu56kzBh9O1V5GHTPNeYtr3iGbjzFX02xjNIZNfugBJeXOD2Ximk+wOS7no0tyiL+8YD3PArB1XxBY2ysGuYtx/hU7ifwFcsPDmoXTZuDNJ673Jrb0TwDeXb4hiOD944wMfWq5WyedIybdr7xhrEGkaXG0UMjAySP1I7k+gr6U8O6XbaHpFtYWQ/dwoF3f3j61zfgnwfZ+HVlfaJLlxhpTwQPQe1daznHB4HQVSSitDOUnN3ZK6rIpOFw3II4471BMvBIIHr3pQSy+qnjINQSsVC7GYYpiOS8TeELDWZGlMZt7vtNDwT9R0IrgLrwHrUczLbta3EfZy+w/iK9mKsxywHTqR3/CmNACfmQ59uKhxTNI1JR2PMiw7Db/AC/CnCVSQo2k4wc1gfbHbgNgfWrdoz9UPNcFmj1rXNcKpOSc+vapIwq5w+CeSM9KrwxM+A6tnHByKlwIiBtQk+pFPlBPoPZ2OOVIHfOc1J5jHq5x6n/AVk3NzKpaRCuD95toyPcVNaXMpj3SXDEk4HGOKrluh6o2E27QBuDEdhSlGVfvsB/c9feoYW6F97D0yKshozgZ2juO9KxDZLEPm2lQwAyflHFJuEUpHADYYY9fSmq2SFHA7DOaeyoV2sRxyMVOorkkpXaAyjOc+mM012S3RmZwsYXcTtzgjk8CochWAGWxyMnpUUriVHVgSjfKRnr6ikC1Od8NeLW8Rajcwrp0kNpEOJi2fmz0I7ZHTGa35l3btw2/wgelNsYoYNtvFCkaqMKgOBgf1qWSLdtx8oHYnqPanFM0m1fTQ57Woi8OFkwGOEAGO3T9K560guZLlUXA3Nt5/hrtZ4N0pOcDGMn09KptpxYsUGSOc+lbRts0ZtvoynFC9tcJaXYUTsQo2kHr0IIrUzsdo5CBJGSCgGefwostIitT59xIXl/gSPqD605l8uRHk3gsQJGKYU+h/wDr1MqcVqgjJsp6ncTi2cJE5HfJC5/CvFNeN1qmsXMJwjg5Qg8D2Pt/WvcdWUfZZHZ9qgcE9vevM/h/pX9seMtQsbgAzOrsmTjIB7Uo/EkzdX9lKUehx/8Awj13JJmaSNW9FWtS2sb6MKv2vcqjhWQECvcYvh4xQI8RY/wnFWIfh390NEcseDj+ddXs09zyvrNRbM8NWzvN+TdNk8YCACpV0+5LlhIwyCPljAHPWvf7f4cdMwEeuRitBPh9BagPdNBChPDSuqA/TJ5pqlFdCXiar+0fN9to8tvf219AZ0vbaRZYZl6xupyrDtkHnmq8+h2ks8k1yivM7FpHlJLMxOSSfUmvpufw34e02wkvtT1PS7ezQgPPLMvlqewLdAfauW1G0+G8U90bzxnYqJlW4KRfOFQ8gjAOQc1ailsZuc5O7bPErfQLb5/KhiVUwWPQD0q2ugkjenkgb/LJ6nPp659q9Yj1v4RGS8ceJ5LkhBK+22dQgUjkHaMntjnr0qG58ffCWKzZvt+qTPvSVHityJFPOMdPTnPt607CvI80bRZZFQR4VMEZbg/L1JFTf8I3Ls3byYtm8OyMAV9Rmu9b4j/C23tUuLbRPEV7G8jFAsIzu/iBy/Q5HFJD8UvChUDTPhx4luRt2AOmRt/u/wAXFCQnc4L/AIR0qrGXepADYMeCQehHtV+y8HS3M00SKwkhI3qy4xnpXeReOru8iaLTfgtq86OFH7+RlyB90Z8voK0LbXviJNK8lh8IrS1aTG5p7zBOOmelFhHmdp4PnnuRDuUSZkDqf+We3ue+KsaZ4QWZJZWmUwKVCsxwTnjJHYE9K9QWT4uXBZ4PBHhKzkcbS00zOSPfDc1Pb6P8Y5hhx4H0/PaK0Zz+uaLAeZjwFL9svYHMn7uISLxzznirEXgNJrJgm8TeQJDhTnkcf/qr0/8A4Q/4uT8t430a0P8A076TGcfmKnHw9+IUoX7d8T78Z6+RaRR8+2BTsB5ZB8P7mV4TFY3TvKsLRsIGwB/GCccV06/DSUA7dNu2P/XFh/Suqb4Ra7OSb/4k+LZl/ux3hi/9BoHwRsrncLzxH4ku8cHzdUlYZ/OlYZz0Xw4n5/4lsq4xkuAuPzNSt4Jitcfan063H/Ta7iX/ANmrdT9n/wAIk5uIrm4OeTPdSSfoWq/D8DPBEONujWZA/vx7j+tMRxUtn4Zsm23Pinwzbn0fUos/kCahfWfAtpxL400Qn0hZ5v8A0Fa9OtPhV4TszmLTLJB6C3jGP0rTi8FaJBjyYYIz/sxqPwoA8rh8WeAYin2bVbi/f+L7PpVzKM+3yitOLxzpQGLLSPFFyB93y9HeMH6bmFejNoMEOfIuIV4wARjJ+tVDo90h4QSp/sODQPQ4+PxdNNxB4T8TuncyLbxAH/gT1MmuauSPL8HXaK3O+41WBcfgoNb0kBWXbgq2ejgg5p7W6P8Ax8A5+bpj2pXAwF1DxDNnGhaVAnRfP1ORz/45HTopfEjE7/8AhH4znJ2efL+hIreMEcUexVIY+nP41V2qAd3XOQMc0m7AUTb69KpY6vp8WTnMWnDg/wDAnNM+xa6Pva8QT/dsoQP5VpByuFUYJ6c4/nSGRj1U/jRcDxm00J0TPzZHPPPH0rbtrUxpyCpXnJ6e3WobTX1uXKsoVwcYHBFSfbEYHzInXuNo61z8p6ik3uWHij2/NKjv1OPmP4elV5Yi/O3IHbAAqMXiMrA7yx/iIAX86BMrAvjcBxncBU8padhpABLOMg+vOPwqlPEh4BGdp+bdjHpxirqyxvG2wbWHJy+R+VUXvoInZZ8EZ52kDkdeaLMpMmsJp43xmNk6YHAArRjkKrmNAreoAJ/xrJh1CCWMbW2Ec4JGCf5VNBcfOw2sw46jjn2pNCa6moJmHfI9SKck7EkKdrdfaq6SRl+RwccDsP6UO2WEaqTHycjk4+lLlIJJpwMFyWjHU56f/Wp4dWGWcEg9c9B7VRE2TjbwQTlqfGTEMRn5euw/w/T/AApNWKSLtu6zRhMAoPbBH4/1qzGZFOQvmR8H1YfX1rPhORvjfaT0A6MPSpDe/PhFAcH5h7ULQUky1JtmXCNuOeR3HtQCImaRV2hcLt9TTBIkh/eFQR028YHsetDTqhUzsPLBJ3uME4HenzE2NFIERcSfM7/NvB6+tQ3sSSEozfIynLYyAMcVWF1K6gRfNkDBPQDsarXN3NHexxQiKSF0YNk4dW7N6YHpS5kwUXcLyxWexniMxMT5QccYI7V53eibRtYsNVsoguoWEigrjCyKD39K9NkkzAbaOQxjaAJF4Zff61Q1TTYdQhUOB5oGPN7t9fWolC+qOmhV9n8Wx6h8PviD4d8ZR+Vbulpqqj99ZTEBwe+3+8M+nNdyEhUY2gfhXxZq2h3tlqaTWh8i6jYsjp247H/OK7BfjDr2gaeI9espr6RIv3U8TYLtjjf7epHNdFLEX92e5zYrL0l7Sht2/wAu/wCfqeyfFzx+fCdjBpnh+3GoeLdS/d2Fko3FcnHmuP7oPTPU+wJHFaP8DP8AhI2t9V+K2pTalquwhra3uHCAk5y7E9egxGEUY79a8m+HnjC3tfHV/wCJ9c1KS71a7tQyyPAwKOxIYDPA2KAoI4546GvS5vjJYLwLwSNjoeM1vzx6s45UpxXLFfM77/hTfgDyfKn02a4hGD5U+oXDpkDAO0vjOAO1ZKeA/hjFatNa+D7K4KhhtCu+WBGQMk+v6GuGn+L0DffmTYegU4pk3xdWKFJVhCQOSiSsG2uw6gN0JHcdqOeJHsqnY9PtfDHgyAILXwRpgjMnezTPQ84I47DPrV+KPR7e2DWvg6xjYxK+xbaIYYnBQ8dQOa8Uf4tSOd6mPHXIBIA7HNVG+L0mTsaMnuAho54i9jU7H0TJe2UEsQsrS1EDKuQiIuzHVTxyKW78QHeRYCIJtGGeTauQemAOO/1r5ytvifeT2140UQP2aLz/APV9RuAJ/WswfFfVMER224E5/wBT/wDXo9pFD9hNn0zNrrixhjFzF9oUsHcl9rA+nfP1qOXxDdPE2bu1VS42ny2xtwOM+vevmC4+KmroMvb7B2ygH9aqD4i6xcTqQgDsNq5wA3tR7VDWHmfUknicrBGj3oaRXLM4X7wPb2qCfxWJGjK3UsW0BXCgHfjP5df5V8tz/EDXFkdGKI6nBBdRzTbPxf4k1BboWhaRoFDFUbGQe49fpSdVIf1aZ9PjxR5MITzpnYY+Y4DEDP8AjVeXxapkZ/3xyAuC+AMZ6ce5r5ft/Emv3ZPnyyquMkZOR9eeK6LSLHVL+BJ7qaREcfKATu+pB6Ck6yXQtYOdr3Pdh4yaKG4jdgyzOZCWfBGccAg8YxVM+PWgkdo5UVnxu/e53EcZI9fevL/+EdVhy8ue+XzT/wCwYIwPMQkHpmTrS9r5E/V/M9Cn+JM3T7SufTdVGb4lSkZN1+ANcnHotlxiBvfPNXI9GtMYEKY9cU/aNh7BLc0p/iNKQdssrfTNUJfiHfMf3Yc49acumRKflijK/TBog0q2RCI4kCsdxBHOaTnIaow6lOXx1qzDg4z3wTUA8c62rbluWTHTapzWwLJUHyr7fWo5bVDwyKSfUYxRzSfUXJFdC3o/xP1aNlXURFqFuOqTDDD/AHXHIPvzXpWjatY6/pZu9LlJRSFmhkA8yB+wbHUHs3Q/WvFr7SVOWiG04yBjFVvDGuz+GfE1rdIx+zzEQXKHo8bHHP0PI+lNSd7MUqaavE9/ViVG0llHJIOT9KbtO7AdQ/XB4p7qvkhoThSM9jmsPxNr9p4W0a61bVJP3CD7gPzO3ZFB7mqauYC+I9b07wzpUmoa5dLb2g4BIDM5P8KAHk145efFLxbqc7XHhzQ7O30w/LELtN8jgfxE5HX0HFYhXUPG+rDX/E3MP/LjYc7I0zwcen8+tdZFYHYN2KastilHqzNjLRksgLY4+U4wPr6UPeSeZtUuuR0diQR9e9an2aIElY+vXjI/KlithGgIjXPT1x/hXF7RnrWRn/aFkwFLA/d2jv74pf3bHI2oc9H4yfatE2aOAfLJI6HHFI1kwwNqr26U3UGkVI0UZDgebj5Qo7/hTZoF2g5bI4IXv9Per6aYqtlR82M5BwKmS3RFycFj09PfNLmK0MmLTtqkITIx43bcZX1/+tVu1t5odwAJTttHP/1q0oVAOchnHftVhZUbCtjeegHSpugcmVbSHJJL5dvTgirTwMrjy2IA6DHOas+XG4VtgB7sRzipgi9V6diDVoxkzKWJx0TLAncoOM0suWiVioOehbHFXJUZzyT8vSqsqc4ycn7yYyD7/Wi5SIQiplgGifjOOhqvd+coDsEZSeSvX6kVaPQFc8cY7rULbjyrZUdh2qdCyuk4WP5ZVY+n8hTWvlLBZCUYGkuFiYEnKdTwBisue13gdZO+Sal+YKNzejnEjfKwKEc5NTxKhZXOFPQL6D1rlI7eVWGBKSDnA6AetacNxOw2GMhs87v6Ck7dBuDNebdGQGQkHjK8ipUYleCQO49qzknn+bNyCg/iZcH8aVzMjblkBI7q3FHNYVnsWrm0jn++Fb69ayLnQ41ZnT5WYEHK7v51dW+ljID4bHqKlhvlYYfaDnqx7UrplKU47HKXPh6PYVeKMxnlkK8H6+3tWf8A8Ivp8jHfaW8h56ggD8q7uRopVJYpj3IxUQSAd4/c56U0X7eVrHGf8IRpEgVHgjQdyqmrB8C6OtuikyeTGxkEbOTFnHLbSev866okEEYyAeoYVFNtkdc/c+8QT1PpV3I55M51vBdpefPcSTFGx+7B2gqM4BHQDk4AHGahl8D6XGNpjbC/dY9R7ZrsfPiQZc8+u6ka9gI4JYj+581VddSOeRxlr4ThhaXypsB0aIr0yG9aot4PlE21JlC9eTkV2803z4t4XEhHHAAqrI1wsqpJb5IPQHAb6GldFKTZyMngd5Aw85CnXhm69jip7fwJuT96Iyx/izn+ddjDOU/19vIh9SM/rV6KVJF+T5R9apNdyXJrocla+BFZMTTIwAwhC/Oo9M9x7VradoEWkxt9mjDORhiTy1b0cgQDJK+54q5FIkgxgEe1HKjNzkef2fhi2hvzPJDM0qvvWNhkD398Gust96gFIWYH+JvlFakkCSc4wQcg9wfaoWjMRLEfUg5B/wAKXLyilNz3Io4mkGZJBGvog/8AZqsRWkCksFGe7E7s/jTke3lADSKjDuDg/pT2jU8x+c3uoyaq5DDyEJyMDPcCnGBCAGXn1BpgSUMSFcZ9WAoHnq+Nv6incVhRB2PI96Q2obBBKnueuakWbBAdSPepAUODkfhQLUqmNl+V+nr1qMxB89z9a0dueeo9KheNRnOVHfFF7CauZdxDwQir06E4rhvFUHlxSEcFSGr0CY8EDn2HP/164jxi6m2mVeuB3zVMSWjPcvDM8t3olhKcurwJwR3x2NeIeNtTPjvx61qjFtA0ZtuB0ml6E/mMfQe9eu+J9RXwp8El1BRi6WxSOLn+N+Bj868j8D6SbPRbaJlzPL+/lY9STz/KtpysctOPM9TprKzBQPxjooH+FW/LI7f0p8SFB8p4xgipDKT1JH61MdC5amXbSoyAbWHsOPwqzFvjL+YP3RAbK9qx7WV0OMcdqvCVuG3b9pzjPUVxNnptGgkYblDtHXA6U8fuhgoGH+zxVeF2B3R4APIJ71OZGYkMCP6UibkTTpjIV93pspvyy87T9CelOYqCWwG/z2NSRbScbQD1wR1qdS3bdFZkTePNk3KBnaOAaeDGf9WoU/7XFXXVGHQKR3FQkL90gE9M07CU7lVrqUZIIYD+En7tOW5IB2q3v6flSz/KQXAx0JPYetUmkc8Rhtmfvf4Umykkyz/aIB+ZWGOmKbLeqy4ACk9yajS1BG5s5PXmmvBE+TkluwzRdjtESR5C4KYcgY+9/OmPFM7by8an+6BRCjgfKvHTPapnRsclQf8AZHajcTdiFQindJsd/wC8ef0pssvmgCMbTjrxUj2x25fJz0I6iq725jAZpGxjjCjOad7DWogJVR5gYt2K96lVF25BKt71EAseGyW3jO8H+nap47nach+nYjmjmG4sQO3Ck5Ue2f1oTKrtcuFHQegqdJoJzmNwrjqucZ9xVgGUrgsuDx6073IbsZ6iNWPcH15qRVic5VwNvbPX86svApbDcD2GBTmtYtgwob69KYnIrYhJ+6re7AYqubaM7iqqzE52qM1aazCkFfl/DIpJJYoDsZlEnZQeT+FP1C/YqsJFXrhfQ9aW2jl+YKQHH94ZP5VZj8yU58vnHGT0+lOe3Y4KkROOhzmi4eRWa2cOpdQQOueatBYSM7Vz0HSmqXJVXyD9Mg1KhTduCEkdAB0q010M5N9QCxhSC3zHnP8AntSMIypU4JPcjPNTl1yDgq3vSmRWJVhjt04qiUyOFSQC7AKP4c9PxpJILYNuJKv/AHhwf0pxmjhkIzGV9CeR/jSi5iY/IGb3CmjQd30E3eWAFkDkc5z1+vapraeNwQF+b8sf41FuR1OIn5/2cVGEeMgrhcevWldrYNHuaYGfut+fNN4AO/p9OKpLLhCzzMoAzkDH5irVvmQBpd3spOdv/wBenzCsIyBhkR+27GB+VKnnISVZSMdGJH61YYAZy7Y6AYyT9KYsLnBfa2Oi+n+NLQBouiesbj3HI/Opg+4ZbZ/30D/+qnbioXcm3JwOalCRsMsAfwpr1Ibt0IfNXo4+U9CORT4liA+UKQecj1qTykboARUDW4GdvH+6eaBXuSZ2t6AetJJgqTyBUAkljVhIu9fUDH6U9GR1DoeB6dadxNFK9hxzx7YrifEkMTzSLuI3FFPHqa7uZW5AbiuN8RjGoWoIABnjzgf7Qq0loLmdmd5+0a6x+FfB/h+M8XV2hYeqxpn+ZFYGjxqEO0Y54FbPx+Bk8aeB4MnasVxKB6HCis6yidYUwRj6f5xWk/iMaS9xmhsAAwOvQ9/wNNMbZ4P6U5JCGIIwe5A/pSmQHoSPpyKSsxNNHMlCWGGH+AqxbsE+6BuHpzREUb2PtUq4XJyF9OOtceh6Fx0OACG6E547VbA3MDvJPXg1VUgtnGB9KcWkjbEIL56+lIHqWGiUH5WYj2NL5agH5gT9elRqGk4lbb/sjipvKhXHygntnnNFhXImZWICP8w7Dv8AWo1mcuU2hiowT6e31q0yDHCD8KgMbJna6gdcGk0ykyJ7d5SBNKdvXbjGKZJamNf3TllHYn+VTrMy5BVseo5oafORGmTS0GmzP+SNiZXZfbn9Kenl+WC7AIB93OPxNWDbiT5pgxf26CmR2gLkKgwOnvSSLcrjhPJLgW8YCD+J+BSwwyynzHlXj7oC8fWkk3JkbmUfSoWkEmPMaY44GOKfqT6FqS3YsAXz+lRtbMykB/m6YJoRRIBtCg9Ms2TUohUEZcE+y0w5min9lKbtxGe4z1pqxRDIbB+p5FaJiVuSaVbZXwSqn6mixSqPqZ4gts435HoOcUrx7E/cyyAjplcitF7RFAYBFI9KhdIznGdx456UuUOfmM5Z737pZSvr0poa4fI5Yjj5GNaDWp5IRMdO5Jpv2N44mdJlVc846j6iizC8Si1rcOMtLJCpHTOfzpLaz2qcM209D6+9WHMrgKC0y98DH608idkxtKAepyaLBfQWGExkEOU9yODU+52+95bHvgdKqlAflkkYEcgjoal8hNuHL+7A007EtJj2RSMZBDe/UVVmMgwVjdlHTPb8atxWYYBoZ3X075p7JJHkb0f2A5qtRXRmG4uem0Y9X6j8qlWUCMmS6DkdUU7asum5uSqY5Ax81VmghbIk8snrkdfxovYNGSwTjcPLtwR6hen1zVwTMT/qsntjFZ8VshJ8q5kH+6cgfhTJra4AGyQyc5ILYNUpOxLimzTE0nQxMoP97pU5KMAHIB96yrczjIlWZVH8QbcKtwgOPknY/iDVp3M5RsOls1cBtzKncA8cVMhwzIT8yj7w6EeoqvIEjOPMYu38IPX8KfCrbfnAPoq9qT8ikWo5FDlmkViBwBztFWo5UbgVDDtdRlV9OBgipVTHCnI9xmkLQnUoTyQT6elOMatypwaqOr55VTipIwwUYLKfTNK4ONyblB0z7g0yQ7jwAR6dDSb5ADuAcfXFMZt33lI+tUmZuNhr8A8YqFIQrswypfG7HU/WpN655x6YPSlBUcDHPY07XHdojk+6eTjtkVxni8GOW3mHVXD/AFwc/wBK7QoByy1yvi23MlnuYDcG7dhVIjc7L46gP4i8A6gAAJhPFuH+0isP61StADCuRzjqKufEhW1P4MeGNdjG59KeCdz/ALI/dyfz/SsqxlBiBVjjr9RW8tznh8Ni+V4OGzVWVTvOCMe9WPMVlx3qu7DdxnHsaEgbM2SOQ52r9CRRHayNgl93sBxWgwfn5QaeFk2/NgVwtXPRuVktmAOz8eacN4OAmR9as44+XAPr603ftPzrj3pk3K5Dh8+WKkRl43xkH1qXepFG7IA4NAXGFVbqxo8pOo5+lPGBQDjkDJpWHcaQQuM8e4psUS7mYZye9TDLffX8qXDAYAHPenYLjSh7MDj1pBH3Y4NPBI4J5+lPBx9aLCuMEaHrg0jQx4wEyKUsccAZqEvMT0pgkxTbxjoCP6UxoWxgPkU/zGzzilEgONuBU6FK5WlgkP4ehpsJcNhencmrTxyzH5WwB1x3pyR7evFKxfPpYbuRecMT69ailnIb7nB9RV5E46BhUbRLwStNpkJopqzYJWUIP7vWpIiHUkREuP73SpzCM/IBzzyKXymLc8H1FJIbsQKJDnaqqDzjtTiGJw6LVgRHvSkdjmqsJtdCs1ujjB3Lntmq81uyRlVdyQOMAEirzHqmMk9qckeFKE5z0J607Jk3aMyKwkdfmuXTPZeKsLpyY+d5Gx23Yq9sBxjFBjYZwaFFIOZlOOzhj5WMfU8mn+RF/wA81B+lSN5g4puZewB/GgepDJZwsP8AVrn6YqudPjwCS6t6hjV9RIeMKPrSmOTswx9KLIOZmWbNg4CzEY5wwzmmTWUjk4nYD0AH8+tajxPjIwR9MVEwK4yCOadkK7KcdpNGmFlwDwTjP61OiTADLE+4xU+QeOfr3ppygG0/0p8qFzMlEcmQ2859SKnR5Fzu2t+lQLKCAJBirMbZ75osFxUnBOHUj8KnDBl4FMVQeTz+NBQH2I70g0GNMqsy7HLKM5AyDUFnLPLJIJo8KeVOMY9qsEOoyBn2pys2ORio5Xe9zS6taw2WHcCePwqqUI+4cD86vdahkjxyvWtUzB6EJkcAgjn8/wA6zdXjFxayxY5K8Vq5OMMCKgljDAjqa0Rlc6L4TpB4i+HWseHb4hhG7xsh67JB6fXdXnnhwT2JudJ1LP23TnNrN/tY+6/0ZcGtHw1rTeDPF8N+246fc/urlV/unv8AUHn8/Wuz+LPhWSYw+LvDqi4kSIC6hh5Nzb9Qy+rLnI9QSK0WqMn7svJnMkjHy5wBwM1VlchugPvnFQ2V5FeWyTQSK8bjKsD1qtcNN5hymaexJ0BOR0FBX1amlQOrc0wqT05rkO6444XjOaU7TnmmiM45YClVMfdpA7DDGh6ik2IOhOfapinHJo8sAcEU7BchA+tSBRj3qTYT0pyoQOMUWFcjCuRxTvLkH8OTUnzetGARy5oC5A24Z3Dn3pASasFFPck0eWo6A0rMq6Il+mRSkeimpV9lqQZx0oFcriEt2xTPsYU89atfMaMHvRZBzMhWIL0FLsH404jB6Zo69qdguMwAOtAbB68VIEz2pQoB5FFh3GqwzjB9aUtnpilIwfakbHY4NMW43JAzmmEs4wOtSdulJkDoDQFxqRkHk/NTnwEw/wCdM3knHT609dmQD19TSHYQFez5FDMB/Eal2oR0FMMYPQnFArjMhhjjNCqDSmID+I4pDEoJ6/nTHcCrKTg0o6c4NJ5YPqD9aTaD3P50APHHTFNZQw7A03aufvEUNER0c/40AMePHOKYQR16VI8citwwPpSfMB86/lTQrEfHOAPpTo1wcr8p9qXCnjjHvT0AHfIoC9iVHIOGXj2qyjI3bFQJjoCPxqVQDUhclwpxzg0BOTkZNAAI46UmMHgnHcUhDSgHQmgA9OuKcSB1ApvPUNx7UwIpUzz3qpIh57GtHdz81RyRK4x1q0zNo5/VbQXds8ci5BH3h29DWv8ADHx63h+QaF4gZv7Pz+6m6+T/AIof0pJYSo9vasXVdJiu0wwIYcqw6g1qnbVGTSejOs8d/Dy4t55Nf8E+XPFc/vZ9OVwEmJ/5aQt0Vj3HRvY154fEenozR3ky2VzGdskF2PKkRu4Kmt3wx4t13wW4hcfbdKzzC/3QPUH+E/p7V6EvjDwDr0aXuqRQx3JGwpdWokcY7bgDkc+taJp7GTi0cgRgAcCmcg4J/KpQoxnrTlHoK5LHZcjSMnkdKlEZxTlBo2k9TTsFxvl++aMqo6VKIwBkUmzI5osFyMNngDig59KlC4HFKBx0oC5Bg96XYSKnxxSbT26Uh3GICOlSD0NGKUA0AJtGcg0pGO9GD3pRtA5oATr0pSCKAuaUjHSgBhFG0etSAetBUH60Bci20oU96k28U2gBhGO1NI74xUo680Hg9KAGdegpCAODUmfak4PagCPy19qXyx6ZpxX0pNpB60DuGzjg00KcmlIYHrxS896AEK96QrmnKaQvg/0oEJt9qRoxngU/IpD9aAuRtHTVQrnBIFTE9qQnnpTHcYdxxnFJg/8A1qkGc8flSYz2xQK5C6A9VqMxY5RiPapyOaUrkUBcrr5inPBqxHKeuw+/em4PIpUNFguS+cueQ4/ChZe6o5/ClQnrmpFGenSpsO4zzFPDKyn6U7aCP/r0jAA98+lMJIPSgdiUjAIqPkc9qQSZ5zTJHHT+VUtSXoJK2emeKiaMHnFAPORwfelDE9hmtUrHO2RNCpyCM59ax7nRLKSUsYOfbit/OeOKaVFNoSY5QB9KeuKTAxTgBisjYcBTgOeKaM1KvtSAbRjFPA55pTyMGgCMrSg4FPxxSeXQMaR3oGRwKXHqaUcUAMHvS8HpTuM804AUAMB9qXaOtPAoOMUWC40HgikAPrT+MUhFIYznvTwOKCtIvBxQA4DikYDjNPxxwaYybjQCDZil25FJgj3pR0pgNK8U3ywKkOaXPrSAhK4+lGD1qU0hXigZHwe9KMDrTgopNlADSAe1MZAe3NTAUje1AiuQRz6Uq89alwD1ppUdqYxtBHT1pTwaCcmgQ3PPNOwDQcHmkoEHQc/mKbg560p5HFNBx3oGGBnP60EAd6Xn2pDkUAKvHSpFOB7VDSh8d/wosJMnOCMn86jYZ6k80B6V3BGaVikyBxtPp6VDuOT1BqSZiTxyPSoWLKQe1XFWJlK45Se57U/r35qPdupQeOa0Rk0Lk7sdakDcf/WqPdzjH40pNNMmxb2inhBTtozS4rE2IyuKBkGnMDSDJpFDuaDmjBxS4NArCDin9RSAEU4CgBu2kYYFPoxmgCHa2adtapOaUdaB3IwcDBpSwp7Jmk2j0oAbuFL1HWlIHpQBSAKMA0uKOKYBwpGaXI60lKAMcUgFBpv4UuKMgdaADik4zS8Gg0AIQQOKaAR3p5PHA5o69qAGfWg9aUjNG3igAAxSED0pdpoPTmgBjAYqFjzU5INROAT0oY0MJ3UoGOCKYgO49sVYPKikhy0IynpTSvNSYx1NJ1qiCI9elJjmpGXPSmkHpQA3OODTs56CkwfxpcN3oAaevNIRkginHpimYwaYC8gGms1O3c4NMKcZpoljCxzSA5HzYJoIPam+56VaIAHn0pxFNIH40o9c807CbFxxR0pAw/xzSnBPNMRqYpDx0qQ4IpNtYHQhByKUKKXFOUUAMGKKk2ijaKBEdAqTFGMUAMxzSgU7GaDQMaRSd6N3NOABouFhKXAppXmgcUBYcBSEUbqeKBWIjnFAqQik20DIwwyacCKTYM07bxSGwzSEZpRxRTEIeKDSnmikADGaU47U3ApaAExSEkdqfSGgBMkio3yRUmeOKTHrQBAKXgilcEHikK8UihmBmlyQKUrnrRTEN3DOM807jFMwM5705etCBhQevSnYIPSkPJ4pkjM5NLSkUmKYhppu3nrTyBjpSYoGRn3oxzTyOKYc0yRhHXtURRhyKscHtQQBTTEVTkGlGSvIqVlFMCgetWiGMC+hxTx06UjcY7ign2pkmyOaXFAXFOHNc51DacDinbaTFMQjnjimAmpcUuBQBGBS5xTqiekwQpao2JJp6p61Js4pWuVdIgAOacA34VKFFOA4oUQ5iHBPWk2mp9ooIFOxNyJQKcMU7bRt5oAQ0hNOpCKYDAaU0uMUdKAEFIwppbB4p27ikMO2KKOtLigBjDnijPrT8U3HrTAM0h96XbzQeOtIBv0pTmlpCKAExnrUUgI5HSpscU3aD1oaBOxECDSMD2p0i46Ug4FIY3HrSAkdKUZPWl24pgKpPenYpFHHNKRkYpkMaQaAAelLkYxQPamIGFNIFOY+opnU0AhMU08GnFucUhxQFiM9elKMEU/GT0o2U0JkTKcjBpjj1FTsOKbjjmmmKxXPoaQY9amZcCoitWmZtWN3bRsIqTpS54rA6SMClK06imIbigilNFIBuKQrT8UUwGYpQDTulLnigBlBOBRjmlxmkA0HNLTtuKQigBKQ8UtJigBueaXtSYpQMUAIaKWg0wGY5zTGYA1KVyKiaLmkxrzGlhnNAkzSNEccUwREUtSrIlEg6U7cDUWyjaRT1E0iwMYoIBqIMRT1NMmwYpDTwaDikAwD1oxS5waQnmmAyVNwwKj2ECp6SlYLkSrxS+xFPpDTSC42lpuOaXPNMVhpwOtHI6CnZHegMD0oENDA0mATTiO4FNBA60ANK88imnrUrHNRHrQO4GjOBxQeRQQdtNCF980g9xSYwOlL9aYhpHPtTSKeelJg+tFxWNnbShacaN1Zmg3bTehp9G32oAb1oxTwtJwDVANxS4pcil4oEMK5oCU+jNIBjLik6UpPNGRQA0mgnA5ozmkNAxDRikxS0AJg5pcUGikAhox6U49KSgApMUppKYDD0pOtOamjrQMQDFGKfQaBXGBadtpaTPNIAxRilJxQDTEMPWg9KU9aaQaBidqaSaU0lADSTQORxTivFNK7elAAQccUoGRzRzijrTENde9MBxUpHaoyBmgaFDcUNg0zpTutArCHimk8U4g96Rhx70xDOlOU0mcUDrQA/wCtMOD9af25pvemITqKQ0vek3e1IDcpNopaUe9SWJigjFOxTTmgQoFNZaVc04mgCLGKWnEU2gYmaRjTqQCgBhprVIVpjJzQxoaKdmkHBpRQgCkNKRRRYQ2inYpCOKQAaUCkFKOtMBDRSmkBoATFJtp5ooEMpDTqQ0DG96KU0nUUAJ3pe1AGKKAAUhGaU9aKBDCKYRipD1pD0oGNBzS8UmKQDmgLDsccU3oaeDSYzQITGailHcVKeKYfmNMaKEkxVsGp4X3CleEP1FOjh2daSLbVh554prA0ucGgnJp3M7EbdMUKMmpcZphBWmIUimgU7NBxnigQxqMU7vzSHg8GgDaFFFFSWx/akaiimISkoooAD0oHaiikMSkFFFAhx6VE3WiihjQ3vRRRQMWiiimIKT0ooqQCloooGKKYaKKYkJThRRSQMDTTRRTENNIKKKRQ6koopiENAoopgNNIelFFAxD0pKKKQgHSnLRRTEBqI/eoooGhRQ3SiigGRt1NC9aKKBscOlNfpRRQR1GClHWiimtgFNJRRQwP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows a sinus tract related to a hidradenitis suppurativa inflamed nodule. The tract is identified by probing the margins of the wound. The procedure is performed using a local anesthetic with epinephrine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: F William Danby, MD, FRCPC, FAAD. Copyright &copy; 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_27_37296=[""].join("\n");
var outline_f36_27_37296=null;
var title_f36_27_37297="Histoplasma oral ulcers";
var content_f36_27_37297=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mucosal ulcers due to histoplasmosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ulcerative lesions on the oral mucosa in a patient with disseminated histoplasmosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lee T Nesbitt Jr, MD. Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Lippincott Williams &amp; Wilkins, Baltimore 1995. p.268.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_27_37297=[""].join("\n");
var outline_f36_27_37297=null;
var title_f36_27_37298="Vulvar incision drainage";
var content_f36_27_37298=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar incision and drainage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A generous incision overlying the left vulvar abscess has been made and drainage effected. The surgical site is now packed with gauze.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andrea R Thurman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_27_37298=[""].join("\n");
var outline_f36_27_37298=null;
var title_f36_27_37299="Cystic hygroma CT III";
var content_f36_27_37299=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73665%7EPULM%2F58071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73665%7EPULM%2F58071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic hygroma in left axillary region",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 231px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan displays a large cyst in the left axilla.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic hygroma in left axillary region",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spin-echo, T2-weighted MR sequence shows high signal mass in the left axilla, which corresponds to the cyst seen on the CT scan.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_27_37299=[""].join("\n");
var outline_f36_27_37299=null;
var title_f36_27_37300="Pathologic findings in GAE";
var content_f36_27_37300=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F88021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F88021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Pathologic findings in Granulomatous Amebic Encephalitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 176px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Panel A) A case of GAE, showing numerous trophozoites surrounding a blood vessel. Notice the prominent karyosome in most organisms and the cytoplasmic vacuole in a few parasites. Hematoxylin and eosin, X160.",
"    <br/>",
"    (Panel B) Multiple amebic trophozoites surrounding a blood vessel in a case of GAE caused by B. mandrillaris. Periodic acid-Schiff, X160.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sun T. Parasitic Disorders: Pathology, Diagnosis, and Management, 2nd edition. Baltimore: Lippincott Williams &amp; Wilkins, 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_27_37300=[""].join("\n");
var outline_f36_27_37300=null;
var title_f36_27_37301="U-S partial hydatid mole";
var content_f36_27_37301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Ultrasound partial hydatid mole",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 439px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Partial hydatidiform mole: Ultrasound shows endometrial cavity filled with a partially solid and partially multicystic mass measuring 7.5 x 5.5 x 4.4 cm. Focal anechoic spaces can be seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Department of Radiology, Santa Clara Valley Medical Center.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_27_37301=[""].join("\n");
var outline_f36_27_37301=null;
var title_f36_27_37302="Lomustine: Drug information";
var content_f36_27_37302=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lomustine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/60/8133?source=see_link\">",
"    see \"Lomustine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/34/15910?source=see_link\">",
"    see \"Lomustine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F189599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      CeeNU&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F189600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CeeNU&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F189639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Alkylating Agent;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Alkylating Agent (Nitrosourea)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F189604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Repeat courses should only be administered after adequate recovery of leukocytes to  &gt;4000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets to &gt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     . Details concerning dosage in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Brain tumors, Hodgkin&rsquo;s lymphoma:",
"     </b>",
"     Oral: 130 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     as a single dose once every 6 weeks (dosage reductions may be recommended for combination chemotherapy regimens)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Compromised marrow function: Reduce dose to 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     as a single dose once every 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment (based on nadir) for subsequent cycles:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Leukocytes &gt;3000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelets &gt;75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Leukocytes 2000-2999/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelets 25,000-74,999/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Administer 70% of prior dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Leukocytes &lt;2000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelets &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Administer 50% of prior dose",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F189621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/34/15910?source=see_link\">",
"      see \"Lomustine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Repeat courses should only be administered after adequate recovery of leukocytes to  &gt;4000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets to &gt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     . Details concerning dosage in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Brain tumors, Hodgkin&rsquo;s lymphoma:",
"     </b>",
"     Oral: 130 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     as a single dose once every 6 weeks (dosage reductions may be recommended for combination chemotherapy regimens)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Compromised marrow function: Reduce dose to 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     as a single dose once every 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment (based on nadir) for subsequent cycles:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F189605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F189606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. The following adjustments have been recommended:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aronoff, 2007: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 25% to 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: Supplemental dose is not necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous ambulatory peritoneal dialysis (CAPD): Administer 25% to 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Kintzel, 1995:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     46-60 mL/minute: Administer 75% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-45 mL/minute: Administer 70% of normal dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: Avoid use",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5528482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, lomustine is hepatically metabolized and caution should be used in patients with hepatic dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F189575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CeeNU&reg;: 10 mg, 40 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F189559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with fluids on an empty stomach; no food or drink for 2 hours after administration. Administering on an empty stomach will reduce the incidence of nausea and vomiting. Standard antiemetics may be administered if needed. Varying strengths of capsules may be required to obtain necessary dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Do not break capsules; use appropriate precautions (eg, gloves) when handling; avoid exposure to broken capsules.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F189576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of primary and metastatic brain tumors (after surgery and/or radiation therapy); treatment of relapsed or refractory Hodgkin's disease (as part of a combination chemotherapy regimen)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F4044512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of gastric cancer, metastatic melanoma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2136824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lomustine may be confused with bendamustine, carmustine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lomustine should only be administered as a single dose once every 6 weeks; serious errors have occurred when lomustine was inadvertently administered daily.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F189637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea and vomiting, (onset: 3-6 hours after oral administration; duration: &lt;24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Myelosuppression (dose-limiting, delayed, cumulative); leukopenia (65%; nadir: 5-6 weeks; recovery 6-8 weeks); thrombocytopenia (nadir: 4 weeks; recovery 5-6 weeks)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Frequency not defined: Acute leukemia, alkaline phosphatase increased, alopecia, anemia, ataxia, azotemia (progressive), bilirubin increased, blindness, bone marrow dysplasia, disorientation, dysarthria, hepatotoxicity, kidney size decreased, lethargy, optic atrophy, pulmonary fibrosis, pulmonary infiltrates, renal damage, renal failure, stomatitis, transaminases increased, visual disturbances",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F189580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lomustine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F189563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warnings]:  Cumulative and delayed bone marrow suppression, particularly thrombocytopenia and leukopenia, commonly occur; may lead to bleeding and overwhelming infections in an already compromised patient.",
"     </b>",
"     Do not administer courses more frequently than every 6 weeks due to delayed myelotoxicity. Use with caution in patients with depressed platelet, leukocyte or erythrocyte counts. Because bone marrow toxicity is cumulative; dose adjustments should be based on nadir counts from prior dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Reversible hepatotoxicity (transaminase, alkaline phosphatase and bilirubin elevations) has been reported; use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary toxicity: May cause delayed pulmonary toxicity (infiltrates and/or fibrosis); usually related to cumulative doses &gt;1100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     . May be delayed (has been reported up to 17 years after childhood administration in combination with radiation therapy). Patients with baseline below 70% of predicted forced vital capacity or carbon monoxide diffusing capacity are in increased risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal toxicity: Kidney damage has been observed and azotemia, decreased kidney size and renal failure have been reported with long-term use. Use with caution in patients with renal impairment; may require dosage adjustment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancies: Long-term use may be associated with the development of secondary malignancies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration schedule: Lomustine should only be administered as a single dose once every 6 weeks; serious errors have occurred when lomustine was inadvertently administered daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F189633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F189568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F189594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (due to GI irritation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F189571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F189583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects and embryotoxicity have been observed in animal studies. There are no adequate and well-controlled studies in pregnant women. May cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised to avoid pregnancy and should be advised of the potential harm to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F189611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4044513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F189584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with fluids on an empty stomach; no food or drink for 2 hours after administration to decrease nausea.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F189582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (CeeNU Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (20): $211.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (20): $637.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (20): $1212.13",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F189573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count (for at least 6 weeks after dose), hepatic and renal function tests (periodic), pulmonary function tests (baseline and periodic)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F189585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Belustine (ES, FR, HN, IT, RU, TR);",
"     </li>",
"     <li>",
"      C.C.N.U. (ES);",
"     </li>",
"     <li>",
"      CCNU (AE, BH, CY, EG, GB, IL, IQ, IR, JO, KW, LB, LY, OM, PK, QA, SA, SY, TR, YE);",
"     </li>",
"     <li>",
"      Cecenu (BE, DE, GR, NL, PL);",
"     </li>",
"     <li>",
"      CEENU (AR, CN, MX, UY);",
"     </li>",
"     <li>",
"      CeeNU (AU, BF, BJ, CI, CL, ET, GH, GM, GN, HK, KE, LR, MA, ML, MR, MU, MW, NE, NG, NZ, PH, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Ceenu (CZ);",
"     </li>",
"     <li>",
"      Citostal (BR);",
"     </li>",
"     <li>",
"      Lomustine (IN, SE);",
"     </li>",
"     <li>",
"      Lomustine &rdquo;Medac&rdquo; (DK);",
"     </li>",
"     <li>",
"      Lomustinum (PL);",
"     </li>",
"     <li>",
"      Lucostin (AT);",
"     </li>",
"     <li>",
"      Lucostine (FI);",
"     </li>",
"     <li>",
"      Prava (CH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F189562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits DNA and RNA synthesis via carbamylation of DNA polymerase, alkylation of DNA, and alteration of RNA, proteins, and enzymes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F189579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Marrow recovery: ~5-8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses blood-brain barrier to a greater degree than BCNU; CNS concentrations are &ge;50% of plasma concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapidly hepatic via hydroxylation producing at least two active metabolites; enterohepatically recycled",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Parent drug: 16-24 hours; Active metabolite: 16-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Active metabolite: ~3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~50%, as metabolites); feces (&lt;5%); expired air (&lt;10%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 101.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berg SL, Grisell DL, DeLaney TF, et al, &ldquo;Principles of Treatment of Pediatric Solid Tumors,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1991, 38(2):249-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/27/37302/abstract-text/2006077/pubmed\" id=\"2006077\" target=\"_blank\">",
"        2006077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bono VH, &ldquo;Review of Mechanism of Action Studies of the Nitrosoureas,&rdquo;",
"      <i>",
"       Cancer Treat Rep",
"      </i>",
"      , 1976, 60(6):699-702.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/27/37302/abstract-text/182364/pubmed\" id=\"182364\" target=\"_blank\">",
"        182364",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cullinan SA, Moertel CG, Wieand HS, et al, &ldquo;Controlled Evaluation of Three Drug Combination Regimens Versus Fluorouracil Alone for the Therapy of Advanced Gastric Cancer. North Central Cancer Treatment Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1994, 12(2):412-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/27/37302/abstract-text/8113849/pubmed\" id=\"8113849\" target=\"_blank\">",
"        8113849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Federico M, Luminari S, Iannitto E, et al, &ldquo;ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(5):805-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/27/37302/abstract-text/19124807/pubmed\" id=\"19124807\" target=\"_blank\">",
"        19124807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kintzel PE and Dorr RT, \"Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,\"",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1995, 21(1):33-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/27/37302/abstract-text/7859226/pubmed\" id=\"7859226\" target=\"_blank\">",
"        7859226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lakhani S, Selby P, Bliss JM, et al, &ldquo;Chemotherapy for Malignant Melanoma: Combinations and High Doses Produce More Responses Without Survival Benefit,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 1990, 61(2):330-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/27/37302/abstract-text/1690022/pubmed\" id=\"1690022\" target=\"_blank\">",
"        1690022",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee FY, Workman P, Roberts JT, et al, &ldquo;Clinical Pharmacokinetics or Oral CCNU (Lomustine),&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 1985, 14(2):125-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/27/37302/abstract-text/3971475/pubmed\" id=\"3971475\" target=\"_blank\">",
"        3971475",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Medical Research Council Brain Tumor Working Party, &ldquo;Randomized Trial of Procarbazine, Lomustine, and Vincristine in the Adjuvant Treatment of High-Grade Astrocytoma: A Medical Research Council Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(2):509-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/27/37302/abstract-text/11208845/pubmed\" id=\"11208845\" target=\"_blank\">",
"        11208845",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Central Nervous System Cancers,&rdquo; Version 2.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/cns.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oliverio VT, &ldquo;Pharmacology of the Nitrosoureas: An Overview,&rdquo;",
"      <i>",
"       Cancer Treat Rep",
"      </i>",
"      , 1976, 60(6):703-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/27/37302/abstract-text/821608/pubmed\" id=\"821608\" target=\"_blank\">",
"        821608",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pendergrass TW, Milstein JM, Geyer JR, et al, &ldquo;Eight Drugs in One Day Chemotherapy for Brain Tumors: Experience in 107 Children and Rationale for Preradiation Chemotherapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1987, 5(8):1221-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/27/37302/abstract-text/3040919/pubmed\" id=\"3040919\" target=\"_blank\">",
"        3040919",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weiss RB and Issell BF, &ldquo;The Nitrosoureas: Carmustine (BCNU) and Lomustine (CCNU),&rdquo;",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1982, 9(4):313-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/27/37302/abstract-text/6762924/pubmed\" id=\"6762924\" target=\"_blank\">",
"        6762924",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9569 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-E8883028DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_27_37302=[""].join("\n");
var outline_f36_27_37302=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709019\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189599\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189600\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189639\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189604\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189621\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189605\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189606\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528482\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189575\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189559\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803164\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189576\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4044512\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136824\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189637\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189580\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189563\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189633\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189568\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189594\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189571\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189583\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189611\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4044513\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189584\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189582\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189573\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189585\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189562\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189579\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9569\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9569|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/60/8133?source=related_link\">",
"      Lomustine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/34/15910?source=related_link\">",
"      Lomustine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_27_37303="Continuous arteriovenous hemodialysis: Technical considerations";
var content_f36_27_37303=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Continuous arteriovenous hemodialysis: Technical considerations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/27/37303/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/27/37303/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/27/37303/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/27/37303/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/27/37303/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/27/37303/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/27/37303/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous renal replacement therapies (CRRT) involve either dialysis (diffusion-based solute removal) or hemofiltration (convection-based solute and water removal) treatments that operate in a continuous mode [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/1\">",
"     1",
"    </a>",
"    ]. Variations of these techniques may run 12 to 24 hours, particularly during daytime periods of full staffing.",
"   </p>",
"   <p>",
"    The major advantage of continuous therapy is the slower rate of solute or fluid removal per unit of time. Thus, CRRT is generally better tolerated than conventional therapy, since many of the complications of intermittent hemodialysis are related to the rapid rate of solute and fluid loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33174?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One such technique, continuous arteriovenous hemodialysis (CAVHD), may be utilized in the treatment of acute renal failure, particularly in patients who are hemodynamically unstable and hypercatabolic. The technical aspects required to adequately perform CAVHD are reviewed here. A discussion of all continuous renal replacement therapies is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38516?source=see_link\">",
"     \"Continuous renal replacement therapies: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous arteriovenous hemodialysis (CAVHD) was developed to augment the solute clearances obtainable with continuous arteriovenous hemofiltration (CAVH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Although CAVH provides excellent volume control, solute clearances are frequently insufficient to provide satisfactory control of azotemia, particularly in hypercatabolic patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/40/28295?source=see_link\">",
"     \"Continuous renal replacement therapy in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CAVHD is similar to CAVH with one exception: the addition of the continuous perfusion of dialysate through the hemofilter countercurrent to the direction of blood flow, most commonly at a rate of 1 to 2 liters per hour (",
"    <a class=\"graphic graphic_figure graphicRef51549 \" href=\"mobipreview.htm?23/38/24174\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef75680 \" href=\"mobipreview.htm?12/30/12770\">",
"     figure 2",
"    </a>",
"    ). As a result, the technical requirements for the satisfactory performance of CAVHD are similar to those of CAVH.",
"   </p>",
"   <p>",
"    With CAVHD, blood flow through the extracorporeal circuit is driven by the gradient between the mean systemic arterial and venous pressures. Ultrafiltration is achieved by the use of hemofiltration membranes with high hydraulic permeability. The presence of dialysate in CAVHD augments total solute removal by adding the process of diffusive solute clearance to the convective solute transport of CAVH.",
"   </p>",
"   <p>",
"    The term CAVHD has been applied to two closely related therapies: continuous arteriovenous hemodiafiltration (CAVHDF) as well as continuous arteriovenous hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In continuous arteriovenous hemodialysis, ultrafiltration is limited to the rate at which net fluid removal is desired and no intravenous fluid replacement is required.",
"     </li>",
"     <li>",
"      In CAVHDF, ultrafiltration is maximized and the excess fluid removed is replaced with intravenous fluid.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice of CAVHD or CAVHDF to treat patients with acute renal failure is largely a matter of personal preference. By combining convective and diffusive solute clearance, CAVHDF provides modestly augmented solute clearance at any given dialysate flow rate as compared with CAVHD. Improved clearance of \"middle\" molecular weight substances is a theoretical, although not clinically proven, benefit of convective therapy. This benefit is balanced by the increased technical complexity and nursing effort necessitated by the continuous monitoring and replacement of large volumes of ultrafiltrate required with CAVHDF.",
"   </p>",
"   <p>",
"    Nevertheless, CAVHD, of either type, has largely been supplanted by continuous venovenous hemodialysis (CVVHD). Unlike CAVHD, blood flow with CVVHD does not depend upon mean arterial pressure since a blood pump is utilized, thereby providing a higher and more constant blood flow. Although solute removal during CVVHD is independent of blood flow (for blood flows greater than 100",
"    <span class=\"nowrap\">",
"     mL/minute",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/5\">",
"     5",
"    </a>",
"    ]), more stable solute clearances are ensured when such higher blood flow rates are consistently provided. In addition, the venovenous system eliminates the risks associated with prolonged, large-bore arterial catheters. However, the use of a venovenous system mandates increased technological complexity, including blood pumps, air detectors, and pressure monitors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20935?source=see_link\">",
"     \"Continuous venovenous hemodialysis: Technical considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VASCULAR ACCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for adequate angioaccess is one of the major issues in continuous arteriovenous renal replacement therapy. An ideal access for CAVHD would provide optimal blood flow (by maximizing the arteriovenous pressure gradient and minimizing hydraulic resistance), be biocompatible (thereby minimizing the risk of clotting), and have a low risk of causing vascular injury.",
"   </p>",
"   <p>",
"    The most common route for angioaccess is percutaneous cannulation of a large caliber artery and vein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/6\">",
"     6",
"    </a>",
"    ]. Most commonly, the femoral vessels are cannulated, but the brachial and axillary vessels may also be utilized. To minimize the resistance to flow, short (80 to 100 mm), wide-bore (8 French) end-hole catheters should be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/51/26424?source=see_link\">",
"     \"Arterial catheterization techniques for invasive monitoring\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To minimize complications, the patient should be closely monitored for any evidence of hemorrhage, ischemia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    atheroemboli. If the femoral vessels are utilized, the patient must remain supine.",
"   </p>",
"   <p>",
"    The reported complication rate from arterial cannulation for arteriovenous renal replacement therapies ranges between 3 and 28 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]; complications may include arteriovenous fistula, arterial embolization, pseudoaneurysm, arterial hemorrhage, and infection.",
"   </p>",
"   <p>",
"    Scribner or Buselmeir shunts in the arm or leg may also be utilized for angioaccess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/6,7,10\">",
"     6,7,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16442?source=see_link\">",
"     \"Overview of central catheters for acute and chronic hemodialysis access\"",
"    </a>",
"    .) Such shunts may work well in younger patients without peripheral artery disease; when placed in elderly patients, however, particularly those with peripheral artery disease, blood flow may be inadequate and the risk of distal ischemia is increased. Other drawbacks include the need for surgical insertion and high infection and dislodgement rates. These shunts are therefore infrequently used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HEMOFILTER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The artificial kidney device used for CAVHD is usually referred to as a \"hemofilter\", although the term \"hemodialyzer\" may also apply for devices with membrane structures conducive to diffusive transport. There are several considerations for the selection of a hemofilter for CAVHD; these principally include the ability to provide adequate blood flows, ultrafiltration capacity, and biocompatibility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Determinants of blood flow and solute removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;To maintain adequate flow through the extracorporeal circuit, resistance within the hemofilter should be minimized. The two principal types of hemofilters are flat plate and hollow fiber filters. Since flat plate hemofilters have less resistance to flow, they exhibit less of a pressure drop from the arterial to venous end (relative to membrane surface area) compared with hollow fiber filters.",
"   </p>",
"   <p>",
"    Fiber configuration has a significant impact upon the characteristics of hemofilters. As an example, shorter filters with a higher fiber number provide a greater cross-sectional area and permit higher blood flow at a given arteriovenous pressure gradient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, parallel plate hemofilters have been reported in one study to be associated with better diffusive solute equilibration than hollow fiber hemofilters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/11\">",
"     11",
"    </a>",
"    ]; however, this finding may reflect differences in the intrinsic diffusive permeability of the particular membranes studied rather than the geometry of the filters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ultrafiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of a relatively low surface area and transmembrane pressure, the use of a membrane with a high intrinsic ultrafiltration coefficient is necessary to maintain adequate ultrafiltration rates. Nevertheless, sufficient diffusive clearance can be obtained with most commercially available hemodialyzers and hemofilters, although caution must be employed if using membranes designed exclusively for ultrafiltration, as they may have poor diffusive solute flux [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/5\">",
"     5",
"    </a>",
"    ]. The use of bioincompatible membranes (such as cuprophane) should also be discouraged due to their potential negative impact on the recovery of renal function (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4696?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given these considerations, we recommend the use of synthetic high-flux hemodialysis membranes such as polysulfone membranes. However, in patients being treated concomitantly with angiotensin converting enzyme inhibitors, AN69 membranes should be avoided because of an increased risk of anaphylactoid reactions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/12/4295?source=see_link\">",
"     \"Reactions to the hemodialysis membrane\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIALYSATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;With CAVHD, solute removal occurs primarily by diffusion since uremic solutes diffuse down a concentration gradient from the blood to the dialysate. The degree of solute equilibration is dependent primarily upon the dialysate flow rate, with near complete equilibration at low flow rates; decreased equilibration occurs as dialysate inflow increases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/5\">",
"     5",
"    </a>",
"    ]. Similarly, normal blood solutes will diffuse along their concentration gradients from blood to dialysate or from dialysate to blood. The composition of the dialysis fluid should therefore approximate the desired plasma concentration.",
"   </p>",
"   <p>",
"    Although dialysate does not come into direct contact with blood, bacteriologic sterility is an important concern. Given the low blood-side pressures, back-filtration (dialysate to blood) may readily occur, particularly with high permeability membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/12\">",
"     12",
"    </a>",
"    ]. While the hemofilter membrane prevents bacterial migration from the dialysate into the blood, febrile reactions, as have been associated with elevated bacterial counts during conventional dialysis, are a theoretical concern if non-sterile dialysate is utilized. However, this complication has not been reported in CAVHD since only sterile solutions are utilized.",
"   </p>",
"   <p>",
"    A variety of commercially available solutions have been used as dialysate for CAVHD. Early descriptions utilized peritoneal dialysis solution containing 1.5 percent dextrose as dialysate. Although necessary to generate the osmotic gradient for ultrafiltration in peritoneal dialysis, the high glucose concentration in this fluid contributed to the development of hyperglycemia. For this reason a modified solution with a reduced glucose concentration were developed and are now commercially available.",
"   </p>",
"   <p>",
"    Initially, commercially manufactured solutions for CRRT were lactate-buffered since bicarbonate, the physiologic buffer, is unstable in solution when stored for prolonged periods in gas-permeable infusion bags; such solutions may form insoluble precipitates when combined with magnesium and calcium.",
"   </p>",
"   <p>",
"    Sterile bicarbonate-buffered dialysate may be prepared by the admixture of intravenous solutions to achieve final concentrations (",
"    <a class=\"graphic graphic_table graphicRef75357 \" href=\"mobipreview.htm?12/26/12715\">",
"     table 1",
"    </a>",
"    ). Alternatively, the preparation of filtered bicarbonate-buffered dialysate, prepared using a single-pass hemodialysis machine followed by back filtration across a high-flux dialyzer has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These approaches have generally been supplanted by the use of commercially marketed bicarbonate-buffered fluids for continuous hemodialysis and for hemofiltration that are now available in the United States. They have replaced earlier methods for preparing bicarbonate-buffered fluids for CRRT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Electrolytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the electrolyte composition of dialysate for CAVHD should approximate that of normal plasma water, the exact composition should be individualized to treat specific electrolyte derangements. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increasing or decreasing the sodium concentration helps correct hyponatremia and hypernatremia, respectively.",
"     </li>",
"     <li>",
"      The potassium concentration may be adjusted to treat hyper- and hypokalemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If regional citrate anticoagulation is utilized (see below), the dialysate sodium concentrations may need to be reduced to compensate for the infusion of hypernatremic sodium citrate. In addition, the dialysate must be calcium-free to permit citrate to function as an anticoagulant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Glucose",
"    </span>",
"    &nbsp;&mdash;&nbsp;When peritoneal dialysis solution is used as dialysate, glucose uptake is significant and may result in hyperglycemia. In one study of patients undergoing CAVHD, glucose absorption was 5.8 grams per hour when 1.5 percent dextrose containing dialysate was used at a rate of 1 liter per hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/14\">",
"     14",
"    </a>",
"    ]. Using similar dialysate concentrations and rates of infusion, a second study observed a glucose uptake of 7.3 grams per hour, as well as a linear relationship between dialysis fluid glucose content and glucose uptake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/15\">",
"     15",
"    </a>",
"    ]. Conversely, when glucose-free dialysis solution is employed, there is a net loss of glucose into the dialysate.",
"   </p>",
"   <p>",
"    We therefore recommend the use of dialysis solutions with a glucose concentration of approximately 100 to 200",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    If higher glucose concentrations are utilized, the nutritional support prescription needs to be adjusted, with a reduction of the carbohydrate caloric load based upon the anticipated absorption of glucose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Buffer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dialysis fluid should contain sufficient alkali to buffer metabolic acid production. When bicarbonate containing dialysis fluid is used, the bicarbonate concentration should be sufficiently high to correct preexisting acidosis and to buffer ongoing acid generation, but not to induce a metabolic alkalosis. These goals can generally be achieved at a bicarbonate concentration of 32 to 38",
"    <span class=\"nowrap\">",
"     mEq/L.",
"    </span>",
"    When regional citrate anticoagulation is utilized (see below), the buffer may need to be deleted from the dialysate. In this setting, the citrate infusion provides an alkali load and may result in the development of metabolic alkalosis.",
"   </p>",
"   <p>",
"    When lactate-buffered fluids are used there is a net loss of up to 1000 mmol of bicarbonate per day during therapy. The dialysis fluid must therefore provide enough substrate to replace these losses as well as to buffer ongoing acid production and correct preexisting acidosis.",
"   </p>",
"   <p>",
"    Under normal conditions, a healthy individual is able to metabolize approximately 100 mmol per hour of lactate, thereby generating an equimolar amount of bicarbonate. In acutely ill patients, however, lactate metabolism may be impaired and endogenous lactate production increased as a result of hypoxia, sepsis, or hepatic dysfunction. Lactate accumulation is associated with alterations in the NADH:NAD ratio, increased protein catabolism, increased urea generation, and myocardial depression.",
"   </p>",
"   <p>",
"    However, bicarbonate-buffered fluids may provide a therapeutic advantage even in patients without overt lactate intolerance. In a non-randomized crossover cohort study of 54 patients, better control of systemic acidemia was observed using lactate-free dialysate (bicarbonate concentration 24.4",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    than during CAVHD using lactate-buffered (30",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    dialysate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/16\">",
"     16",
"    </a>",
"    ]. There was also an associated significant mean decline in mean arterial blood pressure (MAP) of 2.7 mmHg as compared to an increase in MAP of 5.8 mmHg during CAVHD using lactate-free dialysate. Increased cardiovascular instability has similarly been observed using lactate-buffered replacement fluids in CVVH as compared to treatment using bicarbonate-buffered replacement fluids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/17\">",
"     17",
"    </a>",
"    ]. Despite these observations, no studies have demonstrated differences in survival or recovery of renal function related to the buffer selection in the absence of underlying lactic acidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Temperature",
"    </span>",
"    &nbsp;&mdash;&nbsp;During CAVHD and CVVHD, the use of room temperature dialysate has been associated with the development of hypothermia; thermal energy loss during treatment may exceed 1000 kilocalories per day. The clinical significance of this hypothermia is unclear; it has been suggested that mild hypothermia may be beneficial, contributing to improvement in hemodynamic stability with continuous therapies as observed with traditional hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24690?source=see_link\">",
"     \"Cool temperature hemodialysis: Hemodynamic effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ANTICOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most commonly, anticoagulation is required to maintain patency of the extracorporeal circuit. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/14/38120?source=see_link\">",
"     \"Hemodialysis anticoagulation\"",
"    </a>",
"    .)&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    is the most commonly utilized anticoagulant. Typically, a bolus dose of 1000 to 2000 units of heparin is administered into the arterial limb of the extracorporeal circuit followed by a continuous infusion of between 300 to 500 units per hour. Therapy is monitored every six to twelve hours using the partial thromboplastin time in the venous limb, with a goal of maintaining a value of 1.5 to 2 times control. The heparin dose should be titrated up in patients with evidence of clotting and may be reduced, or even withheld, in the setting of clinical bleeding or severe thrombocytopenia.",
"   </p>",
"   <p>",
"    Regional citrate anticoagulation has also been successfully utilized in CAVHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/14/38120?source=see_link\">",
"     \"Hemodialysis anticoagulation\"",
"    </a>",
"    .)&nbsp;Sodium citrate is infused into the arterial limb of the extracorporeal circuit to chelate calcium, thereby inhibiting clotting. Intravenous calcium is infused systemically (ie, not through the CAVHD circuit) to maintain a normal systemic ionized serum calcium concentration.",
"   </p>",
"   <p>",
"    The use of citrate anticoagulation may require modification in the composition of the dialysate. If the citrate solution that is utilized is hypertonic, the sodium concentration in the dialysate must be reduced to compensate. Divalent cations are also deleted from the solution. In addition, since citrate provides an alkali load, the concentration of the alkali buffer may need to be reduced or eliminated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OPERATIONAL CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In CAVHD, dialysate flow is relatively low in comparison to blood flow. Typical blood flows are on the order of 60 to 100 mL per minute, while dialysate flow is generally set at",
"    <strong>",
"     1 to 2 liters",
"    </strong>",
"    per hour, corresponding to 17 to 33 mL per minute. As a result, the diffusional clearance of low molecular weight species, such as urea, is dialysate flow limited. This is in contradistinction to conventional hemodialysis, in which dialysate flow is greater than blood flow and diffusional clearance is blood flow limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Setup",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strict sterile procedures must be utilized when priming the lines and dialyzer prior to initiation of the procedure. Heparinized saline (2000",
"    <span class=\"nowrap\">",
"     units/Liter)",
"    </span>",
"    is commonly administered. The manufacturer's instructions, which are unique to the dialyzer and blood lines, should be strictly followed.",
"   </p>",
"   <p>",
"    Because no blood pump is used with CAVHD, the position of the dialyzer with respect to the heart is important. The dialyzer should be placed below the heart, such as attached to a lower extremity, to provide adequate blood flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Solute clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clearance can be calculated on the basis of solute appearance in the dialysate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;K = (QDo x CDo - QDi x CDi) &divide; CB",
"   </p>",
"   <p>",
"    where QDi and QDo are the dialysate flow rates at the inlet and outlet of the hemofilter, respectively; CDi and CDo are the concentrations of a given solute in the dialysate flowing into and out of the hemofilter, respectively; and CB is the concentration of the solute in the blood entering the hemofilter.",
"   </p>",
"   <p>",
"    Since QDo = QDi + QUF, where QUF is the ultrafiltration rate, the equation can be rewritten as:",
"   </p>",
"   <p>",
"    &nbsp;K = [QDi x (CDo &ndash; CDi) &divide; CB] + (QUF x CDo) &divide; CB",
"   </p>",
"   <p>",
"    If the solute is not present in the dialysate flowing into the hemofilter, CDi = 0, the equation can be further simplified to the following:",
"   </p>",
"   <p>",
"    &nbsp;K = (QDi x CDo &divide; CB) + (QUF x CDo &divide; CB)",
"   </p>",
"   <p>",
"    where the first term represents diffusional clearance and the second term convective clearance.",
"   </p>",
"   <p>",
"    When ultrafiltration is small in comparison to the dialysate flow rate, as is the case in CAVHD, clearance is primarily dependent upon the product of dialysate flow rate and the degree of equilibration between dialysate and blood. Although there is a decline in dialysate equilibration as dialysate flow increases, this change is small relative to the change in dialysate flow, and clearance increases as a function of dialysate flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/5\">",
"     5",
"    </a>",
"    ]. Increasing dialysate flow rate to 4 liters per hour (67",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    results in a urea clearance of 40 to 50 mL per minute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the relationship between dialysate flow and solute clearance, the impact of blood flow on solute clearance is small. When dialysate flow is 1 liter per hour (17",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    urea clearance is independent of blood flow at flow rates greater than 50 mL per minute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/20\">",
"     20",
"    </a>",
"    ]. Similarly, there is no significant increase in urea clearance in CVVHD when dialysate flow is 2 liters per hour (33",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    and blood flow is increased above 100 mL per minute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/5\">",
"     5",
"    </a>",
"    ]. However, when pumped systems are used, such as in CVVHD, blood-flow dependence may be observed as dialysate flow rate is increased.",
"   </p>",
"   <p>",
"    In CAVHDF, higher ultrafiltration rates are employed, thereby increasing convective solute flux at the expense of a need for intravenous fluid replacement. The impact of the increase in convective clearance on diffusive flux is complex: small increases in ultrafiltration may reduce the unstirred layer adjacent to the hemofilter membrane and augment diffusion whereas greater increments in convection may result in decreased diffusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Ultrafiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrafiltration is increased by maneuvers that increase transmembrane pressure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Negative pressure in the dialysate compartment may be augmented by lowering of the dialysate drain bag (creating a siphoning effect) or by applying suction to the dialysate drain line.",
"     </li>",
"     <li>",
"      Positive pressure in the blood compartment can be increased by enhancing venous resistance (eg, partially occluding the venous return line, in which increasing pressure will decrease blood flow) or by the addition of a pre-filter blood pump.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple complications may occur with CAVHD; these include hypotension, bleeding, clotting of the dialyzer, access-related difficulties, and electrolyte and fluid imbalance. Since many of these problems are shared among the continuous renal replacement therapies, a discussion of their diagnosis and management is presented separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DOSE OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal dose of therapy in continuous renal replacement therapy, particularly relating to continuous arteriovenous hemodialysis, has not been determined. A study of different doses of continuous venovenous hemofiltration (CVVH) found an improved survival when higher solute clearance rates were achieved by increasing the ultrafiltration rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/22\">",
"     22",
"    </a>",
"    ]. Survival at 15 days after stopping hemofiltration was 41, 47, and 58 percent in patients in whom the ultrafiltration rate was 20, 35, and 45",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour, respectively. A similar improvement in survival was observed when CVVH at 25",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour was compared to CVVHDF with an ultrafiltration rate of 24",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour and dialysate flow rate of 18",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour (total effluent flow rate of 42",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of these small single center studies were not confirmed, however, in two large multicenter randomized controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     VA/NIH",
"    </span>",
"    Acute Renal Failure Trial Network (ATN) study which compared outcomes with two dosing strategies in 1124 patients, found that more intensive renal support beyond that obtained with standard CRRT (with an effluent flow rate of 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour) does not improve clinical outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/24\">",
"     24",
"    </a>",
"    ]. Similarly, the RENAL study conducted in Australia and New Zealand found no improvement in survival at 90 days when CVVHDF was provided at 40",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour as compared to 25",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour in 1508 critically ill patients with acute kidney injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37303/abstract/25\">",
"     25",
"    </a>",
"    ]. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25513?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Continuous renal replacement therapies (CRRT) involve either dialysis or hemofiltration treatments that operate in a continuous mode. The major advantage of continuous therapy is the slower rate of solute or fluid removal per unit of time. One such technique, continuous arteriovenous hemodialysis (CAVHD), may be utilized in the treatment of acute renal failure, particularly in patients who are hemodynamically unstable and hypercatabolic. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CAVHD was developed to augment the dose of therapy that could be provided with continuous arteriovenous hemofiltration (CAVH) by the addition of countercurrent dialysate flow. The term CAVHD has been applied to two closely related therapies: continuous arteriovenous hemodiafiltration (CAVHDF) as well as continuous arteriovenous hemodialysis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of CAVHD or CAVHDF to treat patients with acute renal failure is largely a matter of personal preference. Nevertheless, CAVHD, of either type, has largely been supplanted by continuous venovenous hemodialysis (CVVHD). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Technical considerations of CAVHD include issues related to vascular access, hemofilter, dialysate, anticoagulation, operational characteristics, complications, and dose of therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Vascular access'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/1\">",
"      Manns M, Sigler MH, Teehan BP. Continuous renal replacement therapies: an update. Am J Kidney Dis 1998; 32:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/2\">",
"      Geronemus R, Schneider N. Continuous arteriovenous hemodialysis: a new modality for treatment of acute renal failure. Trans Am Soc Artif Intern Organs 1984; 30:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/3\">",
"      Ronco C, Bragantini L, Brendolan A, et al. Arteriovenous hemodiafiltration (AVHDF) combined with continuous arteriovenous hemofiltration (CAVH). Trans Am Soc Artif Intern Organs 1985; 31:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/4\">",
"      Ronco C, Bellomo R. Basic mechanisms and definitions for continuous renal replacement therapies. Int J Artif Organs 1996; 19:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/5\">",
"      Relton S, Greenberg A, Palevsky PM. Dialysate and blood flow dependence of diffusive solute clearance during CVVHD. ASAIO J 1992; 38:M691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/6\">",
"      Uldall, R. Vascular access for continuous renal replacement therapy. Semin Dial 1996; 9:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/7\">",
"      Ronco C. Continuous renal replacement therapies in the treatment of acute renal failure in intensive care patients. Part 1. Theoretical aspects and techniques. Nephrol Dial Transplant 1994; 9 Suppl 4:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/8\">",
"      Tominaga GT, Ingegno M, Ceraldi C, Waxman K. Vascular complications of continuous arteriovenous hemofiltration in trauma patients. J Trauma 1993; 35:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/9\">",
"      Bellomo R, Parkin G, Love J, Boyce N. A prospective comparative study of continuous arteriovenous hemodiafiltration and continuous venovenous hemodiafiltration in critically ill patients. Am J Kidney Dis 1993; 21:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/10\">",
"      Alarabi A, Eklund T, Claesson K, et al. Experience with vascular access for acute renal failure: using Buselmeier shunt and femoral vessel catheter. Nephron 1991; 58:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/11\">",
"      Yohay DA, Butterly DW, Schwab SJ, Quarles LD. Continuous arteriovenous hemodialysis: effect of dialyzer geometry. Kidney Int 1992; 42:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/12\">",
"      Golper TA, Leone M. Backtransport of dialysate solutes during in vitro continuous arteriovenous hemodialysis. Blood Purif 1989; 7:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/13\">",
"      Leblanc M, Moreno L, Robinson OP, et al. Bicarbonate dialysate for continuous renal replacement therapy in intensive care unit patients with acute renal failure. Am J Kidney Dis 1995; 26:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/14\">",
"      Bellomo R, Martin H, Parkin G, et al. Continuous arteriovenous haemodiafiltration in the critically ill: influence on major nutrient balances. Intensive Care Med 1991; 17:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/15\">",
"      Bonnardeaux A, Pichette V, Ouimet D, et al. Solute clearances with high dialysate flow rates and glucose absorption from the dialysate in continuous arteriovenous hemodialysis. Am J Kidney Dis 1992; 19:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/16\">",
"      McLean AG, Davenport A, Cox D, Sweny P. Effects of lactate-buffered and lactate-free dialysate in CAVHD patients with and without liver dysfunction. Kidney Int 2000; 58:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/17\">",
"      Barenbrock M, Hausberg M, Matzkies F, et al. Effects of bicarbonate- and lactate-buffered replacement fluids on cardiovascular outcome in CVVH patients. Kidney Int 2000; 58:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/18\">",
"      Yagi N, Leblanc M, Sakai K, et al. Cooling effect of continuous renal replacement therapy in critically ill patients. Am J Kidney Dis 1998; 32:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/19\">",
"      Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 1990; 38:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/20\">",
"      Sigler MH, Teehan BP. Solute transport in continuous hemodialysis: a new treatment for acute renal failure. Kidney Int 1987; 32:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/21\">",
"      Pichette V, Leblanc M, Bonnardeaux A, et al. High dialysate flow rate continuous arteriovenous hemodialysis: a new approach for the treatment of acute renal failure and tumor lysis syndrome. Am J Kidney Dis 1994; 23:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/22\">",
"      Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000; 356:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/23\">",
"      Saudan P, Niederberger M, De Seigneux S, et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney Int 2006; 70:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/24\">",
"      VA/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH, et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008; 359:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37303/abstract/25\">",
"      RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009; 361:1627.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1889 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-E57427EB1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_27_37303=[""].join("\n");
var outline_f36_27_37303=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VASCULAR ACCESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HEMOFILTER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Determinants of blood flow and solute removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ultrafiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIALYSATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Electrolytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Glucose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Buffer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Temperature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OPERATIONAL CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Setup",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Solute clearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Ultrafiltration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DOSE OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1889\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1889|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/38/24174\" title=\"figure 1\">",
"      Schematic of CAVHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/30/12770\" title=\"figure 2\">",
"      Circuitry of CAVHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1889|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/26/12715\" title=\"table 1\">",
"      Bicarbonate buffered dialysate",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/51/26424?source=related_link\">",
"      Arterial catheterization techniques for invasive monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38516?source=related_link\">",
"      Continuous renal replacement therapies: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/40/28295?source=related_link\">",
"      Continuous renal replacement therapy in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20935?source=related_link\">",
"      Continuous venovenous hemodialysis: Technical considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24690?source=related_link\">",
"      Cool temperature hemodialysis: Hemodynamic effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/14/38120?source=related_link\">",
"      Hemodialysis anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16442?source=related_link\">",
"      Overview of central catheters for acute and chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/12/4295?source=related_link\">",
"      Reactions to the hemodialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25513?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33174?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4696?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_27_37304="Paraneoplastic syndromes affecting peripheral nerve and muscle";
var content_f36_27_37304=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Paraneoplastic syndromes affecting peripheral nerve and muscle",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/27/37304/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/27/37304/contributors\">",
"     Josep Dalmau, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/27/37304/contributors\">",
"     Myrna R Rosenfeld, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/27/37304/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/27/37304/contributors\">",
"     Jerome B Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/27/37304/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/27/37304/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/27/37304/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic neurologic syndromes are a heterogeneous group of neurologic disorders associated with systemic cancer and caused by mechanisms other than metastases, metabolic and nutritional deficits, infections, coagulopathy, or side effects of cancer treatment. These syndromes may affect any part of the nervous system from cerebral cortex to neuromuscular junction and muscle, either damaging one area or multiple areas.",
"   </p>",
"   <p>",
"    This topic will review those syndromes affecting peripheral nerve and muscle. An overview of paraneoplastic syndromes other paraneoplastic disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40968?source=see_link\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6583?source=see_link\">",
"     \"Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/22/26983?source=see_link\">",
"     \"Paraneoplastic cerebellar degeneration\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/56/906?source=see_link\">",
"     \"Paraneoplastic and autoimmune encephalitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/4/7239?source=see_link\">",
"     \"Paraneoplastic visual syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PERIPHERAL NERVE SYNDROMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Subacute sensory neuronopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subacute sensory neuronopathy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6583?source=see_link&amp;anchor=H8#H8\">",
"     \"Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia\", section on 'Subacute sensory neuronopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chronic sensorimotor neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic sensorimotor neuropathy is common in cancer patients. Approximately 10 to 15 percent of patients with solid tumors develop a clinically apparent paraneoplastic sensorimotor neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], while up to 35 to 50 percent have subclinical abnormalities demonstrable on electrodiagnostic testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/3\">",
"     3",
"    </a>",
"    ]. Symptoms typically develop in patients with advanced disease, well after the diagnosis of malignancy has been made. Most affected patients have lung cancer. Some believe the neuropathy may be nutritional [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with chronic sensorimotor neuropathy are not very debilitated by their neurologic symptoms, which typically consist of mild to moderate distal symmetric sensorimotor deficits. Nerve conduction studies are consistent with an axonal neuropathy, but decreased conduction velocities such as with demyelination may be seen. The differential diagnosis includes side effects of cancer treatment and disorders unrelated to malignancy such as diabetes, alcoholism, and vitamin B12 deficiency. Anti-ganglioside antibodies have been identified in some patients; because they are also found in patients with non-paraneoplastic neuropathy, they are of uncertain significance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with paraneoplastic sensorimotor neuropathy may harbor anti-CV2 (or CRMP5) antibodies; these antibodies usually associate with SCLC or thymoma. Electrophysiological studies show axonal-neuronal or mixed axonal-demyelinating features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/6\">",
"     6",
"    </a>",
"    ]. These neuropathies are very disabling and respond poorly to immunotherapy or treatment of the tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Association with plasma cell dyscrasias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 percent of patients with chronic sensorimotor neuropathy of unknown origin have a monoclonal gammopathy, including monoclonal gammopathy of undetermined significance (MGUS), primary amyloidosis (amyloid AL), multiple myeloma, Waldenstr&ouml;m&rsquo;s macroglobulinemia, or the POEMS syndrome (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Familial forms have been described, occasionally in association with antibodies directed against myelin-associated glycoprotein (MAG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with a monoclonal gammopathy and neuropathy are a particular challenge, as 25 percent ultimately develop a hematologic malignancy. In a study of 104 patients with MGUS and neuropathy, 22 percent were found to have a malignancy, including lymphoma, multiple myeloma, plasmacytoma, and POEMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/10\">",
"     10",
"    </a>",
"    ]. Risk factors for malignancy included weight loss, progression of the neuropathy, and an M-protein level &gt;1",
"    <span class=\"nowrap\">",
"     g/L.",
"    </span>",
"    These factors and unexplained fever or night sweats were also found to be associated with the subsequent diagnosis of malignancy in a prospective follow-up study of 176 patients with MGUS and neuropathy who were free of malignancy at study onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/11\">",
"     11",
"    </a>",
"    ]. In approximately two-thirds of the patients, treatment of the malignancy is associated with improvement of the neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Four syndromes of plasma cell dyscrasias with associated neuropathy are described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteolytic myeloma without amyloidosis &mdash; Fewer than 10 percent of patients with classic osteolytic myeloma develop a neuropathy that is not related to amyloidosis. Plasma exchange has no consistent effect on the neuropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35034?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Neurologic disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Amyloid neuropathy &mdash; Symptoms associated with amyloid neuropathy include numbness in the feet and hands, lancinating electrical sensations, burning and aching pains, predominant loss of thermal sensation in the distal limbs, and signs of autonomic dysfunction (postural hypotension, diarrhea, impotence, and bladder dysfunction). Treatment of the underlying plasma cell dyscrasia produces little improvement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/12\">",
"       12",
"      </a>",
"      ], but stem cell transplantation may be beneficial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/9/35994?source=see_link&amp;anchor=H15769190#H15769190\">",
"       \"Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\", section on 'Hematopoietic cell transplantation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Osteosclerotic",
"      <span class=\"nowrap\">",
"       myeloma/POEMS",
"      </span>",
"      syndrome &mdash; Approximately 3 percent of myelomas are associated with osteosclerotic lesions involving the axial skeleton (vertebral bodies and proximal long bones), and 75 percent of these patients have a slowly progressive sensorimotor polyneuropathy with a subacute or chronic onset that resembles a chronic inflammatory demyelinating polyneuropathy on electrophysiologic testing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/7,8,14\">",
"       7,8,14",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      These patients may also have other abnormalities as indicated by the mnemonic POEMS (",
"      <strong>",
"       p",
"      </strong>",
"      olyneuropathy,",
"      <strong>",
"       o",
"      </strong>",
"      rganomegaly [lymphadenopathy, hepatosplenomegaly],",
"      <strong>",
"       e",
"      </strong>",
"      ndocrinopathy,",
"      <strong>",
"       m",
"      </strong>",
"      onoclonal protein, and",
"      <strong>",
"       s",
"      </strong>",
"      kin changes) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/15\">",
"       15",
"      </a>",
"      ]. The neuropathy often improved with irradiation of the bone lesions, or with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      alone or in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/14/35049?source=see_link\">",
"       \"POEMS syndrome\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Up to 50 percent of patients with the POEMS syndrome also have multicentric Castleman's disease, itself associated with a number of malignancies, including Kaposi's sarcoma and various types of non-Hodgkin lymphoma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/51/6970?source=see_link\">",
"       \"Castleman's disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Waldenstr&ouml;m&rsquo;s macroglobulinemia &mdash; Patients with Waldenstr&ouml;m&rsquo;s macroglobulinemia may develop a predominantly demyelinating sensorimotor neuropathy. The presenting symptoms include sensory deficits in the feet, followed by weakness, and foot drop with an abnormal gait; involvement of the upper extremities occurs in the later stages of the disease. In some patients, the IgM paraprotein has reactivity against myelin-associated glycoprotein (MAG), but the pathogenetic significance of these antibodies is uncertain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/17\">",
"       17",
"      </a>",
"      ]. Plasma exchange, the use of intravenous immune globulin, and treatment of the primary disease may produce short-term relief",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      slow the progression of symptoms (",
"      <a class=\"graphic graphic_table graphicRef54804 \" href=\"mobipreview.htm?7/59/8125\">",
"       table 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link\">",
"       \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Acute sensorimotor neuropathy (GBS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once limited to acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and the Miller Fisher variant, Guillain-Barr&eacute; syndrome (GBS) now also includes acute motor axonal neuropathy (AMAN) and acute motor sensory axonal neuropathy (AMSAN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/20\">",
"     20",
"    </a>",
"    ]. Hodgkin lymphoma is the cancer most often associated with GBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]; the relationship to other malignancies is less clear. Nine of 435 GBS patients developed cancer in the six months preceding or following the neurologic disorder in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/22\">",
"     22",
"    </a>",
"    ]. Using a local database for cancer incidence, the number of cancer cases was significantly higher than expected in patients with GBS. Five patients had electrophysiological findings consistent with AIDP, two with AMAN, one with AMSAN, and one was not characterized. Three patients had non-SCLC, and one each chronic lymphocytic leukemia, Hodgkin lymphoma, metastatic disease of unknown primary, kidney, esophageal, and vocal cord cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of GBS, regardless of the presence of cancer, includes plasma exchange and intravenous immune globulin&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/23\">",
"     23",
"    </a>",
"    ]. Response to therapy is similar to that seen in patients without associated cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/265?source=see_link\">",
"     \"Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Paraneoplastic autonomic neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic autonomic dysfunction frequently accompanies other paraneoplastic symptoms, including encephalomyelitis and sensory neuronopathy, but it can be the only manifestation of an underlying malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/24\">",
"     24",
"    </a>",
"    ]. Autonomic dysfunction is associated with a variety of symptoms, including hypothermia, hypoventilation, sleep apnea, gastroparesis, intestinal pseudo-obstruction, and cardiac arrhythmias that can lead to sudden death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/25\">",
"     25",
"    </a>",
"    ]. Signs of sympathetic hyperactivity, such as excessive spontaneous sweating, may occur as a true paraneoplastic phenomenon or from local infiltration of sympathetic nerves by the tumor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7226?source=see_link\">",
"     \"Malignancy-associated gastroparesis: Pathophysiology and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The tumor most frequently involved is SCLC; these patients usually have anti-Hu antibodies. Other tumors include carcinoma of the pancreas, thyroid, and rectum, Hodgkin lymphoma, and carcinoid tumors of the lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/24,26,27\">",
"     24,26,27",
"    </a>",
"    ]. Some of these patients have antibodies against ganglionic acetylcholine receptors (AChR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/26\">",
"     26",
"    </a>",
"    ]. While the pathogenetic significance of these antibodies in humans remains uncertain, immunization of rabbits with recombinant alpha-3 AchR subunits causes a syndrome with marked similarity to systemic autonomic dysfunction, with mydriasis, intestinal pseudo-obstruction, and urinary bladder dilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Along with antitumor treatment, immune therapy may be tried, although symptoms often do not improve (",
"    <a class=\"graphic graphic_table graphicRef54804 \" href=\"mobipreview.htm?7/59/8125\">",
"     table 1",
"    </a>",
"    ). However, in one series of three patients with nonparaneoplastic autonomic neuropathy and antibodies to ganglionic AChR, combined immunosuppressive treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil along with plasmapheresis provided substantive and sustained clinical improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Paraneoplastic peripheral nerve vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A paraneoplastic peripheral nerve vasculitis typically presents with painful, asymmetrical sensorimotor deficits resembling a mononeuritis multiplex and, in some patients, proximal motor weakness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/30\">",
"     30",
"    </a>",
"    ]. The diagnosis is confirmed by biopsy, which shows a predominantly mononuclear infiltrate in small-sized vessels in the absence of necrosis and malignant cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnosis of the vasculitis usually precedes the discovery of a cancer. The tumors most frequently involved are cancer of the lung (usually SCLC), prostate, endometrium, and both Hodgkin's and non-Hodgkin lymphomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other vasculitides that are not associated with cancer, the administration of corticosteroids or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    may lead to improvement in symptoms (",
"    <a class=\"graphic graphic_table graphicRef54804 \" href=\"mobipreview.htm?7/59/8125\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/30,32,34\">",
"     30,32,34",
"    </a>",
"    ]. Treatment of the tumor may also improve the neurologic disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MUSCLE FUNCTION SYNDROMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Myasthenia gravis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myasthenia gravis is characterized by the development of autoantibodies directed against the acetylcholine receptor (AChR). Approximately 75 percent of patients have thymic disease, most of whom have thymic hyperplasia, but about 10 percent have a thymic epithelial tumor (",
"    <a class=\"graphic graphic_table graphicRef77919 \" href=\"mobipreview.htm?31/60/32717\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31287?source=see_link\">",
"     \"Pathogenesis of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/17/8474?source=see_link\">",
"     \"Clinical presentation and management of thymoma and thymic carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with thymoma often have additional antibodies against skeletal muscle proteins such as titin and others. Contrary to early reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/36\">",
"     36",
"    </a>",
"    ], titin antibodies have limited value in predicting thymoma in patients with myasthenia gravis. In contrast, anti-cytokine antibodies (anti-IFN-gamma, anti-IL2) are more useful in predicting thymoma or tumor recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/37\">",
"     37",
"    </a>",
"    ]. Anti-muscle-specific receptor tyrosine kinase (MuSk) antibodies do not associate with thymoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/38\">",
"     38",
"    </a>",
"    ]. Myasthenia gravis has occasionally been associated with other tumors (SCLC, thyroid, and breast cancers, and Hodgkin lymphoma) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of myasthenia gravis, which often includes thymectomy even if a thymoma is not present, is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7066?source=see_link\">",
"     \"Treatment of myasthenia gravis\"",
"    </a>",
"    .) The presence of a thymoma does not necessarily indicate a poorer outcome from myasthenia therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lambert-Eaton myasthenic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Lambert-Eaton myasthenic syndrome (LEMS) shares the same site of involvement (ie, the neuromuscular junction) with myasthenia gravis, and it is associated with similar pathophysiology (ie, an autoimmune disease usually associated with malignancy). Antibodies directed against the voltage-gated calcium channel play a central role in the pathophysiology of LEMS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/9/35992?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical presentation of LEMS is markedly different from that of myasthenia gravis. The gradual onset of hip girdle weakness is typically an early symptom of LEMS. Less dramatic shoulder girdle weakness eventually occurs. The motor weakness tends to progress in a caudocranial direction with decreased or absent reflexes. Less common presenting symptoms in LEMS include generalized weakness, myalgias and muscle stiffness, and upper extremity weakness. Autonomic dysfunction, consisting of erectile impotence in men or dry mouth, is a frequent finding in LEMS. When oculobulbar symptoms occur in LEMS, they are typically less severe than in myasthenia gravis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/9/35992?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 50 percent of patients with LEMS have cancer, almost always a SCLC (",
"    <a class=\"graphic graphic_table graphicRef54804 \" href=\"mobipreview.htm?7/59/8125\">",
"     table 1",
"    </a>",
"    ). As is often seen with paraneoplastic neurologic syndromes, the neurologic symptoms usually precede the detection of the neoplasm. Some patients have combined paraneoplastic cerebellar degeneration and LEMS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/22/26983?source=see_link\">",
"     \"Paraneoplastic cerebellar degeneration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, effective antitumor treatment usually results in neurologic improvement. Symptomatic therapies for LEMS include medications that increase the amount of acetylcholine available at the postsynaptic membrane. These are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/5/31826?source=see_link\">",
"     guanidine",
"    </a>",
"    , aminopyridines such as 3,4-diaminopyridine (3,4-DAP), and acetylcholinesterase inhibitors such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    . Immunologic therapies for LEMS include plasma exchange, intravenous immune globulin, and oral immunosuppressive agents. These agents are thought to dampen the aberrant immune response that causes LEMS by reducing the antibodies directed at voltage-gated calcium channels in the presynaptic terminal of the neuromuscular junction.",
"   </p>",
"   <p>",
"    The approach to the treatment of LEMS is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/43/2744?source=see_link\">",
"     \"Treatment of Lambert-Eaton myasthenic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Dermatomyositis and polymyositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignancy has been associated with two inflammatory myopathies: dermatomyositis and polymyositis. Approximately 9 percent of patients with polymyositis develop a neoplasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/42\">",
"     42",
"    </a>",
"    ]. However, since the diagnosis of a tumor is sometimes made many years before or after the diagnosis of polymyositis, the association may represent a coincidental occurrence rather than a tumor-induced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/42/38566?source=see_link\">",
"     \"Malignancy in dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In comparison, there is probably a real association between dermatomyositis and malignancy. Some studies indicate that by the time the neuromuscular symptoms develop, cancer is identified in about 15 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/42\">",
"     42",
"    </a>",
"    ]. It has been suggested that the risk of malignancy is at its highest within the first two years after diagnosis, and that active tumor surveillance should be performed during this period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/42\">",
"     42",
"    </a>",
"    ]. The risk appears to be higher in women. The most common tumors are cancer of the breast, lung, ovary, and stomach, and non-Hodgkin lymphoma.",
"   </p>",
"   <p>",
"    The diagnosis and treatment of dermatomyositis are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/22/11626?source=see_link\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Paraneoplastic neuromyotonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuromyotonia (Isaacs' syndrome) is characterized by muscle stiffness caused by continuous muscle fiber activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/44\">",
"     44",
"    </a>",
"    ]. The cause of some cases of neuromyotonia was initially thought to be related to antibodies directed against voltage-gated potassium channels (VGKC), either in isolation or as a paraneoplastic process. However, whether these antibodies target VGKC or a related protein remains unknown.",
"   </p>",
"   <p>",
"    Symptoms include undulating muscle twitching during rest (myokymia), cramps, pseudomyotonia (delayed relaxation), increased sweating, and sometimes motor weakness. Intestinal pseudoobstruction occurs rarely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/45\">",
"     45",
"    </a>",
"    ]. The serum creatine kinase concentration may be elevated.",
"   </p>",
"   <p>",
"    Patients with neuromyotonia may develop symptoms of CNS dysfunction, including confusion, memory loss, insomnia, hallucinations, or seizures. The association of neuromyotonia and CNS symptoms is called Morvan's syndrome; it also may occur with antibodies against VGKC-related proteins and, in some patients, is a paraneoplastic manifestation of cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The electrophysiologic hallmark of neuromyotonia is the presence of spontaneous firing of single motor units as doublet, triplet, or multiplet discharges that have a high intraburst frequency and occur at irregular intervals. These motor discharges persist during sleep, general anesthesia, and proximal nerve block, and they may disappear by blocking the neuromuscular junction.",
"   </p>",
"   <p>",
"    The autoimmune basis of this disorder, whether paraneoplastic or otherwise acquired, is suggested by the demonstration of antibodies against voltage-gated potassium channels (",
"    <a class=\"graphic graphic_table graphicRef77919 \" href=\"mobipreview.htm?31/60/32717\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/44,48,49\">",
"     44,48,49",
"    </a>",
"    ]. Thymoma, SCLC, and Hodgkin lymphoma are the most commonly associated neoplasms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/44,50\">",
"     44,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with plasma exchange or intravenous immune globulin is usually of benefit; other potentially effective treatments include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef54804 \" href=\"mobipreview.htm?7/59/8125\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/44,47\">",
"     44,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Acute necrotizing myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic necrotizing myopathy is a rare disorder characterized by symmetric, painful, predominantly proximal weakness leading to severe disability over one to three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/51\">",
"     51",
"    </a>",
"    ]. The serum creatine kinase concentration is markedly elevated, and muscle biopsy shows minimal inflammation, patchy necrosis, and perimysial alkaline phosphatase staining. A number of tumors have been associated with this disorder, primarily cancers of the lung, breast, and gastrointestinal tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients, treatment of the tumor and immunosuppression (corticosteroids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ) result in neurologic improvement (",
"    <a class=\"graphic graphic_table graphicRef54804 \" href=\"mobipreview.htm?7/59/8125\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cachectic myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of cachectic myopathy associated with cancer are similar to those found in other debilitating diseases. Despite diffuse muscle wasting, muscle strength is often preserved until late in the course of the neoplastic disease.",
"   </p>",
"   <p>",
"    Cytokine activation and several tumor-derived and potentially cachexia-inducing substances are thought to play an important role in this process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37304/abstract/52\">",
"     52",
"    </a>",
"    ]. These include tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and proteolysis-inducing factor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17960?source=see_link\">",
"     \"Clinical features and pathogenesis of cancer cachexia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Peripheral nerve syndromes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic sensorimotor neuropathy is common in cancer patients, occurring in approximately 10 to 15 percent of patients with solid tumors. In most cases this is not disabling. Exceptions include those with anti-CV2 (or CRMP5) antibodies that are associated with SCLC or thymoma. Patients with plasma cell dyscrasias may also develop a disabling neuropathy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Chronic sensorimotor neuropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute sensorimotor neuropathy or the Guillain-Barr&eacute; syndrome may occur as a paraneoplastic syndrome, usually in association with Hodgkin lymphoma. Treatment and prognosis is similar to that for GBS that is not associated with cancer. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Acute sensorimotor neuropathy (GBS)'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/265?source=see_link\">",
"       \"Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Paraneoplastic autonomic dysfunction manifests with a variety of symptoms, including dry mouth, blurry vision, erectile dysfunction, hypothermia, hypoventilation, sleep apnea, gastroparesis, intestinal pseudo-obstruction, and cardiac arrhythmias that can lead to sudden death. This syndrome is often associated with SCLC and anti-Hu antibodies. It is often treatment-resistant. Some patients may have ganglionic acetyl choline receptor antibodies (against a3 subunit) and these cases are more responsive to immunotherapy (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Paraneoplastic autonomic neuropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Paraneoplastic peripheral nerve vasculitis typically presents with painful, asymmetrical sensorimotor deficits resembling a mononeuritis multiplex. Biopsy demonstrates the vasculitis. Immunotherapy and antitumor treatment may improve symptoms. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Paraneoplastic peripheral nerve vasculitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Muscle function syndromes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myasthenia gravis and Lambert-Eaton myasthenic syndrome are paraneoplastic disorders affecting the neurotransmission at the neuromuscular junction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31287?source=see_link\">",
"       \"Pathogenesis of myasthenia gravis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7066?source=see_link\">",
"       \"Treatment of myasthenia gravis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/9/35992?source=see_link\">",
"       \"Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/43/2744?source=see_link\">",
"       \"Treatment of Lambert-Eaton myasthenic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dermatomyositis and polymyositis are inflammatory myopathies; an association with malignancy is better associated with the former. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/42/38566?source=see_link\">",
"       \"Malignancy in dermatomyositis and polymyositis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neuromyotonia (Isaacs' syndrome) is characterized by muscle stiffness, muscle twitching during rest (myokymia, fasciculations), cramps, pseudomyotonia (delayed relaxation), increased sweating, and sometimes motor weakness. Electromyography shows muscle fiber activity and motor units with a high intraburst and irregular frequency. Thymoma, SCLC, and Hodgkin lymphoma are the most commonly associated neoplasms. A small subgroup of patients develops antibodies against Caspr2 (previously attributed to VGKC). Treatment with plasma exchange or intravenous immune globulin is usually of benefit. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Paraneoplastic neuromyotonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other muscle disorder syndromes associated with malignancy include acute necrotizing myopathy and cachectic myopathy. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Acute necrotizing myopathy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Cachectic myopathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/1\">",
"      Trojaborg W, Frantzen E, Andersen I. Peripheral neuropathy and myopathy associated with carcinoma of the lung. Brain 1969; 92:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/2\">",
"      Gomm SA, Thatcher N, Barber PV, Cumming WJ. A clinicopathological study of the paraneoplastic neuromuscular syndromes associated with lung cancer. Q J Med 1990; 75:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/3\">",
"      Paul T, Katiyar BC, Misra S, Pant GC. Carcinomatous neuromuscular syndromes. A clinical and quantitative electrophysiological study. Brain 1978; 101:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/4\">",
"      Hawley RJ, Cohen MH, Saini N, Armbrustmacher VW. The carcinomatous neuromyopathy of oat cell lung cancer. Ann Neurol 1980; 7:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/5\">",
"      Antoine JC, Camdessanch&eacute; JP, Ferraud K, Caudie C. Antiganglioside antibodies in paraneoplastic peripheral neuropathies. J Neurol Neurosurg Psychiatry 2004; 75:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/6\">",
"      Antoine JC, Honnorat J, Camdessanch&eacute; JP, et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 2001; 49:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/7\">",
"      Ropper AH, Gorson KC. Neuropathies associated with paraproteinemia. N Engl J Med 1998; 338:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/8\">",
"      Kelly JJ Jr. Peripheral neuropathies associated with monoclonal proteins: a clinical review. Muscle Nerve 1985; 8:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/9\">",
"      Manschot SM, Notermans NC, van den Berg LH, et al. Three families with polyneuropathy associated with monoclonal gammopathy. Arch Neurol 2000; 57:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/10\">",
"      Eurelings M, Notermans NC, Van de Donk NW, Lokhorst HM. Risk factors for hematological malignancy in polyneuropathy associated with monoclonal gammopathy. Muscle Nerve 2001; 24:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/11\">",
"      Eurelings M, Lokhorst HM, Kalmijn S, et al. Malignant transformation in polyneuropathy associated with monoclonal gammopathy. Neurology 2005; 64:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/12\">",
"      Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/13\">",
"      Comenzo RL, Vosburgh E, Simms RW, et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 1996; 88:2801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/14\">",
"      Kelly JJ Jr, Kyle RA, Miles JM, Dyck PJ. Osteosclerotic myeloma and peripheral neuropathy. Neurology 1983; 33:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/15\">",
"      Miralles GD, O'Fallon JR, Talley NJ. Plasma-cell dyscrasia with polyneuropathy. The spectrum of POEMS syndrome. N Engl J Med 1992; 327:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/16\">",
"      Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood 2003; 101:2496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/17\">",
"      Nobile-Orazio E, Marmiroli P, Baldini L, et al. Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins. Neurology 1987; 37:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/18\">",
"      Dalakas MC, Flaum MA, Rick M, et al. Treatment of polyneuropathy in Waldenstr&ouml;m's macroglobulinemia: role of paraproteinemia and immunologic studies. Neurology 1983; 33:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/19\">",
"      Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-Myelin-Associated Glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2003; :CD002827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/20\">",
"      Asbury AK. New concepts of Guillain-Barr&eacute; syndrome. J Child Neurol 2000; 15:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/21\">",
"      Julien J, Vital C, Aupy G, et al. Guillain-Barr&eacute; syndrome and Hodgkin's disease--ultrastructural study of a peripheral nerve. J Neurol Sci 1980; 45:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/22\">",
"      Vigliani MC, Magistrello M, Polo P, et al. Risk of cancer in patients with Guillain-Barr&eacute; syndrome (GBS). A population-based study. J Neurol 2004; 251:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/23\">",
"      Donofrio PD. Immunotherapy of idiopathic inflammatory neuropathies. Muscle Nerve 2003; 28:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/24\">",
"      Veilleux M, Bernier JP, Lamarche JB. Paraneoplastic encephalomyelitis and subacute dysautonomia due to an occult atypical carcinoid tumour of the lung. Can J Neurol Sci 1990; 17:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/25\">",
"      Lennon VA, Sas DF, Busk MF, et al. Enteric neuronal autoantibodies in pseudoobstruction with small-cell lung carcinoma. Gastroenterology 1991; 100:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/26\">",
"      Vernino S, Adamski J, Kryzer TJ, et al. Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology 1998; 50:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/27\">",
"      Horta E, McKeon A, Lennon VA, Benarroch EE. Reversible paraneoplastic tonic pupil with PCA-Tr IgG and Hodgkin lymphoma. Neurology 2012; 78:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/28\">",
"      Lennon VA, Ermilov LG, Szurszewski JH, Vernino S. Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease. J Clin Invest 2003; 111:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/29\">",
"      Gibbons CH, Vernino SA, Freeman R. Combined immunomodulatory therapy in autoimmune autonomic ganglionopathy. Arch Neurol 2008; 65:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/30\">",
"      Oh SJ. Paraneoplastic vasculitis of the peripheral nervous system. Neurol Clin 1997; 15:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/31\">",
"      Vincent D, Dubas F, Hauw JJ, et al. Nerve and muscle microvasculitis in peripheral neuropathy: a remote effect of cancer? J Neurol Neurosurg Psychiatry 1986; 49:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/32\">",
"      Oh SJ, Slaughter R, Harrell L. Paraneoplastic vasculitic neuropathy: a treatable neuropathy. Muscle Nerve 1991; 14:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/33\">",
"      Johnson PC, Rolak LA, Hamilton RH, Laguna JF. Paraneoplastic vasculitis of nerve: a remote effect of cancer. Ann Neurol 1979; 5:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/34\">",
"      Matsumuro K, Izumo S, Umehara F, et al. Paraneoplastic vasculitic neuropathy: immunohistochemical studies on a biopsied nerve and post-mortem examination. J Intern Med 1994; 236:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/35\">",
"      Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/36\">",
"      Wirtz PW, Nijnuis MG, Sotodeh M, et al. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol 2003; 250:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/37\">",
"      Buckley C, Newsom-Davis J, Willcox N, Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? Neurology 2001; 57:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/38\">",
"      Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003; 126:2304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/39\">",
"      Fujita J, Yamadori I, Yamaji Y, et al. Myasthenia gravis associated with small-cell carcinoma of the lung. Chest 1994; 105:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/40\">",
"      Abrey LE. Association of myasthenia gravis with extrathymic Hodgkin's lymphoma: complete resolution of myasthenic symptoms following antineoplastic therapy. Neurology 1995; 45:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/41\">",
"      de Perrot M, Liu J, Bril V, et al. Prognostic significance of thymomas in patients with myasthenia gravis. Ann Thorac Surg 2002; 74:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/42\">",
"      Sigurgeirsson B, Lindel&ouml;f B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992; 326:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/43\">",
"      Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991; 325:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/44\">",
"      Newsom-Davis J, Mills KR. Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature review. Brain 1993; 116 ( Pt 2):453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/45\">",
"      Viallard JF, Vincent A, Moreau JF, et al. Thymoma-associated neuromyotonia with antibodies against voltage-gated potassium channels presenting as chronic intestinal pseudo-obstruction. Eur Neurol 2005; 53:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/46\">",
"      Liguori R, Vincent A, Clover L, et al. Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 2001; 124:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/47\">",
"      Issa SS, Herskovitz S, Lipton RB. Acquired neuromyotonia as a paraneoplastic manifestation of ovarian cancer. Neurology 2011; 76:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/48\">",
"      Vincent A, Jacobson L, Plested P, et al. Antibodies affecting ion channel function in acquired neuromyotonia, in seropositive and seronegative myasthenia gravis, and in antibody-mediated arthrogryposis multiplex congenita. Ann N Y Acad Sci 1998; 841:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/49\">",
"      Newsom-Davis J, Buckley C, Clover L, et al. Autoimmune disorders of neuronal potassium channels. Ann N Y Acad Sci 2003; 998:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/50\">",
"      Walsh JC. Neuromyotonia: an unusual presentation of intrathoracic malignancy. J Neurol Neurosurg Psychiatry 1976; 39:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/51\">",
"      Levin MI, Mozaffar T, Al-Lozi MT, Pestronk A. Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology 1998; 50:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37304/abstract/52\">",
"      Tisdale MJ. Wasting in cancer. J Nutr 1999; 129:243S.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5194 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-B1CD8C1B47-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_27_37304=[""].join("\n");
var outline_f36_27_37304=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PERIPHERAL NERVE SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Subacute sensory neuronopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chronic sensorimotor neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Association with plasma cell dyscrasias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Acute sensorimotor neuropathy (GBS)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Response to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Paraneoplastic autonomic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Response to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Paraneoplastic peripheral nerve vasculitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Response to therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MUSCLE FUNCTION SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lambert-Eaton myasthenic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Paraneoplastic neuromyotonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Response to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Acute necrotizing myopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Response to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cachectic myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Muscle function syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5194\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5194|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/59/8125\" title=\"table 1\">",
"      Treatment of paraneoplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/60/32717\" title=\"table 2\">",
"      Paraneoplastic antibodies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/51/6970?source=related_link\">",
"      Castleman's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/9/35992?source=related_link\">",
"      Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17960?source=related_link\">",
"      Clinical features and pathogenesis of cancer cachexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/17/8474?source=related_link\">",
"      Clinical presentation and management of thymoma and thymic carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/22/11626?source=related_link\">",
"      Initial treatment of dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/42/38566?source=related_link\">",
"      Malignancy in dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7226?source=related_link\">",
"      Malignancy-associated gastroparesis: Pathophysiology and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40968?source=related_link\">",
"      Overview of paraneoplastic syndromes of the nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/14/35049?source=related_link\">",
"      POEMS syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/56/906?source=related_link\">",
"      Paraneoplastic and autoimmune encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/22/26983?source=related_link\">",
"      Paraneoplastic cerebellar degeneration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6583?source=related_link\">",
"      Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/4/7239?source=related_link\">",
"      Paraneoplastic visual syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31287?source=related_link\">",
"      Pathogenesis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/9/35994?source=related_link\">",
"      Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/265?source=related_link\">",
"      Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/43/2744?source=related_link\">",
"      Treatment of Lambert-Eaton myasthenic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7066?source=related_link\">",
"      Treatment of myasthenia gravis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_27_37305="Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')";
var content_f36_27_37305=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/27/37305/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/27/37305/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/27/37305/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/27/37305/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/27/37305/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/27/37305/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/27/37305/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In late March and early April 2009, an outbreak of H1N1 influenza A virus infection was detected in Mexico, with subsequent cases observed in many other countries, including the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In June 2009, the World Health Organization (WHO) raised its pandemic alert level to the highest level, phase 6, indicating widespread community transmission on at least two continents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/3\">",
"     3",
"    </a>",
"    ]. The pandemic was declared to be over in August 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of pandemic H1N1 influenza A virus infection will be reviewed here. The epidemiology, treatment, and prevention of pandemic H1N1 influenza A virus infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/2/31786?source=see_link\">",
"     \"Epidemiology of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38234?source=see_link\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of seasonal and avian (H5N1) influenza viruses are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18456?source=see_link\">",
"     \"Clinical manifestations of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24346?source=see_link\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/4/22599?source=see_link\">",
"     \"Clinical manifestations and diagnosis of avian influenza\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5528?source=see_link\">",
"     \"Diagnosis of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CASE DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following case definitions have been provided by the United States Centers for Disease Control and Prevention (CDC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Influenza-like illness (ILI) is defined as fever (temperature of 100&ordm;F [37.8&ordm;C] or greater) with cough or sore throat in the absence of a known cause other than influenza.",
"     </li>",
"     <li>",
"      A confirmed case of pandemic H1N1 influenza A is defined as an individual with an ILI with laboratory-confirmed H1N1 influenza A virus detection by real-time reverse transcriptase (rRT)-PCR or culture.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEFINITIONS OF ILLNESS SEVERITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Centers for Disease Control and Prevention (CDC) categorized the severity of illness from pandemic H1N1 influenza A as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mild or uncomplicated illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild or uncomplicated illness is characterized by fever, cough, sore throat, rhinorrhea, muscle pain, headache, chills, malaise, and sometimes diarrhea and vomiting, but no shortness of breath and little change in chronic health conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Progressive illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive illness is characterized by typical symptoms plus signs or symptoms, such as chest pain, poor oxygenation (eg, tachypnea, hypoxia, labored breathing in children), cardiopulmonary insufficiency (eg, hypotension), central nervous system (CNS) impairment (eg, confusion, altered mental status), severe dehydration, or exacerbations of chronic conditions (eg, asthma, chronic obstructive pulmonary disease, chronic renal failure, diabetes, or other cardiovascular conditions).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Severe or complicated illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe or complicated illness is characterized by signs of lower respiratory tract disease (eg, hypoxia requiring supplemental oxygen, abnormal chest radiograph, mechanical ventilation), CNS findings (encephalitis, encephalopathy), complications of hypotension (shock, organ failure), myocarditis or rhabdomyolysis, or invasive secondary bacterial infection based on laboratory testing or clinical signs (eg, persistent high fever and other symptoms beyond three days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transmission, incubation period, and duration of shedding of pandemic H1N1 influenza A are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/2/31786?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology of pandemic H1N1 influenza ('swine influenza')\", section on 'Transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5806937\">",
"    <span class=\"h1\">",
"     ASYMPTOMATIC INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study that characterized the household transmission of pandemic H1N1 influenza A, 5 of 53 (9.4 percent) individuals who became infected from cohabitation with a primary case patient had asymptomatic infection that was detected by real-time reverse transcriptase polymerase chain reaction of nasopharyngeal specimens or serology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a serologic study of influenza transmission among 79 household contacts of index case patients during the first wave of pandemic H1N1 influenza infection in New York City, 19 percent had serologically confirmed infection and 28 percent of those who were infected were asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms of influenza caused by pandemic H1N1 influenza A virus were similar to those of seasonal influenza [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/9\">",
"     9",
"    </a>",
"    ], although gastrointestinal manifestations appeared to be more common with pandemic H1N1 influenza A [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. The overall severity was substantially less than what was observed during the influenza pandemic of 1918 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18456?source=see_link\">",
"     \"Clinical manifestations of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/58/15272?source=see_link\">",
"     \"Epidemiology of influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an active surveillance study that compared the clinical characteristics for 2009 pandemic H1N1 influenza A, 2008 to 2009 seasonal H1N1 influenza A, and 2007 to 2008 seasonal H3N2 influenza A infections in children and adults, the clinical manifestations and risk of hospital admission were similar among those infected with each of the three strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/13\">",
"     13",
"    </a>",
"    ]. However, adults with 2009 pandemic H1N1 infection were more likely to have pneumonia than adults with seasonal H1N1 or seasonal H3N2 influenza infection (4 versus 2.3 versus 1.1 percent).",
"   </p>",
"   <p>",
"    In a prospective observational study that compared patients with pandemic H1N1 influenza infection with patients with seasonal influenza infection, those with pandemic H1N1 influenza A had higher rates of extrapulmonary complications (23 versus 16 percent) and intensive care unit admission",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    death (adjusted odds ratio 2.13, 95% CI 1.25-3.62), despite being younger and having fewer comorbidities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Adults and adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common clinical findings of the 2009 H1N1 influenza A pandemic were fever, cough, sore throat, malaise, and headache; vomiting and diarrhea were also common, both of which are unusual features of seasonal influenza [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/10,11,16-22\">",
"     10,11,16-22",
"    </a>",
"    ]. Other frequent findings included chills, myalgias, and arthralgias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/10,18\">",
"     10,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During the spring of 2009 in New York City, 95 percent of patients with pandemic H1N1 influenza A met the case definition for influenza-like illness (subjective fever plus cough",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sore throat) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/18\">",
"     18",
"    </a>",
"    ]. In contrast, approximately one-third of patients seen at two hospitals in Mexico had no fever at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/23\">",
"     23",
"    </a>",
"    ]. Similarly, one-third of patients in a multicenter study from China did not have a fever at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/17\">",
"     17",
"    </a>",
"    ]. When fever was present, it usually lasted for three days (range 1 to 11 days). In Singapore, 79 percent of patients with pandemic H1N1 influenza had a fever at presentation, compared with 88 percent among those who had seasonal influenza [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18456?source=see_link\">",
"     \"Clinical manifestations of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among 268 patients in the United States requiring hospitalization for pandemic H1N1 influenza A infection, clinical findings included fever (93 percent), cough (83 percent), shortness of breath (54 percent), fatigue or weakness (40 percent), chills (37 percent), myalgias (36 percent), rhinorrhea (36 percent), sore throat (31 percent), headache (31 percent), vomiting (29 percent), wheezing (24 percent), and diarrhea (24 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective study that included 74 patients with pandemic H1N1 influenza A, those with severe disease were older, more likely to be obese or have comorbidities, and to have lower respiratory tract symptoms such as dyspnea at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients who developed acute respiratory distress syndrome (ARDS) or died had a slower decline in nasopharyngeal viral load, had higher plasma concentrations of proinflammatory cytokines and chemokines, and were more likely to have bacterial coinfections, myocarditis, or viremia than patients who survived and did not have ARDS.",
"   </p>",
"   <p>",
"    Complications of pandemic H1N1 influenza A infection are discussed below. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women and their fetuses or neonates were more likely than nonpregnant individuals to have severe pandemic H1N1 influenza infection. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/2/31786?source=see_link&amp;anchor=H22#H22\">",
"     \"Epidemiology of pandemic H1N1 influenza ('swine influenza')\", section on 'Pregnant women'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/2/31786?source=see_link&amp;anchor=H23#H23\">",
"     \"Epidemiology of pandemic H1N1 influenza ('swine influenza')\", section on 'Fetuses and neonates'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Young children with influenza may present with fever, cough, irritability",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nausea and vomiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/27\">",
"     27",
"    </a>",
"    ]. In one series from Argentina, the most common symptoms and signs among children with pandemic H1N1 influenza A were fever, cough, rhinorrhea, and hypoxemia; wheezing was noted in 16 percent and gastrointestinal complaints were frequent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/28\">",
"     28",
"    </a>",
"    ]. In a cohort study of children with influenza in Nicaragua, children had a higher incidence of lower respiratory tract and gastrointestinal symptoms than children with seasonal influenza [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants with influenza may present with fever and lethargy, and may not have cough or other respiratory symptoms. Symptoms of severe disease in infants and young children may include apnea, tachypnea, dyspnea, cyanosis, dehydration, altered mental status, and extreme irritability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24346?source=see_link\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Young children (&lt;5 years of age, and especially &lt;2 years of age) were at increased risk for influenza complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5177853\">",
"    <span class=\"h2\">",
"     Immunocompromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severely immunocompromised hosts were at increased risk for severe disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/2/31786?source=see_link&amp;anchor=H21189334#H21189334\">",
"     \"Epidemiology of pandemic H1N1 influenza ('swine influenza')\", section on 'Immunocompromised hosts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with certain medical conditions, those at the extremes of age, and pregnant women are at increased risk for influenza complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Respiratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some cases of rapidly progressive pneumonia, respiratory failure, acute respiratory distress syndrome (ARDS), and multisystem organ failure were reported during the 2009 to 2010 H1N1 influenza A pandemic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/11,12,16,30-35\">",
"     11,12,16,30-35",
"    </a>",
"    ]. Some patients with respiratory failure had profound hypoxemia that has been refractory to routine mechanical ventilation; these patients have required such measures as neuromuscular blockade, inhaled nitric oxide, high-frequency oscillatory ventilation, extracorporeal membrane oxygenation (ECMO),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prone positioning ventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/32,35-37\">",
"     32,35-37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37863?source=see_link&amp;anchor=H3#H3\">",
"     \"Extracorporeal membrane oxygenation (ECMO) in adults\", section on 'Acute respiratory failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an observational study of adults hospitalized for pandemic H1N1 influenza A infection at 13 hospitals in Spain, 234 of 543 patients who underwent chest radiography (43 percent) had pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/38\">",
"     38",
"    </a>",
"    ]. Of the 210 patients who had microbiologic studies, 174 (83 percent) had primary influenza virus pneumonia and 36 (17 percent) had concomitant or secondary bacterial pneumonia. Patients with pneumonia had higher rates of shock, mechanical ventilation, intensive care unit (ICU) admission, mortality, and had a longer length of hospital stay. Similar results were observed in a study from the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Bacterial superinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial superinfection of the lung was reported in 4 to 29 percent of cases that resulted in hospitalization or death in the United States, Argentina, Australia, New Zealand, and Spain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/16,38,40-46\">",
"     16,38,40-46",
"    </a>",
"    ]. In the study of hospitalized patients in Spain with pandemic H1N1 infection and pneumonia described above, Streptococcus pneumoniae was the most common bacterial cause, occurring in 26 of 36 cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/38\">",
"     38",
"    </a>",
"    ]. Among the fatal cases described in the United States, the following pathogens were identified: S. pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Streptococcus mitis, and Haemophilus influenzae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/40,44\">",
"     40,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among 838 children and adolescents admitted to 35 ICUs in the United States with confirmed or probable severe H1N1 influenza A infection, 71 (8.5 percent) had a presumed diagnosis early (within 72 hours of ICU admission) S. aureus coinfection of the lung, 48 percent of which were caused by methicillin-resistant Staphylococcus aureus (MRSA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/47\">",
"     47",
"    </a>",
"    ]. Early presumed MRSA infection was a risk factor for mortality on multivariate analysis (relative risk 3.3, 95% CI 1.7-6.4). Among the 251 previously healthy children and adolescents, early presumed MRSA coinfection of the lung was a strong risk factor for mortality (RR 8.0, 95% CI 3.1-20.6).",
"   </p>",
"   <p>",
"    An increase in the incidence of invasive pneumococcal disease was detected in Denver, Colorado, which is one of the United States Centers for Disease Control and Prevention&rsquo;s (CDC&rsquo;s) Active Bacterial Core surveillance sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/48\">",
"     48",
"    </a>",
"    ]. The majority of cases occurred in individuals between 20 and 59 years of age, whereas during nonpandemic years, most cases of invasive pneumococcal disease occur in individuals &ge;65 years of age. Between August and mid-December 2009, which was the period of the highest pandemic activity in the United States, a significant increase in hospitalizations for pneumococcal pneumonia was observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/49\">",
"     49",
"    </a>",
"    ]. Individuals between 5 and 19 years of age had the highest relative increase in hospitalizations for pneumococcal pneumonia compared with the nonpandemic seasonal baseline over the previous six years. There were no excess pneumococcal pneumonia hospitalizations in individuals &ge;65 years of age. Geographic variation in the timing of increased pneumococcal pneumonia hospitalizations tracked with the geographic patterns for the fall pandemic wave. Coinfection with S. pneumoniae was correlated with an increased case-fatality ratio among patients with pandemic H1N1 influenza A infection in Argentina [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study compared rates of bloodstream infections during the H1N1 influenza A pandemic with previous periods of no influenza activity or seasonal influenza activity in Israel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/50\">",
"     50",
"    </a>",
"    ]. Compared with summer weeks without influenza activity and winter weeks in which seasonal influenza was active, the 2009 H1N1 influenza A pandemic was associated with higher rates of S. pneumoniae bacteremia in children, and higher rates of S. aureus and S. pyogenes bacteremia in both children and adults.",
"   </p>",
"   <p>",
"    Clinical findings that are suggestive of secondary bacterial pneumonia in patients with influenza pneumonia include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/51\">",
"     51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Secondary fever after a period of defervescence.",
"     </li>",
"     <li>",
"      Sputum Gram stain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      culture showing a predominant organism (eg, S. pneumoniae, S. aureus, S. pyogenes, H. influenzae, Moraxella catarrhalis).",
"     </li>",
"     <li>",
"      Lobar consolidation on chest imaging, rather than the diffuse pattern that is typical of viral pneumonia.",
"     </li>",
"     <li>",
"      Leukocytosis, rather than a normal or low white blood cell count; the latter two are more common with influenza infection.",
"     </li>",
"     <li>",
"      Onset of respiratory compromise occurring four to seven days after initial symptoms, rather than one to two days after initial symptoms, the latter more suggestive of primary influenza pneumonia",
"     </li>",
"     <li>",
"      A lower rate of positive diagnostic tests for influenza virus compared with patients with primary influenza pneumonia because secondary bacterial pneumonia occurs later in the course of illness, when viral shedding may have ceased.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of possible bacterial pneumonia in patients with H1N1 influenza infection is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38234?source=see_link&amp;anchor=H532740#H532740\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\", section on 'Antibacterial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Neurologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;A range of neurologic complications may occur in patients with pandemic H1N1 influenza A infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of 2069 patients with fatal or severe pandemic H1N1 influenza A infection in California, 77 (3.7 percent) had primary influenza-associated neurologic manifestations; patients were defined as having severe illness if they were admitted to the ICU [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/52\">",
"       52",
"      </a>",
"      ]. Among these, 44 (2.1 percent) had seizures, 29 (1.4 percent) had encephalopathy or encephalitis, 3 (0.1 percent) had meningitis, and one (0.05 percent) had Guillain-Barr&eacute; syndrome. The median age of patients with influenza-associated neurologic complications was 9 years (range 4 months to 92 years), and the estimated incidence of such complications was 1.2 per 100,000 symptomatic pandemic H1N1 cases.",
"     </li>",
"     <li>",
"      Among 506 children &lt;15 years of age in Australia who were hospitalized with pandemic H1N1 influenza A infection, 49 (9.7 percent) had neurologic complications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/53\">",
"       53",
"      </a>",
"      ]. Seizure was the most common complication, occurring in 38 patients (7.5 percent), followed by",
"      <span class=\"nowrap\">",
"       encephalitis/encephalopathy",
"      </span>",
"      in 7 (1.4 percent),",
"      <span class=\"nowrap\">",
"       confusion/disorientation",
"      </span>",
"      in 5 (1 percent), loss of consciousness in 5 (1 percent), and",
"      <span class=\"nowrap\">",
"       paralysis/Guillain-Barr&eacute;",
"      </span>",
"      syndrome in 2 (0.4 percent). Fifty-five percent of the children with neurologic complications had preexisting medical conditions, and 43 percent had preexisting neurologic conditions.",
"     </li>",
"     <li>",
"      A similar incidence of encephalitis (1.7 percent) was observed in 838 children and adolescents admitted to ICUs in the United States with severe pandemic H1N1 influenza A [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/47\">",
"       47",
"      </a>",
"      ]. On multivariate analysis, encephalitis was a risk factor for mortality (relative risk 3.4, 95% CI 1.6-7.5).",
"     </li>",
"     <li>",
"      In a review of 826 hospitalized patients between the ages of 15 and 57 with pandemic H1N1 influenza A infection in Singapore, nine had neurologic complications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/54\">",
"       54",
"      </a>",
"      ]. The most common complication was seizure, which occurred in six patients.",
"     </li>",
"     <li>",
"      Other reported neurologic manifestations included confusion, unconsciousness, acute or postinfectious encephalopathy, quadriparesis, encephalitis, severe acute disseminated encephalomyelitis, stroke, and transient ischemic attack [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/12,15,55,56\">",
"       12,15,55,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective study of narcolepsy onset in patients in China from 1996 to 2010, a threefold increase in narcolepsy onset was observed five to seven months following the winter peak of the 2009 H1N1 influenza A pandemic compared with other years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/57\">",
"       57",
"      </a>",
"      ]. This study is limited by its retrospective design and by the fact that it relied upon self-reported month and year of onset of narcolepsy. It does not establish a causal link between pandemic H1N1 influenza A infection and the onset of narcolepsy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The complications of seasonal influenza are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18456?source=see_link\">",
"     \"Clinical manifestations of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24346?source=see_link\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neurologic complications of pandemic H1N1 influenza vaccination are also presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38234?source=see_link&amp;anchor=H415326#H415326\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\", section on 'Guillain-Barr&eacute; syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38234?source=see_link&amp;anchor=H1047182254#H1047182254\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\", section on 'Other neurologic syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1148990771\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other complications reported in patients with pandemic H1N1 influenza A infection included myocarditis, renal insufficiency, rhabdomyolysis, hemophagocytic syndrome, and multisystem organ failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/15,32,47,58-61\">",
"     15,32,47,58-61",
"    </a>",
"    ]. Among 838 severely ill children and adolescents with pandemic H1N1 influenza admitted to ICUs in the United States, six had myocarditis (0.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/47\">",
"     47",
"    </a>",
"    ]. Myocarditis was a risk factor for mortality on multivariate analysis (relative risk 3.8, 95% CI 1.2-12.0).",
"   </p>",
"   <p>",
"    In a retrospective study of 119 hospitalized adults with pandemic H1N1 influenza A, seven were diagnosed with thrombotic vascular events, four of which were venous and three of which were arterial in origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/62\">",
"     62",
"    </a>",
"    ]. The extent, as well as the arterial location of some of these cases, suggests that pandemic H1N1 influenza A infection may be associated with hypercoagulability, although further study is necessary to establish whether such an association exists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of 272 patients requiring hospitalization in the United States for pandemic H1N1 influenza A, the following laboratory abnormalities were observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Elevated alanine aminotransferase &mdash; 58 of 130 (45 percent)",
"     </li>",
"     <li>",
"      Elevated aspartate aminotransferase &mdash; 57 of 131 (44 percent)",
"     </li>",
"     <li>",
"      Anemia &mdash; 87 of 238 (37 percent)",
"     </li>",
"     <li>",
"      Leukopenia &mdash; 50 of 246 (20 percent)",
"     </li>",
"     <li>",
"      Leukocytosis &mdash; 44 of 246 (18 percent)",
"     </li>",
"     <li>",
"      Thrombocytopenia &mdash; 33 of 234 (14 percent)",
"     </li>",
"     <li>",
"      Thrombocytosis &mdash; 20 of 234 (9 percent)",
"     </li>",
"     <li>",
"      Elevated total bilirubin &mdash; 6 of 121 (5 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rates of lymphopenia have varied among studies. Among 426 patients with confirmed pandemic H1N1 infection in China, lymphopenia occurred in 68 percent of adults and 92 percent of children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/17\">",
"     17",
"    </a>",
"    ]. In a study of individuals in the United States with probable pandemic H1N1 influenza A infection, relative lymphopenia (&le;21 percent of white blood cells) without leukopenia was observed in 23 of 25 adults, but in only 3 of 16 children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/63\">",
"     63",
"    </a>",
"    ]. Low rates of leukopenia were also seen in a study of hospitalized children in Argentina (2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevations of creatine kinase levels were reported in some patients with severe illness, including one patient with severe rhabdomyolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/31,58\">",
"     31,58",
"    </a>",
"    ]. Lactate dehydrogenase was elevated in all 16 patients with severe illness in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of 833 hospitalized patients with probable or confirmed pandemic H1N1 influenza A infection, 547 (66 percent) had infiltrates suggestive of pneumonia or acute respiratory distress syndrome (ARDS) on chest radiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/16\">",
"     16",
"    </a>",
"    ]. In other studies that used chest radiography and computed tomography, common findings included patchy consolidation or ground glass opacities, with or without consolidation; there was a lower lung zone predominance and the most commonly affected regions were the peripheral and central perihilar areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Of 14 critically-ill patients who required intensive care unit admission and mechanical ventilation, extensive disease involving &ge;3 lung zones was observed in 13 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 251 hospitalized children, 92 of whom had chest radiographs, the most frequent diagnosis was pneumonia, which was focal in one-third and multifocal in almost half [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nodular opacities and pulmonary emboli were reported in one study of critically-ill patients with pandemic H1N1 influenza A who underwent CT chest imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autopsy findings of patients who died from pandemic H1N1 influenza A infection included both upper and lower respiratory tract abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/45,66-68\">",
"     45,66-68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 100 fatal cases of pandemic H1N1 influenza A, the following findings were observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Histopathologic findings in the trachea and bronchi included inflammation and edema (in 66 percent), necrosis (in 26 percent), and hemorrhage (in 18 percent).",
"     </li>",
"     <li>",
"      Diffuse alveolar damage was present in the lungs of all cases. Specific histopathologic findings in the lungs included edema (in 63 percent), hyaline membranes (in 59 percent), fibrin (in 58 percent), hemorrhage (in 58 percent), inflammation (in 48 percent), type II pneumocyte hyperplasia (in 46 percent), and organizing fibrosis (in 28 percent).",
"     </li>",
"     <li>",
"      The primary cells infected with influenza virus were alveolar lining cells, including type I and type II pneumocytes.",
"     </li>",
"     <li>",
"      Bacterial coinfection, particularly with Staphylococcus aureus and Streptococcus pneumoniae, were present in the lungs of 29 percent of cases. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Bacterial superinfection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PREDICTORS OF OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a cohort study of patients in Australia and New Zealand admitted to the intensive care unit (ICU) with confirmed pandemic H1N1 influenza A infection, older age, the presence of preexisting conditions, and a requirement for mechanical ventilation were independently associated with mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/41\">",
"     41",
"    </a>",
"    ]. As noted above, encephalitis was an independent predictor of mortality in a study of children and adolescents admitted to ICUs in the United States with severe pandemic H1N1 influenza A [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Neurologic'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC ASSAYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Real-time reverse transcriptase (rRT)-PCR is the most sensitive and specific test for the diagnosis of pandemic H1N1 influenza A virus infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Isolation of pandemic H1N1 influenza A virus using culture is also diagnostic, but culture is usually too slow to help guide clinical management. A negative viral culture does not exclude pandemic H1N1 influenza A infection.",
"   </p>",
"   <p>",
"    Several rapid antigen and immunofluorescent antibody tests are available for the diagnosis of influenza virus infection. However, the sensitivity of these tests varies widely, and although some assays are able to distinguish between influenza A and B viruses, they are not able to distinguish between pandemic and seasonal strains of H1N1 influenza A.",
"   </p>",
"   <p>",
"    The diagnosis of seasonal influenza is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5528?source=see_link\">",
"     \"Diagnosis of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nucleic acid amplification tests, such as real-time reverse transcriptase (rRT)-PCR, are the most sensitive and specific tests for the diagnosis of influenza virus infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/69\">",
"     69",
"    </a>",
"    ]. However, they are often not readily available",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    may require several days for processing since many hospitals and clinics must send samples to be processed at public health or commercial laboratories. Test performance depends on the individual rRT-PCR assay used, as well as the quality of the sample obtained.",
"   </p>",
"   <p>",
"    One study, which compared the use of combined nasopharyngeal and throat swabs (CNTS) with nasopharyngeal aspirates (NPA) using rRT-PCR, showed that CNTS had the highest sensitivity, and that the use of both CNTS and NPA had a higher sensitivity than either method alone. Of 115 patients with confirmed pandemic H1N1 influenza A infection, 109 (95 percent) had positive results from CNTS, whereas only 98 (85 percent) had positive results from NPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/71\">",
"     71",
"    </a>",
"    ]. In 93 patients (80 percent), results were positive from both CNTS and NPA.",
"   </p>",
"   <p>",
"    Among 21 critically-ill patients with pandemic H1N1 influenza A infection, lower respiratory tract specimens were positive by rRT-PCR in all patients, but upper respiratory tract specimens were positive in only 17 of 21 patients (81 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a multicenter study from China, the median length of time during which patients had a positive rRT-PCR was six days (range 1 to 17 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/17\">",
"     17",
"    </a>",
"    ]. Independent risk factors for prolonged rRT-PCR positivity included age &lt;14 years, male gender, and a delay from onset of symptoms to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    of &gt;48 hours. Among 35 patients in the United States with confirmed pandemic H1N1 influenza A infection, the median duration of virus detection from nasopharyngeal specimens by rRT-PCR was 4.2 days, which was similar to the duration of fever (3.5 days) but shorter than the duration of cough (11 days); however, few specimens were collected between days five to nine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Rapid antigen tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain rapid influenza antigen tests that are commercially available can distinguish between influenza A and B viruses, but cannot distinguish among different subtypes of influenza A (eg, pandemic H1N1 influenza A versus seasonal H1N1 or H3N2 influenza A). Confirmation of pandemic H1N1 influenza A infection can only be made by real-time reverse-transcriptase (rRT)-PCR or culture.",
"   </p>",
"   <p>",
"    It was suggested that clinicians consider using rapid influenza antigen tests as part of their evaluation of patients suspected of having pandemic H1N1 influenza A, but results needed to be interpreted with caution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/69,74\">",
"     69,74",
"    </a>",
"    ]. The sensitivity of rapid antigen testing for pandemic H1N1 influenza A virus infection ranged from 10 to 70 percent compared with rRT-PCR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/19,69,72,74-81\">",
"     19,69,72,74-81",
"    </a>",
"    ]. Thus, a negative result did not rule out infection. The specificity of rapid antigen testing was generally &gt;95 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/69\">",
"     69",
"    </a>",
"    ], although in one study it was only 86 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Immunofluorescent antibody testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct or indirect immunofluorescent antibody testing (DFA or IFA) can distinguish between influenza A and B, but does not distinguish among different influenza A subtypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensitivity of immunofluorescent antibody testing has varied among studies. In one report, among 42 samples that were positive for pandemic H1N1 influenza A by real-time reverse-transcriptase polymerase chain reaction (rRT-PCR), 93 percent were positive by direct fluorescent antibody testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/82\">",
"     82",
"    </a>",
"    ]. However, in another study, among 21 critically-ill patients with pandemic H1N1 influenza A, lower respiratory tract specimens were positive in all patients when tested by rRT-PCR, but in only 25 percent tested by immunofluorescence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/72\">",
"     72",
"    </a>",
"    ]. Thus, a negative DFA or IFA does not exclude pandemic H1N1 influenza A infection since larger studies are required to further define this assay's performance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7867072\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic testing is most useful for influenza surveillance, and can be used to identify patients who have recovered from influenza who were not diagnosed during the acute infection with the tests described above. As an example, in a study of patients admitted to intensive care units with severe respiratory disease during the 2009 H1N1 influenza A pandemic, 9 (69 percent) of 13 patients who tested negative for pandemic influenza A using nucleic acid testing were considered positive for influenza based upon a minimum four-fold increase in hemagglutinin inhibition titer between acute and convalescent serum samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another study that included 881 patients who recovered from pandemic H1N1 influenza A infection diagnosed by real-time reverse transcriptase polymerase chain reaction, 90 percent had seroprotective neutralizing antibody titers (NAT) of &ge;1:40 21 days or longer after symptom onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37305/abstract/84\">",
"     84",
"    </a>",
"    ]. Pneumonia and sputum production were independently associated with higher levels of convalescent NAT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Typical clinical manifestations of pandemic H1N1 influenza A infection included fever, headache, cough, sore throat, myalgias, chills, and fatigue; vomiting and diarrhea were also common, both of which are unusual features of seasonal influenza. Disease severity ranged from mild influenza-like illness to multiorgan failure with severe hypoxemia.&nbsp;(see",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Individuals with certain medical conditions, those at the extremes of age, and pregnant women were at increased risk of influenza complications, including respiratory failure. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many hospitalized patients had infiltrates suggestive of pneumonia or acute respiratory distress syndrome (ARDS). Common findings using chest radiography",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chest tomography included patchy consolidation or ground glass opacities, with or without consolidation; there was a lower lung zone predominance and the most commonly affected regions were the peripheral and central perihilar areas. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autopsy findings of patients who died from pandemic H1N1 influenza A infection included diffuse alveolar damage and viral infection of alveolar lining cells. Bacterial coinfection was detected in a proportion of cases. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Real-time reverse transcriptase (rRT)-PCR was the most sensitive and specific test for the diagnosis of pandemic H1N1 influenza A virus infection. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Diagnostic assays'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several rapid antigen and immunofluorescent antibody tests are available for the diagnosis of influenza virus infection. However, the sensitivity of these tests varies widely, and they do not distinguish between pandemic and seasonal strains of H1N1 influenza A. Confirmation of pandemic H1N1 influenza A infection could only be made by real-time reverse-transcriptase (rRT)-PCR or culture. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Diagnostic assays'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of seasonal influenza is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5528?source=see_link\">",
"       \"Diagnosis of seasonal influenza in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/1\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of swine-origin influenza A (H1N1) virus infection - Mexico, March-April 2009. MMWR Morb Mortal Wkly Rep 2009; 58:467.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Influenza-like illness in the United States and Mexico, 24 April 2009. file://www.who.int/csr/don/2009_04_24/en/index.html (Accessed on April 27, 2009).",
"    </li>",
"    <li>",
"     World Health Organization. World now at the start of 2009 influenza pandemic. file://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/index.html (Accessed on June 11, 2009).",
"    </li>",
"    <li>",
"     World Health Organization. In focus: H1N1 now in the post-pandemic period. August 10, 2010.",
" file://www.who.int/csr/disease/swineflu/en/index.html (Accessed on September 21, 2010).",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. Interim guidance on case definitions to be used for investigations of novel influenza A (H1N1) cases file://www.cdc.gov/h1n1flu/casedef.htm (Accessed on October 13, 2011).",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-2010 season. file://www.cdc.gov/h1n1flu/recommendations.htm (Accessed on December 15, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/7\">",
"      Papenburg J, Baz M, Hamelin M&Egrave;, et al. Household transmission of the 2009 pandemic A/H1N1 influenza virus: elevated laboratoryconfirmed secondary attack rates and evidence of asymptomatic infections. Clin Infect Dis 2010; 51:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/8\">",
"      Jackson ML, France AM, Hancock K, et al. Serologically confirmed household transmission of 2009 pandemic influenza A (H1N1) virus during the first pandemic wave--New York City, April-May 2009. Clin Infect Dis 2011; 53:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/9\">",
"      Cheng VC, To KK, Tse H, et al. Two years after pandemic influenza A/2009/H1N1: what have we learned? Clin Microbiol Rev 2012; 25:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/10\">",
"      Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360:2605.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Human infection with new influenza A (H1N1) virus: clinical observations from Mexico and other affected countries, May 2009 file://www.who.int/wer/2009/wer8421.pdf (Accessed on October 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/12\">",
"      Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza, Bautista E, Chotpitayasunondh T, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/13\">",
"      Belongia EA, Irving SA, Waring SC, et al. Clinical characteristics and 30-day outcomes for influenza A 2009 (H1N1), 2008-2009 (H1N1), and 2007-2008 (H3N2) infections. JAMA 2010; 304:1091.",
"     </a>",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. 2009 H1N1 influenza vaccine and pregnant women: information for healthcare providers file://www.cdc.gov/h1n1flu/vaccination/providers_qa.htm (Accessed on October 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/15\">",
"      Lee N, Chan PK, Lui GC, et al. Complications and outcomes of pandemic 2009 Influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza? J Infect Dis 2011; 203:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/16\">",
"      Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009; 302:1896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/17\">",
"      Cao B, Li XW, Mao Y, et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med 2009; 361:2507.",
"     </a>",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. Interim guidance for clinicians on identifying and caring for patients with swine-origin influenza A (H1N1) virus infection file://www.cdc.gov/swineflu/identifyingpatients.htm (Accessed on May 05, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/19\">",
"      Crum-Cianflone NF, Blair PJ, Faix D, et al. Clinical and epidemiologic characteristics of an outbreak of novel H1N1 (swine origin) influenza A virus among United States military beneficiaries. Clin Infect Dis 2009; 49:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/20\">",
"      Cauchemez S, Donnelly CA, Reed C, et al. Household transmission of 2009 pandemic influenza A (H1N1) virus in the United States. N Engl J Med 2009; 361:2619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/21\">",
"      Echevarr&iacute;a-Zuno S, Mej&iacute;a-Arangur&eacute; JM, Mar-Obeso AJ, et al. Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 2009; 374:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/22\">",
"      Fajardo-Dolci G, Gutierrez-Vega R, Arboleya-Casanova H, et al. Clinical characteristics of fatalities due to influenza A (H1N1) virus in Mexico. Thorax 2010; 65:505.",
"     </a>",
"    </li>",
"    <li>",
"     The New York Times. Many swine flu cases have no fever file://www.nytimes.com/2009/05/13/health/13fever.html?_r=1&amp;ref=health (Accessed on October 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/24\">",
"      Tang JW, Tambyah PA, Lai FY, et al. Differing symptom patterns in early pandemic vs seasonal influenza infections. Arch Intern Med 2010; 170:861.",
"     </a>",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. 2009 H1N1 early outbreak and disease characteristics file://www.cdc.gov/h1n1flu/surveillanceqa.htm (Accessed on October 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/26\">",
"      To KK, Hung IF, Li IW, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 2010; 50:850.",
"     </a>",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. Recommendations for use of antiviral medications for the management of influenza in children and adolescents for the 2009-2010 season - pediatric supplement for healthcare providers file://www.cdc.gov/h1n1flu/recommendations_pediatric_supplement.htm (Accessed on December 14, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/28\">",
"      Libster R, Bugna J, Coviello S, et al. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. N Engl J Med 2010; 362:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/29\">",
"      Gordon A, Sabor&iacute;o S, Videa E, et al. Clinical attack rate and presentation of pandemic H1N1 influenza versus seasonal influenza A and B in a pediatric cohort in Nicaragua. Clin Infect Dis 2010; 50:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/30\">",
"      Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/31\">",
"      Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009; 361:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/32\">",
"      Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009; 302:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/33\">",
"      Chowell G, Bertozzi SM, Colchero MA, et al. Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med 2009; 361:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/34\">",
"      Dom&iacute;nguez-Cherit G, Lapinsky SE, Macias AE, et al. Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 2009; 302:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/35\">",
"      Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators, Davies A, Jones D, et al. Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome. JAMA 2009; 302:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/36\">",
"      Bishop JF, Murnane MP, Owen R. Australia's winter with the 2009 pandemic influenza A (H1N1) virus. N Engl J Med 2009; 361:2591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/37\">",
"      Noah MA, Peek GJ, Finney SJ, et al. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). JAMA 2011; 306:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/38\">",
"      Viasus D, Pa&ntilde;o-Pardo JR, Pach&oacute;n J, et al. Pneumonia complicating pandemic (H1N1) 2009: risk factors, clinical features, and outcomes. Medicine (Baltimore) 2011; 90:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/39\">",
"      Jain S, Benoit SR, Skarbinski J, et al. Influenza-associated pneumonia among hospitalized patients with 2009 pandemic influenza A (H1N1) virus--United States, 2009. Clin Infect Dis 2012; 54:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/40\">",
"      Centers for Disease Control and Prevention (CDC). Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) - United States, May-August 2009. MMWR Morb Mortal Wkly Rep 2009; 58:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/41\">",
"      ANZIC Influenza Investigators, Webb SA, Pettil&auml; V, et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009; 361:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/42\">",
"      Palacios G, Hornig M, Cisterna D, et al. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS One 2009; 4:e8540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/43\">",
"      Murray RJ, Robinson JO, White JN, et al. Community-acquired pneumonia due to pandemic A(H1N1)2009 influenzavirus and methicillin resistant Staphylococcus aureus co-infection. PLoS One 2010; 5:e8705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/44\">",
"      Jean C, Louie JK, Glaser CA, et al. Invasive group A streptococcal infection concurrent with 2009 H1N1 influenza. Clin Infect Dis 2010; 50:e59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/45\">",
"      Shieh WJ, Blau DM, Denison AM, et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol 2010; 177:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/46\">",
"      Mart&iacute;n-Loeches I, Sanchez-Corral A, Diaz E, et al. Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A(H1N1) virus. Chest 2011; 139:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/47\">",
"      Randolph AG, Vaughn F, Sullivan R, et al. Critically ill children during the 2009-2010 influenza pandemic in the United States. Pediatrics 2011; 128:e1450.",
"     </a>",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. Questions &amp; answers: 2009 H1N1 flu in the news file://www.cdc.gov/h1n1flu/in_the_news.htm (Accessed on October 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/49\">",
"      Weinberger DM, Simonsen L, Jordan R, et al. Impact of the 2009 influenza pandemic on pneumococcal pneumonia hospitalizations in the United States. J Infect Dis 2012; 205:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/50\">",
"      Tasher D, Stein M, Sim&otilde;es EA, et al. Invasive bacterial infections in relation to influenza outbreaks, 2006-2010. Clin Infect Dis 2011; 53:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/51\">",
"      Wright PF, Kirkland KB, Modlin JF. When to consider the use of antibiotics in the treatment of 2009 H1N1 influenza-associated pneumonia. N Engl J Med 2009; 361:e112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/52\">",
"      Glaser CA, Winter K, DuBray K, et al. A population-based study of neurologic manifestations of severe influenza A(H1N1)pdm09 in California. Clin Infect Dis 2012; 55:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/53\">",
"      Khandaker G, Zurynski Y, Buttery J, et al. Neurologic complications of influenza A(H1N1)pdm09: surveillance in 6 pediatric hospitals. Neurology 2012; 79:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/54\">",
"      Tan K, Prerna A, Leo YS. Surveillance of H1N1-related neurological complications. Lancet Neurol 2010; 9:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/55\">",
"      Noriega LM, Verdugo RJ, Araos R, et al. Pandemic influenza A (H1N1) 2009 with neurological manifestations, a case series. Influenza Other Respi Viruses 2010; 4:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/56\">",
"      Webster RI, Hazelton B, Suleiman J, et al. Severe encephalopathy with swine origin influenza A H1N1 infection in childhood: case reports. Neurology 2010; 74:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/57\">",
"      Han F, Lin L, Warby SC, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol 2011; 70:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/58\">",
"      Ayala E, Kagawa FT, Wehner JH, et al. Rhabdomyolysis associated with 2009 influenza A(H1N1). JAMA 2009; 302:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/59\">",
"      Kumar K, Guirgis M, Zieroth S, et al. Influenza myocarditis and myositis: case presentation and review of the literature. Can J Cardiol 2011; 27:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/60\">",
"      Beutel G, Wiesner O, Eder M, et al. Virus-associated hemophagocytic syndrome as a major contributor to death in patients with 2009 influenza A (H1N1) infection. Crit Care 2011; 15:R80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/61\">",
"      Martin-Loeches I, Papiol E, Rodr&iacute;guez A, et al. Acute kidney injury in critical ill patients affected by influenza A (H1N1) virus infection. Crit Care 2011; 15:R66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/62\">",
"      Bunce PE, High SM, Nadjafi M, et al. Pandemic H1N1 influenza infection and vascular thrombosis. Clin Infect Dis 2011; 52:e14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/63\">",
"      Cunha BA, Pherez FM, Schoch P. Diagnostic importance of relative lymphopenia as a marker of swine influenza (H1N1) in adults. Clin Infect Dis 2009; 49:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/64\">",
"      Agarwal PP, Cinti S, Kazerooni EA. Chest radiographic and CT findings in novel swine-origin influenza A (H1N1) virus (S-OIV) infection. AJR Am J Roentgenol 2009; 193:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/65\">",
"      Karadeli E, Ko&ccedil; Z, Ulusan S, et al. Chest radiography and CT findings in patients with the 2009 pandemic (H1N1) influenza. Diagn Interv Radiol 2011; 17:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/66\">",
"      Mauad T, Hajjar LA, Callegari GD, et al. Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Respir Crit Care Med 2010; 181:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/67\">",
"      Soto-Abraham MV, Soriano-Rosas J, D&iacute;az-Qui&ntilde;&oacute;nez A, et al. Pathological changes associated with the 2009 H1N1 virus. N Engl J Med 2009; 361:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/68\">",
"      Gill JR, Sheng ZM, Ely SF, et al. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med 2010; 134:235.",
"     </a>",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. Interim Recommendations for Clinical Use of Influenza Diagnostic Tests During the 2009-10 Influenza Season file://www.cdc.gov/h1n1flu/guidance/diagnostic_tests.htm (Accessed on November 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/70\">",
"      Kumar S, Henrickson KJ. Update on influenza diagnostics: lessons from the novel H1N1 influenza A pandemic. Clin Microbiol Rev 2012; 25:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/71\">",
"      de la Tabla VO, Masi&aacute; M, Antequera P, et al. Comparison of combined nose-throat swabs with nasopharyngeal aspirates for detection of pandemic influenza A/H1N1 2009 virus by real-time reverse transcriptase PCR. J Clin Microbiol 2010; 48:3492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/72\">",
"      Blyth CC, Iredell JR, Dwyer DE. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 361:2493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/73\">",
"      Suryaprasad A, Morgan OW, Peebles P, et al. Virus detection and duration of illness among patients with 2009 pandemic influenza A (H1N1) virus infection in Texas. Clin Infect Dis 2011; 52 Suppl 1:S109.",
"     </a>",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. Interim guidance for the detection of novel influenza A virus using rapid influenza diagnostic tests file://www.cdc.gov/h1n1flu/guidance/rapid_testing.htm (Accessed on October 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/75\">",
"      Faix DJ, Sherman SS, Waterman SH. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 361:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/76\">",
"      Ginocchio CC, Zhang F, Manji R, et al. Evaluation of multiple test methods for the detection of the novel 2009 influenza A (H1N1) during the New York City outbreak. J Clin Virol 2009; 45:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/77\">",
"      Centers for Disease Control and Prevention (CDC). Evaluation of rapid influenza diagnostic tests for influenza A (H3N2)v virus and updated case count--United States, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/78\">",
"      Centers for Disease Control and Prevention (CDC). Performance of rapid influenza diagnostic tests during two school outbreaks of 2009 pandemic influenza A (H1N1) virus infection - Connecticut, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/79\">",
"      Vasoo S, Stevens J, Singh K. Rapid antigen tests for diagnosis of pandemic (Swine) influenza A/H1N1. Clin Infect Dis 2009; 49:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/80\">",
"      Drexler JF, Helmer A, Kirberg H, et al. Poor clinical sensitivity of rapid antigen test for influenza A pandemic (H1N1) 2009 virus. Emerg Infect Dis 2009; 15:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/81\">",
"      Lucas PM, Morgan OW, Gibbons TF, et al. Diagnosis of 2009 pandemic influenza A (pH1N1) and seasonal influenza using rapid influenza antigen tests, San Antonio, Texas, April-June 2009. Clin Infect Dis 2011; 52 Suppl 1:S116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/82\">",
"      Pollock NR, Duong S, Cheng A, et al. Ruling out novel H1N1 influenza virus infection with direct fluorescent antigen testing. Clin Infect Dis 2009; 49:e66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/83\">",
"      Iwasenko JM, Cretikos M, Paterson DL, et al. Enhanced diagnosis of pandemic (H1N1) 2009 influenza infection using molecular and serological testing in intensive care unit patients with suspected influenza. Clin Infect Dis 2010; 51:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37305/abstract/84\">",
"      Hung IF, To KK, Lee CK, et al. Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H1N1 2009. Clin Infect Dis 2010; 51:274.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7005 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-197.136.42.3-AA8FF843F1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_27_37305=[""].join("\n");
var outline_f36_27_37305=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CASE DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEFINITIONS OF ILLNESS SEVERITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mild or uncomplicated illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Progressive illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Severe or complicated illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5806937\">",
"      ASYMPTOMATIC INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Adults and adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5177853\">",
"      Immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Respiratory",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Bacterial superinfection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Neurologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1148990771\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PREDICTORS OF OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DIAGNOSTIC ASSAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Rapid antigen tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Immunofluorescent antibody testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7867072\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24346?source=related_link\">",
"      Clinical features and diagnosis of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/4/22599?source=related_link\">",
"      Clinical manifestations and diagnosis of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18456?source=related_link\">",
"      Clinical manifestations of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5528?source=related_link\">",
"      Diagnosis of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/58/15272?source=related_link\">",
"      Epidemiology of influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/2/31786?source=related_link\">",
"      Epidemiology of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37863?source=related_link\">",
"      Extracorporeal membrane oxygenation (ECMO) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38234?source=related_link\">",
"      Treatment and prevention of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_27_37306="Specific learning disabilities in children: Educational management";
var content_f36_27_37306=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Specific learning disabilities in children: Educational management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/27/37306/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/27/37306/contributors\">",
"     L. Erik von Hahn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/27/37306/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/27/37306/contributors\">",
"     Carolyn Bridgemohan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/27/37306/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/27/37306/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/27/37306/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/27/37306/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Learning disabilities (LD) are a heterogeneous group of disorders characterized by the unexpected failure of an individual to competently acquire, retrieve, and use information. They are caused by inborn or acquired abnormalities in brain structure and function and have multifactorial etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/1\">",
"     1",
"    </a>",
"    ]. LD are the most severe, pervasive, and chronic form of learning difficulty in children with average or above-average intellectual abilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Definitions of LD vary, but the crucial element is an intrinsic cognitive difficulty that results in academic achievement at a level less than expected for the individual's intellectual capacity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Most children with LD have primary deficits in basic reading skills (ie, dyslexia), and the majority of information about LD is derived from studies of these children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/4\">",
"     4",
"    </a>",
"    ]. Children with reading difficulty typically have deficits in writing skills as well, but a writing LD can be identified as a separate entity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/16/6409?source=see_link\">",
"     \"Normal reading development and etiology of reading difficulty in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/21/1370?source=see_link\">",
"     \"Clinical features and evaluation of reading difficulty in children\"",
"    </a>",
"    .) Math LD is less common.",
"   </p>",
"   <p>",
"    The educational management and prognosis of LD in children will be presented here. The definition, epidemiology, clinical features, evaluation, and role of the primary care provider are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/38/37480?source=see_link\">",
"     \"Definitions of specific learning disability and laws pertaining to learning disabilities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32665?source=see_link\">",
"     \"Specific learning disabilities in children: Clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35944?source=see_link\">",
"     \"Specific learning disabilities in children: Evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/18/44329?source=see_link\">",
"     \"Specific learning disabilities in children: Role of the primary care provider\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some countries, the term \"learning disability\" is used to refer to intellectual disability (mental retardation). Intellectual disability is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/10/26793?source=see_link\">",
"     \"Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40887?source=see_link\">",
"     \"Intellectual disability (mental retardation) in children: Management; outcomes; and prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/8/5257?source=see_link\">",
"     \"Intellectual disability (mental retardation) in children: Evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11284702\">",
"    <span class=\"h1\">",
"     PREVENTIVE MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of the student with learning disability (LD) begins with quality instruction, even before the student is identified as having an LD. Inadequate exposure to quality instruction may account for the student&rsquo;s learning failure as early as kindergarten or first grade. It is generally believed that early intervention with quality instruction improves outcomes for all students with learning failure (including those with LD) and that it is more difficult to educate students with LD when they are older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, quality instruction should be provided early and should be provided before attempts are made to identify an LD. This approach is the rationale for the No Child Left Behind Act (NCLB), which requires schools to provide &ldquo;highly qualified&rdquo; teachers. Quality instruction is also required upon identification of LD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/38/37480?source=see_link&amp;anchor=H5#H5\">",
"     \"Definitions of specific learning disability and laws pertaining to learning disabilities\", section on 'No Child Left Behind'",
"    </a>",
"    .) The US Department of Education provides a definition for quality instruction in its practice guide for organizing instruction to improve student learning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/8\">",
"     8",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11284710\">",
"    <span class=\"h2\">",
"     Quality instruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quality instruction in regular education classrooms includes, but is not limited to, teacher practices, such as:",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Spacing learning over time",
"     </li>",
"     <li>",
"      Combining graphics with verbal descriptions",
"     </li>",
"     <li>",
"      Using preworked sample solutions with problem-solving exercises",
"     </li>",
"     <li>",
"      Quizzing to promote learning",
"     </li>",
"     <li>",
"      Helping students to allocate their time efficiently",
"     </li>",
"     <li>",
"      Connecting and integrating abstract and concrete representations of concepts",
"     </li>",
"     <li>",
"      Asking deep explanatory questions to develop greater awareness of the material being taught",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some consensus is emerging on what constitutes quality instruction for students with LD. However, the current evidence base remains weak. Specific examples of quality instruction for students with LD are discussed below. (See",
"    <a class=\"local\" href=\"#H11284731\">",
"     'Quality instruction for LD'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11284717\">",
"    <span class=\"h2\">",
"     Response to intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;For students who are not succeeding academically, a &ldquo;response to intervention&rdquo; (RTI) model is favored over early testing to attempt to identify an LD and before providing special education services. This approach is also required by the 2004 revision of the Individuals with Disability Education Act (IDEA). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/38/37480?source=see_link&amp;anchor=H13#H13\">",
"     \"Definitions of specific learning disability and laws pertaining to learning disabilities\", section on 'Individuals with Disabilities Education Act'",
"    </a>",
"    .) RTI services frequently are provided before the student is tested for the presence or absence of an LD because the student&rsquo;s response to intervention can help distinguish learning failure related to inadequate instruction from learning failure related to specific learning disability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35944?source=see_link&amp;anchor=H21#H21\">",
"     \"Specific learning disabilities in children: Evaluation\", section on 'Diagnostic process'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A common model for RTI services is to identify the students in a regular classroom setting who are performing at &le;25th percentile and to provide more intensive instruction to them. &ldquo;Intensive&rdquo; is defined differently by different authors but refers to quality instruction that is provided in a small group setting with a focus on remediation of deficits to help the students achieve grade-level performance. This instruction is provided for 30 to 60 minutes per day, 3 to 5 times per week, for 8 to 24 weeks. Progress is measured frequently, and an estimate of the rate of improvement is made. Based on the student&rsquo;s rate of progress, he or she may be returned to the general education setting or may undergo an evaluation to determine eligibility for special education services [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the reasons for the shift to an RTI model is that providing preventive services is considered to be better than waiting for students to fail. Support for this position is based on results of intensive, high-quality reading instruction, which shows greater effect sizes when the interventions are provided early (eg, in kindergarten or first grade, before LDs are typically diagnosable), as opposed to later. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17592?source=see_link&amp;anchor=H8#H8\">",
"     \"Interventions for children with reading difficulty\", section on 'Remediation'",
"    </a>",
"    .) It is not yet certain to what extent RTI may reduce the number of students identified as having LD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/11\">",
"     11",
"    </a>",
"    ]. The long-term merits of RTI have yet to be determined and will be difficult to measure because of the great variability in RTI practices across school districts and states [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/10,12\">",
"     10,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11284724\">",
"    <span class=\"h1\">",
"     REFERRAL FOR EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under the Individuals with Disability Education Act (IDEA), parents, teachers, and other professionals inside and outside of the school system can refer a child who is not succeeding academically for an evaluation to determine whether the child is eligible for special education services. RTI services do not have to be provided before an evaluation takes place, though the period of RTI services can provide valuable information about the student&rsquo;s learning abilities and learning needs, including the type of testing that may be required during a subsequent evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35944?source=see_link&amp;anchor=H18#H18\">",
"     \"Specific learning disabilities in children: Evaluation\", section on 'Evaluation and identification of LD in school settings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the request for an evaluation is made in writing, schools have to respond with a proposal to conduct an evaluation (or to deny the evaluation) within five business days. The school can refuse to conduct the evaluation if an evaluation was done within the previous year, or if they have data to show that the evaluation is not needed. If no evaluation has been completed recently, schools typically agree to the request for an evaluation. Once the parents have provided written permission to the school for the evaluation to begin, the school is obliged to complete the evaluation within 60 calendar days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/38/37480?source=see_link\">",
"     \"Definitions of specific learning disability and laws pertaining to learning disabilities\"",
"    </a>",
"    .) Specialized instruction for a learning disability begins after the school has created an &ldquo;individualized education program&rdquo; (IEP), and after the student&rsquo;s parents have agreed to and signed the IEP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11284731\">",
"    <span class=\"h1\">",
"     QUALITY INSTRUCTION FOR LD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the examples of quality instruction for learning disabilities (LD) that are described below are considered to be &ldquo;researched&rdquo; and even &ldquo;evidence-based,&rdquo; it is important to understand the limitations of educational research in general. The basic pattern in educational research is that the researcher identifies, labels, and counts specific teacher behaviors and then attempts to determine the association between those behaviors and student outcomes. &ldquo;Teacher behaviors&rdquo; in this case refers to the teacher&rsquo;s organization of the lesson plan, the amount of repetition provided, the types of classroom groupings used, the types of technologies used, and other behaviors and features. Students must also be taught skills that they are developmentally or educationally ready to learn, a facet of educational research that is more difficult to evaluate but is addressed in some studies.",
"   </p>",
"   <p>",
"    Different researchers select varying teacher behaviors or classroom features for study and use different terms to describe them, making comparisons across studies difficult. Thus, there is limited consensus about which terms to use to describe teacher practices, let alone define or describe quality teacher practices. Because teachers do not rely on any one behavior or teaching strategy, any improvement in student outcomes is likely to be due to a variety of teacher behaviors or practices acting together, making it difficult to determine which specific types of teaching behaviors or methods are the most effective. In addition to these two important intrinsic limitations to educational research, educational research often lacks methodologic integrity. For example, educational research studies often (1) do not make use of a randomized or experimental design, (2) often do not describe or discuss what measures were taken to assure treatment integrity, and (3) often use researcher-created outcome measures rather than standardized measures. These methodologic limitations make it difficult to know which teacher practices are associated with the highest effect size, if any. Use of research-created outcomes makes it difficult to know how a student might perform when he or she is assigned tasks that were not specifically taught during the intervention.",
"   </p>",
"   <p>",
"    All of the above factors make it difficult to draw firm conclusions about the nature of quality instruction. In one oft-cited meta-analysis of 180 studies of instructional practices for students with LD, the authors estimated that only 10 percent of the studies were of high methodologic quality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/14\">",
"     14",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    With these caveats in mind, the remainder of this topic review discusses quality teaching practices for students with LD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11284747\">",
"    <span class=\"h2\">",
"     Types of instruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The components of quality instruction described below are considered to be especially critical for students with LD but are beneficial for students without LD, as well. The practices described below do not interfere with the learning of average or high-achieving students being educated in the same classroom setting.",
"   </p>",
"   <p>",
"    Two main types of instruction, explicit and strategy instruction, are described below. The principles of direct and strategy instruction are not new. However, they often are not implemented in a consistent manner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Furthermore, controversy exists among practitioners about the best way to engage students in learning and about the relative merits of direct and strategy instruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/17\">",
"     17",
"    </a>",
"    ]. The educational research makes a clear case for the importance of both. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11284754\">",
"    <span class=\"h3\">",
"     Explicit or direct instruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Special education is known for its tradition of &ldquo;drill and practice,&rdquo; referred to as explicit or direct instruction. In its most basic form, explicit or direct instruction refers to instruction that is dedicated to the acquisition of basic academic skills, largely by repetition and memorization. Although criticized for being a dull form of learning and for not addressing the higher-order thinking that is the ultimate goal of education, there is broad consensus among educational researchers that direct instruction is an important component of special education instruction.",
"   </p>",
"   <p>",
"    Direct instruction typically entails frequent and direct measurement of clearly observable behaviors and responses, such as acquiring phoneme-grapheme awareness in reading, letter writing and spelling skills in writing, or basic calculation skills in math. Progress must be measured frequently. The specific skills taught during direct instruction should be taught in a logical sequence, with rational transitions from one set of basic skills to the next, until mastery is achieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/17\">",
"     17",
"    </a>",
"    ]. Although direct instruction traditionally refers to instruction in basic academic skills, any form of instruction that insists upon rote learning of a skill can be referred to as direct or explicit instruction. Strategy instruction, discussed in the next section, is typically considered to be a separate kind of instruction, but can also be taught through direct instruction.",
"   </p>",
"   <p>",
"    A detailed discussion of explicit instruction is provided in reference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11284761\">",
"    <span class=\"h3\">",
"     Strategy instruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strategy instruction is another important component of quality instruction for students with LD. Strategy instruction refers to instruction in a process or a procedure that the student can use to approach learning systematically. Strategy instruction helps the student memorize what he or she needs to learn; to detect and correct errors encountered during learning or task completion; to monitor and revise tasks when needed; or to reflect upon what was learned.",
"   </p>",
"   <p>",
"    A strategy can be as simple as prompting oneself to check one&rsquo;s spelling errors, using mnemonics to memorize information, or underlining the topic sentences in written text to improve reading comprehension. Strategies can also be more complex, such as the strategy or set of strategies used to write a five-page essay, or the strategy used to develop a deeper understanding of the material being learned. For example, in reading-strategy instruction, the student is taught to use a set of steps, such as stopping while reading to check comprehension; asking questions, such as, &ldquo;What does this remind me of?&rdquo;; making links with prior knowledge; etc.",
"   </p>",
"   <p>",
"    Students with LD often fail to approach learning strategically and do not monitor their own comprehension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    success. Failure to approach learning strategically may reflect the executive dysfunctions that are a common comorbid condition in students with LD. However, students with LD are unlikely to approach learning strategically. They use excessive cognitive resources to perform basic academic skills (eg, reading decoding, spelling, calculation), and therefore have insufficient remaining cognitive resources to approach learning strategically or develop meta-cognitive awareness of what was learned.",
"   </p>",
"   <p>",
"    Additional information about strategy instruction, with examples, is provided in reference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/18-20\">",
"     18-20",
"    </a>",
"    ] &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11284768\">",
"    <span class=\"h3\">",
"     Other methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other methods of quality instruction for students with LD include teacher behaviors, such as stating the learning objectives clearly, having a clearly organized lesson plan, teaching in a recursive manner (concepts and learning objectives are reviewed multiple times over the course of the lesson or of the unit), providing examples, and proceeding through the material in appropriately small steps, etc.",
"   </p>",
"   <p>",
"    Successful LD programs provide teachers with professional development focused on specific teaching methods. The effective teacher imparts a positive attitude to the student(s); has a variety of texts, strategies, and teaching methods to provide both direct and strategy instruction; and uses ongoing assessment to continually tailor instruction to the student&rsquo;s ability level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/21\">",
"     21",
"    </a>",
"    ]. Teacher behaviors that are strongly associated with positive effect sizes include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presenting smaller amounts of material at a time",
"     </li>",
"     <li>",
"      Using small interactive groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/16,23\">",
"       16,23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Using directed questioning",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Peer tutoring is also considered to be an evidence-based practice and can have positive outcomes on student learning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/16,23-25\">",
"     16,23-25",
"    </a>",
"    ]. Peer instruction is discussed in more detail in the sections on math and writing. (See",
"    <a class=\"local\" href=\"#H11284862\">",
"     'Writing disability'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11284970\">",
"     'Math disability'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7835933\">",
"    <span class=\"h2\">",
"     Accommodations and modifications for students with LD in the general education classroom",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section provides examples of accommodations and modifications that may be appropriate for students with LD (",
"    <a class=\"graphic graphic_table graphicRef55692 \" href=\"mobipreview.htm?4/41/4765\">",
"     table 1",
"    </a>",
"    ). The accommodations or modifications provided by a special education teacher or in a special education classroom often are the same as the instructional strategies described above. Thus, presenting smaller amounts of material at a time, using small interactive groups, providing more individualized direct questioning, and using peer group discussion can serve as accommodations or modifications. Strategy instruction and advance organizers (providing key information to the student in advance of a lesson) may also be used as accommodations or modifications. For students with reading disability, accommodations might include oral administration of tests, especially for tests where reading skills are not the primary goal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/26\">",
"     26",
"    </a>",
"    ]. Dictation or scribing, or the use of preprinted lecture notes, may be used for students with writing disability. For all types of LD, the amount of time allowed to complete work (including a test) can be increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/27\">",
"     27",
"    </a>",
"    ], or the number of items that the student is expected to complete can be reduced.",
"   </p>",
"   <p>",
"    Another approach to the use of accommodations or modifications is to offer curricular material that uses different means of representation and that allows different means of expression for all of the students in the classroom. This is known as Universal Design and is most easily accomplished through the use of digital media [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Information can be presented using text, voice, or images. Text can be presented in varying sizes or can be presented as speech",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in the context of images. Text can be presented with hyperlinks to associated glossaries, to related background information, to queries that support strategic thinking, and to tools that allow the student to express and organize text, recorded voice, or images [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Curricular materials that offer these options allow easier access to the general education curriculum for all students, and perhaps especially to students with disabilities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11284775\">",
"    <span class=\"h2\">",
"     Reading disability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interventions for children with reading disability are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17592?source=see_link&amp;anchor=H8#H8\">",
"     \"Interventions for children with reading difficulty\", section on 'Remediation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17592?source=see_link&amp;anchor=H16#H16\">",
"     \"Interventions for children with reading difficulty\", section on 'Accommodation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11284862\">",
"    <span class=\"h2\">",
"     Writing disability",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11284870\">",
"    <span class=\"h3\">",
"     Instruction in writing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Writing instruction involves drill and practice (explicit or direct instruction) of lower-order skills in the service of higher-order skills. Direct instruction is required for the student to achieve accurate letter formation and fluency in writing, spelling, and English language conventions (punctuation and grammar). Spelling and handwriting skills are predictive of differences in writing competence. Thus, explicit instruction in these lower-order &ldquo;text production skills&rdquo; also can lead to improvements in written compositions.",
"   </p>",
"   <p>",
"    Consensus about quality instruction for students with writing disability (WD) is less clear than it is for reading disability. There is no equivalent to the National Reading Panel to provide guidance or make recommendations for quality writing instruction. However, based upon the educational literature and research in writing instruction, writing instruction should consist of the following components [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Handwriting accuracy and fluency",
"      </strong>",
"      . Having basic writing skills automatized is the first step to writing. Handwriting is taught by direct or explicit instruction, through significant drilling and practice. Learning to write letters follows a logical sequence. Visually similar letters (&ldquo;b&rdquo; and &ldquo;d&rdquo;; &ldquo;v&rdquo; and &ldquo;u&rdquo;); letters with directional shifts (&ldquo;z&rdquo; and &ldquo;s&rdquo;); and less frequent letters (&ldquo;q&rdquo; and &ldquo;w&rdquo;) are typically learned later than other letters. Printing and cursive are typically taught sequentially, but it is not clear that one should follow the other, nor that one leads to faster writing output than the other. Handwriting instruction is typically conducted by teachers, but occupational therapists, who focus on the motor components of writing instruction, also play a role. No one handwriting program is clearly superior to another, and the role of the occupational therapist in teaching handwriting skills varies within and between school districts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/33\">",
"       33",
"      </a>",
"      ]. Once letter production skills are mastered, students can develop their personal handwriting style [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. Learning to type may be preferred for older students or for students with motor impairments, especially when the focus is on writing compositions. (See",
"      <a class=\"local\" href=\"#H88270081\">",
"       'Accommodations'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Phonologic awareness and phonics instruction",
"      </strong>",
"      . Phonologic awareness and phonics instruction are important components in spelling instruction. The value of phonologic awareness and phonics instruction in students with WD has not been studied specifically. However, they have been shown to help typically developing students improve their spelling skills. A small number of studies suggest that spelling improves as a part of reading instruction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/36\">",
"       36",
"      </a>",
"      ]. Teaching writing includes direct and explicit instruction in these language and reading skills [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/35,37\">",
"       35,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Spelling and grammar",
"      </strong>",
"      . Spelling improves with direct and explicit instruction in spelling that includes multiple practice opportunities and immediate corrective feedback when words are misspelled. Spelling instruction should include words that the student already knows how to spell, along with words that the student has not yet mastered. Spelling lists based on an individual student&rsquo;s spelling competence are a favored means of spelling instruction. Monitoring the student&rsquo;s progress and showing the student how many words he or she has mastered can enhance motivation.",
"      <br/>",
"      <br/>",
"      Direct and explicit spelling instruction can only help students learn a small fraction of the total number of words that they will ultimately need to use in writing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/37\">",
"       37",
"      </a>",
"      ]. Thus, instruction in spelling as a part of text composition is recommended; this makes spelling more relevant and assures that it is an ongoing learning process. Spelling improves when the student is taught error correction strategies. Error correction strategies include having the student analyze his or her spelling and check for what is plausible; read (decode) the words aloud; have a peer read the word; read the text backward; or use a dictionary",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      computerized spell checker [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. For older struggling writers, handwriting, spelling, and English language conventions can be taught as part of the process of teaching composition skills.",
"     </li>",
"     <li>",
"      <strong>",
"       Writing compositions",
"      </strong>",
"      . Writing compositions is the ultimate goal of mastery in the lower-level skills discussed above. Writing compositions is complex because of the higher-order cognitive skills required for producing compositions successfully. Composition instruction requires significant instruction in strategy use. The specific strategies used by the student will vary according to the type of text that has to be produced and according to student preferences and needs. Some of the approaches for composition instruction are listed below: &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Focus composition writing at the sentence or paragraph level, for which specific strategy instruction is also available [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/38\">",
"       38",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Teach the process of writing (planning, revising, editing) through writing strategy instruction. The specific steps in the strategy can vary from teacher to teacher. What is important is that the teacher provides a strategy for writing and uses a consistent vocabulary to describe each of the steps (",
"      <a class=\"graphic graphic_table graphicRef52054 \" href=\"mobipreview.htm?6/53/7005\">",
"       table 2",
"      </a>",
"      ). This facilitates the student&rsquo;s learning because it allows the teacher and the peers to analyze the steps of the writing process together. It also provides a mechanism for feedback and correction from the teacher",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      peers at each of the steps. Students with LD can be taught to use the same strategies as students in regular education. (See",
"      <a class=\"local\" href=\"#H11284877\">",
"       'Effective writing programs'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Teach different kinds of composition (genre). Students can be asked to write in a variety of genres, such as a newspaper article, a business letter, an advertisement, a personal essay, etc. Developing a shared vocabulary for the types of writing genres facilitates teacher-peer and peer-peer discussion and feedback.",
"     </li>",
"     <li>",
"      Provide feedback. Feedback gives the student additional opportunities for planning, writing, and revising. Feedback from peers may be as valuable as feedback from the teacher and is important for the revising process, as well as to induce greater self-monitoring.",
"      <br/>",
"      <br/>",
"      For students with WD, provide extra time to master lower-order skills, or extra time to understand, memorize, and apply the strategies involved in writing. The student with LD may need to learn the steps of writing in smaller groups, or as part of direct and explicit instruction when initially learning the writing strategy. Students with WD may also need increased motivation (eg, by allowing them to choose their own topic) and more frequent and more structured opportunities to share their writing in a supportive environment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Older students with WD may benefit from accommodations such as a keyboard for lower-order weaknesses (eg, handwriting, spelling), allowing them to devote their mental energy to the ideas and organization of writing; this sometimes allows them to perform at a higher level of conceptual awareness than would otherwise be predicted, and to write longer and better text [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/16,35\">",
"       16,35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88270081\">",
"    <span class=\"h3\">",
"     Accommodations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accommodations that may be used to facilitate the production of compositions for students who have not yet mastered handwriting or spelling skills include dictation to a teacher and the use of pictures, word processors, spell checkers, etc. All of the accommodations that may be required by a writer can potentially be provided by a computer, which reduces the fine motor and physical demands of handwriting. Using a computer with word recognition, voice recognition, or dictation applications helps to reduce the number of strokes required to produce a word. Technology reduces the amount of work involved in correcting errors and reduces the problem of frequent erasures. In addition, computers help students with WD manage spelling errors and generate sentences, and may help with grammatic and stylistic errors. Computerized writing programs can also help with planning, by providing outlines for specific kinds of text structures, or by prompting the writer with questions that help assure that certain kinds of content are included. For writers early in their writing development, computers can generate pictures and a variety of other media, which can be used to scaffold writing. Finally, word processing and computers linked with one another can create a collaborative forum for writing to be shared, reviewed, and",
"    <span class=\"nowrap\">",
"     revised/edited",
"    </span>",
"    by peers and teachers. Many of the accommodations listed here are, in fact, used in writing instruction in the general education classroom and thus may not be accommodations in all circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. As is often true for the atypical learner, extra time also can play a role in providing accommodations to writers with WD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11284877\">",
"    <span class=\"h3\">",
"     Effective writing programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Components of effective writing programs for general education students are the same as those for quality instruction for WD. (See",
"    <a class=\"local\" href=\"#H11284747\">",
"     'Types of instruction'",
"    </a>",
"    above.) Successful writing instruction includes teacher professional development in writing, an effective teacher, instruction in the components of writing listed above, and maximum student participation. The use of peer-mediated instruction appears to be an especially favored instructional technique for teaching students how to write text because it provides a mechanism for obtaining feedback.",
"   </p>",
"   <p>",
"    Few effective writing programs are recognized in the educational literature. Two researched writing (composition) programs include the Self-Regulated Strategy Development (SRSD) writing program and Cognitive Strategy Instruction in Writing (CSIW), designed for general education students but also used for students with WD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/20,43-45\">",
"     20,43-45",
"    </a>",
"    ]. Both programs teach text composition skills by using a specific writing strategy. The writing strategy, which students can work through over the course of several days, includes steps such as learning about different kinds of text structures, planning, writing an initial draft, revising the draft, obtaining feedback from peers and teacher, writing a final draft, etc. These programs can be used in conjunction with instruction in handwriting, spelling, and punctuation skills and can be used for students of all ages.",
"   </p>",
"   <p>",
"    The general idea in SRSD, for example, is that the teacher presents information about a genre of writing (story, persuasive essay, news article) and about the specific steps for writing in that genre [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/44\">",
"     44",
"    </a>",
"    ]. The steps of the strategy are identified by vocabulary chosen by the teacher, and as dictated by the genre. The students learn about the type of writing they will do by analyzing examples and learning the vocabulary needed to discuss that genre of writing; they then learn the vocabulary for the strategy that is used to write in that genre (",
"    <a class=\"graphic graphic_table graphicRef52054 \" href=\"mobipreview.htm?6/53/7005\">",
"     table 2",
"    </a>",
"    ). This step in the strategy is an example of direct instruction, because students are asked to memorize new information.",
"   </p>",
"   <p>",
"    The students are then asked to work through each of the steps and to practice using the strategy in writing a composition. This is called guided practice: the teacher guides the student through each of the steps. Interactive dialogue is emphasized in this model, between teacher and student, between peers, and by using self-statements (thinking aloud with oneself as one writes). Dialogue with others and with oneself is used to monitor one&rsquo;s own use of the steps in the strategy, but also to identify and overcome frustration during the task of writing. Over time, the dialogic component transfers the teacher&rsquo;s guidance to the student.",
"   </p>",
"   <p>",
"    The multiple components of this example of strategy instruction include learning vocabulary; memorizing a mnemonic for the strategy (",
"    <a class=\"graphic graphic_table graphicRef71856 \" href=\"mobipreview.htm?28/16/28940\">",
"     table 3",
"    </a>",
"    ); specific examples for how to complete each of the steps of the strategy; guided practice (the teacher monitors the student&rsquo;s use of the strategy); self-guidance (self-monitoring) using dialogue; and self-regulation (changing one&rsquo;s behavior to overcome barriers along the way). Dialogue is used to help the student monitor whether or not",
"    <span class=\"nowrap\">",
"     s/he",
"    </span>",
"    completes each of the steps, and to identify and address obstacles (including frustration) along the way. The emphasis of this model is not simply giving the student a list of steps to follow, but helping the student &ldquo;own&rdquo; the strategy by seeing it in action; seeing for",
"    <span class=\"nowrap\">",
"     him/herself",
"    </span>",
"    how it gets completed; and even how the strategy can be modified by the student to meet his or her personal needs. Over time as the student matures, self-dialogue is internalized.",
"   </p>",
"   <p>",
"    The instruction described above is appropriate for students with WD, as well as for general education students. The literature is not clear about the intensiveness of instruction required by students with WD. Students with WD may need intensive instruction in handwriting accuracy and fluency, spelling (including phonics instruction), and English language conventions. For students who are still mastering lower-order skills, text composition can be taught by teaching (oral) narrative skills, and by use of dictation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pictures. Over-emphasis on handwriting, spelling, text composition, or text meaning in isolation is likely to hamper the student&rsquo;s writing progress. All of the writing skills should be taught simultaneously, as well as sequentially [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When all of the components of writing instruction are addressed, writing outcomes in students in both regular and special education improve. However, not all states include a writing component in state-mandated examinations. Consequently, not all states or school districts address writing skills as a formal part of the general education curriculum, let alone as part of the curriculum for students with LD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. The consistency with which writing instruction strategies are offered is highly variable across school districts and states.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11284970\">",
"    <span class=\"h2\">",
"     Math disability",
"    </span>",
"    &nbsp;&mdash;&nbsp;As is the case for reading and writing, competence in math depends upon a set of sub-skills. In math disability (MD), primary deficits occur in number sense and in math facts (arithmetic combinations or arithmetic calculations), two of the basic sub-skills that are necessary to develop competence in higher math [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. Students with MD also have difficulty solving word problems. This can be due to weak number sense, calculation skills, or coexistent reading disability. Finally, visual-spatial and organizational problems can interfere with success in math. The clinical manifestations of MD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32665?source=see_link&amp;anchor=H12#H12\">",
"     \"Specific learning disabilities in children: Clinical features\", section on 'Math LDs'",
"    </a>",
"    .) For a more detailed description of the difficulties faced by students with math LD, please see references [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/48,49,51-53\">",
"     48,49,51-53",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11284978\">",
"    <span class=\"h3\">",
"     Components of instruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A true understanding of MD may be more complex than what is proposed here, as students may show other weaknesses, as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/51\">",
"     51",
"    </a>",
"    ]. However, the framework provided below serves as a starting point for discussing the content that should be addressed for students with difficulty learning math.",
"   </p>",
"   <p>",
"    Based upon &ldquo;expert opinion,&rdquo; effective math instruction must address difficulties in the following areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/38,48,49\">",
"     38,48,49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Number sense",
"      </strong>",
"      . Number sense refers to having mental representation of quantity (ie, the ability to estimate and judge magnitude). It is an early-emerging skill that can fail to develop in students with MD.",
"      <br/>",
"      <br/>",
"      Number sense should be teachable, just as phonemic awareness is teachable. It can be taught by practicing identifying or estimating quantity (less and more); 1:1 correspondence (eg, correlating the number of coins being dropped into a box with the sound each of the coins makes as it drops); serial ordering; &ldquo;counting on&rdquo; (ie, identifying changes in quantity by adding up from a quantity to create a larger quantity); showing the link between addition and subtraction while using objects; using more than one type of visual representation for numbers (eg, a number line both horizontal and vertical); and other visual representations that show differences in volume, etc. [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/52,53\">",
"       52,53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Arithmetic combination and calculation skills",
"      </strong>",
"      . Automatic use of math facts (the automatic retrieval of answers to basic addition, subtraction, multiplication, and division of numbers) is a prerequisite to solving higher-order math problems efficiently. Students with MD have difficulty completing higher order math problems when they have not yet developed automaticity in basic arithmetic combinations and cannot retrieve answers to basic arithmetic combinations quickly. Remediation is crucial for students who continue to have deficiencies in arithmetic combinations at the beginning of third grade. The use of a computer can &ldquo;force&rdquo; students to use retrieval strategies, rather than allowing them to count using their fingers. Strategy instruction can help the student identify errors in their calculations",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in their retrieved answers (eg, by using known number combinations, using associations between number combinations, etc.). Drilling and memorization alone are not as effective as the combination of drilling with strategy instruction.",
"     </li>",
"     <li>",
"      <strong>",
"       Efficient and effective counting-strategy use",
"      </strong>",
"      . For students with MD, counting strategies need to be taught explicitly alongside number facts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/48,49,54\">",
"       48,49,54",
"      </a>",
"      ]. Students with MD may not develop their own strategic learning. For example, they may not learn that &ldquo;counting upward&rdquo; from the larger addend can save time when doing addition problems. Counting strategies can help develop both number sense and arithmetic combination skills [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/38,48,49\">",
"       38,48,49",
"      </a>",
"      ]. As they become more proficient in counting strategies, students of math gradually develop memory-based retrieval of answers, which increases their overall efficiency.",
"     </li>",
"     <li>",
"      <strong>",
"       Math vocabulary",
"      </strong>",
"      . Students with MD have difficulty with the language of math. They may reverse numbers, or make errors when reading numbers aloud. Confusion about number symbols and signs (eg,&ldquo;+,&rdquo; &ldquo;-,&rdquo; &ldquo;&times;,&rdquo; &ldquo;&divide;,&rdquo; &ldquo;=,&rdquo; etc.) is a distinguishing characteristic of math LD. In math, there are no context clues to help students decipher terms that they may not understand. The language of math must be taught directly and explicitly, not incidentally.",
"     </li>",
"     <li>",
"      <strong>",
"       Word problems.",
"      </strong>",
"      Reading difficulties can aggravate difficulty acquiring math skills. Students with a reading disability and MD have greater difficulty with word problems than students with isolated MD. They also have greater difficulty understanding the meaning of the sentences describing the problem, understanding what the problem is asking, and identifying extraneous or irrelevant information. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/21/1370?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical features and evaluation of reading difficulty in children\", section on 'Clinical features'",
"      </a>",
"      .) General strategy instruction may be helpful in solving word problems (eg, &ldquo;Read the problem; highlight the key words; solve the problems; check your work&rdquo;).",
"     </li>",
"     <li>",
"      <strong>",
"       Visual-spatial weaknesses",
"      </strong>",
"      . Students with MD may have difficulty organizing math problems on the page. They may copy numbers incorrectly, write numbers illegibly, misalign numbers, have left-right disorientation of numbers, misplace digits in multidigit numbers, skip rows or columns during calculations, fail to carry numbers (eg, regrouping when appropriate), reverse number problems, start a calculation in the wrong place, or may not recognize operator signs. The use of lined or graph paper, or specific strategy instruction to prevent errors such as these, can help improve the student&rsquo;s performance.",
"     </li>",
"     <li>",
"      <strong>",
"       Organization and planning",
"      </strong>",
"      . Students with MD have difficulty planning and organizing their approach to math problems. They have difficulty with multistep problems; they may fail to verify answers and may settle for the first answer they reach for a given problem. Teaching can include strategy instruction that requires the student to follow a prescribed sequence when solving math problems; to check solutions to basic math facts using a computer; or to prompt the student to ask if the answer is a reasonable one.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24764929\">",
"    <span class=\"h3\">",
"     General teaching strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;General teaching strategies that are important components of math instruction include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/50,55\">",
"     50,55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Explicit instruction (drill and practice)",
"     </li>",
"     <li>",
"      Verbalizing the steps (think-aloud strategy)",
"     </li>",
"     <li>",
"      Immediate error correction and feedback",
"     </li>",
"     <li>",
"      Cumulative review",
"     </li>",
"     <li>",
"      Small group instruction",
"     </li>",
"     <li>",
"      Adequate practice opportunities",
"     </li>",
"     <li>",
"      Motivators",
"     </li>",
"     <li>",
"      Instructional design to minimize the learning challenge",
"     </li>",
"     <li>",
"      Frequent assessment and the provision of feedback to the student and the teacher alike",
"     </li>",
"     <li>",
"      Peer-assisted instruction",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11284985\">",
"    <span class=\"h3\">",
"     Effective math programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective instruction in math is less well studied than effective instruction in reading and writing in typically developing children, let alone children with LD. In one review of the effectiveness of math instruction in general education classrooms, no conclusions could be drawn as to what constitutes effective math programs. This failure to draw firm conclusions was due to the inadequate study design of the studies available for review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/56\">",
"     56",
"    </a>",
"    ]. As such, there are no specific math programs that can be recommended as &ldquo;evidence-based,&rdquo; though there are evidence-based practices for components to math instruction.",
"   </p>",
"   <p>",
"    In a synthesis of effective elementary school math programs, the biggest effect sizes (which were in the small range) were for instructional process strategies, such as cooperative learning methods, in which students work in pairs or in small groups, or class-wide peer tutoring. These types of strategies are not specific to math instruction and are used in other subject areas. There were no significant effect sizes associated with the type of mathematic curriculum or with the use of computer-assisted instruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommendations listed below are taken from a practice guide produced by the United States Department of Education [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/58\">",
"     58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Instructional materials for students receiving interventions should focus intensively on in-depth treatment of whole numbers in kindergarten through grade five and on rational numbers (fractions) in grades four to eight (develops number sense, among other skills).",
"     </li>",
"     <li>",
"      Intervention materials should include opportunities for students to work with visual representations of mathematical ideas, and interventionists should be proficient in the use of visual representations of mathematical ideas (develops number sense. There is strong evidence for this recommendation).",
"     </li>",
"     <li>",
"      Interventions at all grade levels should devote about 10 minutes in each session to building fluent retrieval of basic arithmetic facts.",
"     </li>",
"     <li>",
"      Instruction during the intervention should be explicit and systematic. This includes providing models of proficient problem solving, verbalization of thought processes, guided practice, corrective feedback, and frequent cumulative review.",
"     </li>",
"     <li>",
"      Interventions should include instruction on solving word problems that is based on common underlying structures (there is strong evidence for this recommendation).",
"     </li>",
"     <li>",
"      The progress of students receiving supplemental instruction and other students who are at risk should be monitored.",
"     </li>",
"     <li>",
"      Include motivational strategies in &ldquo;response to intervention&rdquo; models. (See",
"      <a class=\"local\" href=\"#H11284717\">",
"       'Response to intervention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      General teaching principles of effective instruction apply to math instruction as they do to instruction in other domains. For example, verbalizing the steps (think-aloud strategy); immediate error correction and feedback; small group instruction; adequate practice opportunities; motivators; frequent assessment and the provision of data as feedback to the student; and peer assisted instruction are all important components in math instruction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11285093\">",
"    <span class=\"h1\">",
"     GRADE RETENTION AND SOCIAL PROMOTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Grade retention is defined as the practice of having a student repeat a grade because of academic failure and is a common intervention for students who experience academic failure. The philosophy behind grade retention is that, if given another year to &ldquo;catch up,&rdquo; the student&rsquo;s academic progress can improve over time. Proponents of grade retention may also say that students use the (undesirable) possibility of grade retention as a motivator to perform better. Social promotion is defined as advancing a student to the next grade even if he or she is not functioning at grade level.",
"   </p>",
"   <p>",
"    The educational literature generally concludes that grade retention should be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/59\">",
"     59",
"    </a>",
"    ]. Neither grade retention nor social promotion on its own is an effective educational intervention. Without classroom modifications and individualized instruction, students with learning problems, and especially students with LD, will continue to experience learning difficulties. Alternatives to grade retention and social promotion are discussed below. (See",
"    <a class=\"local\" href=\"#H11285128\">",
"     'Alternatives to grade retention'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H546789319\">",
"    <span class=\"h2\">",
"     Which students are retained?",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no uniform practice for deciding how a student who shows academic failure is promoted versus retained. Many factors are associated with grade retention, including poor academic performance, behavioral regulation problems, poor attendance, and lower socioeconomic status. A disproportionate number of African-American and Hispanic students are retained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/60\">",
"     60",
"    </a>",
"    ]. Another important factor that contributes to the practice of grade retention is the degree to which the school staff believes in grade retention as a useful intervention. A positive attitude among school staff toward grade retention increases the likelihood of grade retention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/61\">",
"     61",
"    </a>",
"    ]. Grade retention may be more common as a result &ldquo;high-stakes&rdquo; testing that requires students to achieve a minimum score on statewide testing before being promoted. State-to-state variations in school expenditure and special education enrollment figures do not account for differences in grade retention between school districts. Grade retention is thus more dependent on individual, family, and neighborhood characteristics than on state-wide characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/62\">",
"     62",
"    </a>",
"    ]. Grade retention that occurs early (eg, in kindergarten or grade one) does not appear to be more beneficial or more harmful than grade retention that occurs later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H546789333\">",
"    <span class=\"h2\">",
"     Prevalence of grade retention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data available to measure changes in the prevalence of grade retention are limited. A proxy for grade retention is the prevalence of students &ldquo;below modal grade for age.&rdquo; Using this proxy, and correcting for late entry into school, the prevalence of grade retention is estimated to be between 10 and 20 percent in any given grade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11285121\">",
"    <span class=\"h2\">",
"     Is grade retention beneficial?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most researchers do not believe that grade retention is effective for improving long-term outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/59\">",
"     59",
"    </a>",
"    ]. Several outcome measures in grade retention research support this conclusion.",
"   </p>",
"   <p>",
"    The outcomes measured in grade retention research include subsequent academic achievement, socioemotional status, and high school drop-out rates. When compared with same-age promoted peers, retained students show temporary gains in academic achievement and socioemotional status (behavioral regulation, emotional status, and peer acceptance), but these gains are not sustained over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/61,65,66\">",
"     61,65,66",
"    </a>",
"    ]. An oft-quoted meta-analysis concludes that the majority of studies (95 percent) show that grade retention is associated with either no difference in effect (48 percent) or is associated with harm (47 percent) and should therefore be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of specific concern is the association of grade retention with high school drop-out. Grade retention is considered to be the single most powerful predictor of high school drop-out, and students who drop out of high school are likely to have poor outcomes following high school, including lower wages and a lower likelihood of participating in postsecondary education, and to have poor employment competence ratings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although grade retention is associated with negative long-term outcomes, the limitations of grade retention research (described in the next section) do not clearly answer the question of whether it is grade retention, versus characteristics intrinsic to the student, that are cause for the negative outcomes.",
"   </p>",
"   <p>",
"    Considering the multiple factors associated with retaining a student, including undiagnosed LD, socioemotional factors, poverty, lower parental participation in school, and poor attendance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/68,69\">",
"     68,69",
"    </a>",
"    ], it is not surprising that an intervention as nonspecific as grade retention does not, on its own, significantly improve student outcomes. Furthermore, grade retention is an expensive intervention, since the school district takes on the cost of educating the student for at least an additional year of schooling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/70\">",
"     70",
"    </a>",
"    ], though the cost of grade retention in comparison to the cost of providing remedial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    special education services is not certain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1176035\">",
"    <span class=\"h3\">",
"     Quality of grade-retention research",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies on the effects of grade retention are problematic because of a uniform absence of randomized design. Because of the lack of randomized design, the outcomes measures associated with grade retention studies may or may not be due to grade retention itself. Those students who are selected for retention are not likely to be the same (on myriad variables) as those students who are promoted. Thus, the outcome following grade retention may not reflect the intervention (grade retention), but may reflect intrinsic differences in the student who was retained, as well as other confounders.",
"   </p>",
"   <p>",
"    Some authors attempt to control for the lack of randomization by matching retained students with promoted students on academic achievement and other variables. This may enhance the validity of the conclusions drawn, but it would not be possible to control all of the variables that might affect the student&rsquo;s performance. Additional limitations on grade retention research include the lack of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Control for treatment integrity (eg, not controlling for the proportion of retained or promoted students who receive supplemental educational services, such as special education)",
"     </li>",
"     <li>",
"      Control for attendance",
"     </li>",
"     <li>",
"      Uniform",
"      <span class=\"nowrap\">",
"       control/comparison",
"      </span>",
"      population. Retained students may be compared with their same-age (promoted) peers or with same-grade peers during the same calendar year or with their promoted peers, once the retained student has reached the same grade, during the same grade year. Such different comparisons yield different outcomes but are not necessarily accounted for in meta-analyses of grade retention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these variables confound attempts to draw firm conclusions from the retention research literature as a whole. A more detailed discussion of grade retention research is available in reference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. In any case, given the many variables involved in academic failure, a nonspecific intervention, such as grade retention on its own, should not be expected to be effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11285128\">",
"    <span class=\"h2\">",
"     Alternatives to grade retention",
"    </span>",
"    &nbsp;&mdash;&nbsp;On their own, grade retention and social promotion are generally considered to be unfavorable strategies for students who are not succeeding academically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/59,60,68,73\">",
"     59,60,68,73",
"    </a>",
"    ]. Given the multiple factors associated with school difficulty (eg, undiagnosed LD, low self-concept, poor peer relations, poverty, poor attendance, etc.) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/68,69\">",
"     68,69",
"    </a>",
"    ], it is preferable to determine the types of services, interventions, and accommodations that might help the student succeed over both the short and long term.",
"   </p>",
"   <p>",
"    For many students, especially those who start school with fewer academic advantages than their peers, preventive intensive intervention, even before kindergarten, may be the best path to success. For students who are frequently absent, understanding and addressing the reasons for their absence should be considered. Retention usually duplicates an entire year of schooling. Other options, such as summer school, before- or after-school programs, or extra help during the school day, could provide the equivalent extra time that the student requires and could be instructionally more effective. Students who are not succeeding academically might benefit from multi-age classrooms, school-based mental health programs,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    behavioral modification and social-skills training [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/60,68,74-76\">",
"     60,68,74-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Teacher attitude and school culture may be just as important to address when considering grade retention as an intervention. In some cases, retention may be recommended as an educational intervention, even when the local school district offers other, more valid options to address learning failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11285135\">",
"    <span class=\"h1\">",
"     SPECIALIZED EDUCATION PLACEMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Educational remediation is a critical component of treatment and can be provided by the public school system through special education services, by special education private schools, or by private individual special education teaching services [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/15,78\">",
"     15,78",
"    </a>",
"    ]. The eligibility requirements for special education within the public school system are defined by the Individuals with Disabilities Education Act (IDEA), although specifics vary by state and county. Schools may also provide specialized educational supports under the Americans with Disabilities Act, through Section 504 planning. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/38/37480?source=see_link\">",
"     \"Definitions of specific learning disability and laws pertaining to learning disabilities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Not every child with an LD will qualify to receive special education services under the umbrella of IDEA according to the guidelines in his or her school district. When such children are not eligible, it may be necessary for parents to provide specialized educational services privately. In seeking specialized education services for their child in school, parents may find it helpful to maintain a file of relevant documents. A list of important documents for parents to retain, as well as resources and information regarding state learning disability organizations, parent support groups, and advocates, are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef50005 \" href=\"mobipreview.htm?19/19/19772\">",
"     table 4",
"    </a>",
"    ), which may be printed and provided to parents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Services offered under Section 504 and NCLB",
"      </strong>",
"      . Schools offer a multiplicity of specialized services and accommodations to students, with and without learning disability. Services offered under the No Child Left Behind Act and Section 504 of the Rehabilitation Act are typically offered in a regular education setting and can include &ldquo;responsiveness to intervention&rdquo; (RTI) services, paraprofessional supports, and nursing and behavioral supports, among others. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/38/37480?source=see_link&amp;anchor=H5#H5\">",
"       \"Definitions of specific learning disability and laws pertaining to learning disabilities\", section on 'No Child Left Behind'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/38/37480?source=see_link&amp;anchor=H9#H9\">",
"       \"Definitions of specific learning disability and laws pertaining to learning disabilities\", section on 'Section 504 of the Rehabilitation Act'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Services under the IDEA",
"      </strong>",
"      . Under the IDEA, a continuum of placements is offered to qualifying students, who are entitled a &ldquo;free and appropriate public education.&rdquo; Services can be provided in the regular classroom, special classrooms, special schools, and in home, hospital, or other institutional settings. Schools are obliged to provide services in the &ldquo;least restrictive environment&rdquo; (often abbreviated LRE). The legal definition of &ldquo;least restrictive&rdquo; means that, to the maximum extent appropriate, children with disabilities are educated with children who are not disabled [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/79\">",
"       79",
"      </a>",
"      ]. Examples of the continuum are listed below:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Primarily general education classroom",
"      </strong>",
"      &ndash; Children who receive services in the regular classroom are \"mainstreamed\" with non-LD students for at least 80 percent of the day. The remainder of the day is spent in the resource room or special education classroom. The general education teacher typically does not have training in special education, but receives consultative support from the special education teacher who provides indirect services (consultation to the teacher) and direct services (individualized instruction) to the student [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Resource room or special education classroom placement with partial mainstreaming",
"      </strong>",
"      &ndash; Many elementary school children with learning disabilities (LD) receive instruction in the resource room for between 21 to 60 percent of their school days. In the resource room, remedial instruction is provided to small groups of four to eight children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/80,81\">",
"       80,81",
"      </a>",
"      ]. The resource room teacher usually has advanced training in the techniques of instruction and in the modifications required to individualize instruction for children with LD. Instruction in the resource room can focus on basic skills or learning strategies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/82\">",
"       82",
"      </a>",
"      ]. Remediation should be coordinated with the regular classroom teacher so that the student uses the skills acquired in the resource room to participate and learn successfully in the general education classroom [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Self-contained classroom with minimal mainstreaming",
"      </strong>",
"      &ndash; Children with moderate or severe LD are usually served in a self-contained classroom, with 10 to 15 students, for more than 60 percent of the school day [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/83\">",
"       83",
"      </a>",
"      ]. This setting enables more intensive individualized instruction, and students are able to receive more opportunities to practice required skills.",
"     </li>",
"     <li>",
"      <strong>",
"       Substantially separate placement",
"      </strong>",
"      &ndash; The student&rsquo;s education can be provided exclusively in a resource room or special education classroom; a residential facility; or a hospital setting. However, these settings would typically not meet the criterion of &ldquo;least restrictive environment&rdquo; and would typically not be used for a student with a sole diagnosis of LD. An exception might be for the student who is placed in a substantially separate school that is designed for students with LD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although placement questions often are a source of discussion for parents and school personnel, a more important focus for discussion is the type of curriculum and services required by the student and the training of the staff available to provide the necessary curriculum and services. The type of instruction needed by the student and the quality of instruction delivered to the student are not determined by the placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/80,81,83,84\">",
"     80,81,83,84",
"    </a>",
"    ]. Placement questions can be addressed only once the student&rsquo;s curricular and therapeutic needs have been determined. This is especially important for the adolescent with LD, as the curriculum provided has to address transition planning and may thus require service delivery outside a traditional school setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11285149\">",
"     'Transition planning'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11285142\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF LD IN HIGH SCHOOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;As students enter secondary school, the focus of general education becomes more content driven; basic skills are no longer emphasized. Students with learning disabilities (LD) who are still mastering basic language, reading, writing, and math skills would be expected to have difficulty understanding higher-level classroom activities that are focused on content.",
"   </p>",
"   <p>",
"    Lack of special education training among general education staff is more pronounced at the secondary school level. Inclusion in the general education classroom thus requires special attention to the student&rsquo;s capacity to identify, understand, and recall the information that is presented. If the student&rsquo;s education is to be meaningful, information may need to be presented at a slower pace, using alternative types of presentation (visual representations, such as pictures or movies, or more small-group, peer-mediated, or discussion-based presentation) (",
"    <a class=\"graphic graphic_table graphicRef55692 \" href=\"mobipreview.htm?4/41/4765\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/86\">",
"     86",
"    </a>",
"    ]. The student may also need to be permitted to use alternative means to demonstrate his or her knowledge (eg, writing by dictation, using word processors to help with word retrieval and spell checking, etc.) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/82,86\">",
"     82,86",
"    </a>",
"    ]. It is also important to focus on strategy instruction, so that the student with LD learns how to elaborate upon ideas and construct knowledge independently (ie, as opposed to rote memorization of skills or information) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/86-89\">",
"     86-89",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    (See",
"    <a class=\"local\" href=\"#H11284761\">",
"     'Strategy instruction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Because of the difficulty accessing a general education curriculum at the secondary level, students with LD may need to shift the focus of their education to acquiring life skills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/90\">",
"     90",
"    </a>",
"    ]. Specialized vocational-technical training or work-study programs should be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/91-94\">",
"     91-94",
"    </a>",
"    ] in conjunction with individual tutoring, instructional modifications such as reducing the work load while insisting on a higher number of correct responses, and strategy instruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/91-95\">",
"     91-95",
"    </a>",
"    ]. Transition planning is an important component in determining the content of the student&rsquo;s curriculum and preparing the student for adult life, and it is discussed in the following section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11285149\">",
"    <span class=\"h2\">",
"     Transition planning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high school curriculum should prepare students to cope successfully with the requirements of the postsecondary school or of employment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/96\">",
"     96",
"    </a>",
"    ]. In order to be successful, adolescents with LD require planning for the transition to their postsecondary life. Transition planning has traditionally focused on students with severe disabilities. However, students with LD also have significant limitations that affect their postschool success. Over one-third (35 percent) of students with LD drop out of school after the age of 14 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/97\">",
"     97",
"    </a>",
"    ], which may indicate that a significant number of students with LD do not find their school experience to provide valuable knowledge or skills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/98\">",
"     98",
"    </a>",
"    ]. Although this statistic is concerning, there are also many students with LD who make the transition to postsecondary education. Appropriate and specific transition planning is thus needed by the adolescent with LD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/99-101\">",
"     99-101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Individuals with Disability Education Act requires secondary schools to initiate a plan for the transition from secondary school to postsecondary school (college degree programs, college certificate programs, or vocational training) or, depending on the student&rsquo;s interests and abilities, to employment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/102\">",
"     102",
"    </a>",
"    ]. This planning has to be initiated by the age of 15 years and continued throughout the rest of the student&rsquo;s public school career. School counselors are expected to participate in transition planning and to help to ensure that the skills needed for postsecondary education or employment are incorporated into the student's educational program, and to help choose appropriate postsecondary programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Effective transition practices include the following components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Student-focused planning",
"      </strong>",
"      &ndash; The student is actively involved in his or her own transition planning. This means that the student learns how to identify his or her own vocational interests and sets goals, and jointly monitors whether those goals are being reached. The student is expected to attend and participate in relevant planning meetings.",
"     </li>",
"     <li>",
"      <strong>",
"       Student personal development",
"      </strong>",
"      &ndash; The student learns about his or her own disability, learns how to address the limitations of the disability, and learns how to advocate for him- or herself to ensure maximum success. For example, the student is taught how to use strategies to help organize information, study effectively, and circumvent limitations in reading, writing,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      math. In addition, the student is taught how to communicate about his or her disability with others (eg, administrators, employers, educators) and to advocate for his or her own needs. Finally, the student is taught about interpersonal communication in general, so that he or she can interact successfully with peers, accept feedback and criticism from educators or employers, and function successfully in a postsecondary school or work environment.",
"     </li>",
"     <li>",
"      <strong>",
"       Student vocational opportunities",
"      </strong>",
"      &ndash; In developing the skills listed above, the student is provided with vocational or work-site opportunities to acquire vocational skills",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      to generate educational goals to develop a vocation or trade. Enrollment in a regional vocational-technical school in the student&rsquo;s district or in a nearby district should be offered if desired [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Student training in independent living",
"      </strong>",
"      &ndash; Systematic instruction in the basic concepts of maintaining a home, developing satisfactory personal and social relations, and participating in the community is just as important a component of transition planning to individuals with LD as it is to students with other disabilities. A variety of curricular models to achieve this goal, as well as the above goals, are listed in reference [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/104\">",
"       104",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Family involvement",
"      </strong>",
"      &ndash; Family involvement improves school attendance, increases higher-education attendance and assessment scores, improves student self-esteem and confidence, and reduces drop-out rates. Direct routine communication strategies, such as face-to-face conferences, telephone contact, open-house events, teacher notes, and classroom visits, improve educator and family interactions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/101\">",
"       101",
"      </a>",
"      ]. An important component of involving the family and the student is to help both make connections with community agencies, services, employers, etc.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A variety of off-the-shelf curricular models for transition are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/105\">",
"     105",
"    </a>",
"    ]. In addition to the student- and family-focused aspects of transition described above, effective transition practices require the school to develop collaborative relationships with community agencies that offer work or vocational training opportunities and to develop a knowledge base of the colleges and postsecondary institutions and their services for students with LD. The school administration must be supportive of transition practices in general and provide the necessary leadership and vision for successful transition planning. This includes professional development in transition planning, creating collaborative relationships with community agencies and employers, etc. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/99-101\">",
"     99-101",
"    </a>",
"    ]. The types of services described here are not available in a consistent manner across school districts or states [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11285156\">",
"    <span class=\"h1\">",
"     SERVICES FOR LD IN COLLEGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, approximately 6 percent of all undergraduates report having a disability; among these, 29 percent have a learning disability (LD). This means that nearly 2 percent of all postsecondary students have an LD. Among undergraduate students, the average age of students with disabilities (type not specified) was 30 years, compared with 26 years among students without a disability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike public schools, colleges and universities are not required to identify or evaluate students for a disability, nor are they required to provide individualized special instruction. They are only required to provide &ldquo;reasonable accommodations&rdquo; to students with a documented disability. College students with disabilities must self-disclose their disability, must furnish documentation of their disability at personal expense, and must self-advocate to access those reasonable accommodations that may be available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/108\">",
"     108",
"    </a>",
"    ]. A detailed summary of the documentation requirement for college students is found in text of reference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are many services available for students with LD at the college level. Adolescents who are interested in pursuing a postsecondary education will need guidance in selecting appropriate college preparatory courses and will need information regarding the admissions policies of colleges, the special nonstandard conditions available for college entrance examinations, and the types of college programs available for students with LD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/103\">",
"     103",
"    </a>",
"    ]. Additional skills that are necessary for the transition to the postsecondary educational setting are listed in the tables (",
"    <a class=\"graphic graphic_table graphicRef62188 \" href=\"mobipreview.htm?41/20/42317\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Services for students with LD at the college level can include program accommodations, such as a part-time schedule or modified course allowance; longer time to complete a program; ability to repeat classes without penalty; waiver of language requirements; and course substitution. Support services can include an individualized academic plan; tutoring; personal counseling; specific instructional learning strategies, such as training to improve memory and study skills; and training in the use of and access to adaptive technology, such as assistive listening devices or talking computers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/110\">",
"     110",
"    </a>",
"    ]. Students may also have access to alternative exam formats; readers and classroom note-takers; or textbooks on tape [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/107,111\">",
"     107,111",
"    </a>",
"    ]. These accommodations and services are offered in a highly variable manner across colleges and universities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11285170\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcomes for individuals with learning disabilities (LD) are not clearly defined in the research literature. Several questions need clarification before overall adult status of students identified with LD will become clear. Most research addresses outcomes in terms of work performance and functionality. Outcomes research should focus on the employment status of individuals with LD, as well as their capacity to have friendships, create intimate relationships, and raise children, if this is their choice. Only a limited number of studies address all of these outcomes. In addition, many outcomes studies do not separate adults with LD from adults with other kinds of disabilities and only evaluate outcomes for the first few years following graduation from high school.",
"   </p>",
"   <p>",
"    Reading, spelling, and math problems in individuals with LD persist into adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. However, not all individuals with LD have difficulty in the larger task of living an adult life. After their high school education, individuals with LD are employed at the same rate as their nondisabled peers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/114\">",
"     114",
"    </a>",
"    ] but are less likely to have left home to live independently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/115\">",
"     115",
"    </a>",
"    ]; more likely to earn lower wages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/116\">",
"     116",
"    </a>",
"    ]; and more likely to have lower job satisfaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/117\">",
"     117",
"    </a>",
"    ]. Adults with LD are less likely to obtain postsecondary education. Approximately 30 percent of individuals with LD pursue a postsecondary education, which is less than half of the population as a whole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/114\">",
"     114",
"    </a>",
"    ]. However, of those who pursue college training, wages and job satisfaction appear to be just as good as for their nondisabled peers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/118,119\">",
"     118,119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reframing of the meaning of their LD is an important predictor of success in adults with LD. Reframing involves recognizing, understanding, and accepting the LD. It also involves having a plan of action that includes the ability to answer employer questions about the impact of the LD on productivity and the individual&rsquo;s capacity for team work, as well as a consideration of non-work-related factors, such as the capacity to build friendships and intimacy, and the capacity to have a family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/27/37306/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/47/38641?source=see_link\">",
"       \"Patient information: Learning disabilities (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45047427\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of the student with learning disability (LD) begins with quality instruction, even before the student is identified as having an LD. Quality instruction includes certain teacher practices, including spacing learning over time, combining verbal descriptions with graphics, connecting and integrating abstract and concrete representations of concepts, quizzing students to promote learning, helping students with time allocation, asking questions to develop greater awareness of the subject matter, and using preworked solutions for problem-solving exercises. (See",
"      <a class=\"local\" href=\"#H11284702\">",
"       'Preventive measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For students who are not succeeding academically, &ldquo;response to intervention&rdquo; services often are provided before the student is formally evaluated for LD. The student&rsquo;s response to intervention can help distinguish learning failure related to inadequate instruction from learning failure related to specific LD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35944?source=see_link&amp;anchor=H21#H21\">",
"       \"Specific learning disabilities in children: Evaluation\", section on 'Diagnostic process'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H11284717\">",
"       'Response to intervention'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Components of quality instruction for children with LD include: explicit or direct instruction (ie, drill and practice); strategy instruction (ie, instruction in the procedure or process used to approach learning); and various teacher behaviors, such as stating the learning objectives, having a clearly organized lesson plan, reviewing concepts multiple times, providing examples, and proceeding through material in small steps. (See",
"      <a class=\"local\" href=\"#H11284747\">",
"       'Types of instruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interventions for children with reading disability are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17592?source=see_link\">",
"       \"Interventions for children with reading difficulty\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Instruction for children with writing disability should include explicit and strategy instruction in handwriting accuracy, handwriting fluency, phonologic awareness and phonics (to help with spelling), language conventions (spelling and grammar), writing text, and composition. (See",
"      <a class=\"local\" href=\"#H11284862\">",
"       'Writing disability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Instruction for children with math disability should include explicit and strategy instruction in number sense, counting strategy, math vocabulary, arithmetic combination and calculation skills, word problems, visual-spatial relationships, and organizing and planning. (See",
"      <a class=\"local\" href=\"#H11284970\">",
"       'Math disability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The provision of quality services, interventions, and accommodations is preferable to grade retention or social promotion for children with specific LD. (See",
"      <a class=\"local\" href=\"#H11285093\">",
"       'Grade retention and social promotion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Planning for the transition to postsecondary school or employment is an important aspect of the management of LD during high school. (See",
"      <a class=\"local\" href=\"#H11285149\">",
"       'Transition planning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reading, spelling, and math problems in individuals with LD persist into adulthood. After high school, individuals with LD are employed at the same rate as their nondisabled peers. Among those who attend college, wages and job satisfaction appear to be similar to those of their nondisabled peers. Those who do not attend college are less likely to have left home to live independently, more likely to earn lower wages, and more likely to have lower job satisfaction than their nondisabled peers. (See",
"      <a class=\"local\" href=\"#H11285170\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/1\">",
"      American Academy of Pediatrics, Section on Ophthalmology, Council on Children with Disabilities, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists. Joint statement--Learning disabilities, dyslexia, and vision. Pediatrics 2009; 124:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/2\">",
"      Adelman HS. Toward solving the problems of misidentification and limited intervention efficacy. J Learn Disabil 1989; 22:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/3\">",
"      Adelman HS. LD: the next 25 years. J Learn Disabil 1992; 25:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/4\">",
"      Lyon GR. Learning disabilities. Future Child 1996; 6:54.",
"     </a>",
"    </li>",
"    <li>",
"     Keogh BK. A matrix of decision points in the measurement of learning disabilities. In: Frames of Reference for the Assessment of Learning Disabilities, Lyon GR (Ed), Brookes Publishing Company, Baltimore 1994. p.15.",
"    </li>",
"    <li>",
"     MacMillan DL. Development of operational definitions in mental retardation: Similarities and differences with the field of Learning Disabilities. In: Better Understanding Learning Disabilities: New Views from Research and Their Implications for Education and Public Policies, Lyon GR, Gray DB, Krasnegor NA, Kavanagh JF (Eds), Brookes Publishing Company, Baltimore 1993. p.117.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/7\">",
"      Heward WL. Ten faulty notions about teaching and learning that hinder the effectiveness of special education. J Sepc Educ 2003; 36:186.",
"     </a>",
"    </li>",
"    <li>",
"     Pashler H, Bain P, Bottge B, et al. Organizing Instruction and study to improve student learning. IES Practice Guide. US department of Education and the Institute of Education Sciences, September 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/9\">",
"      NJCLD Position Paper: Responsiveness to Intervention and Learning Disabilities. Learn Disabil Q 2005; 28:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/10\">",
"      Fuchs D, Compton D, Fuchs L, et al. Making &ldquo;secondary intervention&rdquo; work in a three-tier responsiveness-to-intervention model: findings from the first grade longitudinal reading study of the National Research Center on Learning disabilities. Reading and Writing 2008; 21:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/11\">",
"      Wanzek J, Vaughn S. Is a Three-Tier Reading Intervention Model Associated With Reduced Placement in Special Education? Remedial and Special Education 2010; 31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/12\">",
"      Vaughn S, Denton CA, Fletcher JM. WHY INTENSIVE INTERVENTIONS ARE NECESSARY FOR STUDENTS WITH SEVERE READING DIFFICULTIES. Psychol Sch 2010; 47:432.",
"     </a>",
"    </li>",
"    <li>",
"     IDEA 2004. (CFR 34 CFR 300.500. Procedural safeguards. Authority: 20 U.S.C. 1415(a)). Downloaded from file://idea.ed.gov. (Accessed on July 29, 2010.).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/14\">",
"      Swanson HL, Hoskyn M. Experimental Intervention Research on students with Learning disabilities: A meta-analysis of Treatment Outcomes. Review of Educational Research 1998; 68:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/15\">",
"      Fleischner JE. Educational management of students with learning disabilities. J Child Neurol 1995; 10 Suppl 1:S81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/16\">",
"      Vaughn S, Gersten R, Chard D. The underlying message in LD intervention research: Findings from research syntheses. Exceptional Children 2000; 67:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/17\">",
"      William L, Heward W. Ten Faulty Notions About Teaching and Learning That Hinder the Effectiveness of Special Education. J Spec Educ 2003; 36:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/18\">",
"      Swanson HL, Deshler D. Instructing adolescents with learning disabilities: converting a meta-analysis to practice. J Learn Disabil 2003; 36:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/19\">",
"      Ellis E. Integrative Strategy Instruction: A potential Model for Teaching Content Area subjects to adolescents with Learning disabilities. J Learn Disabil 1996; 26:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/20\">",
"      Harris K, Graham S. Programmatic Intervention research: illustrations from the evolution of self-regulated strategy development. Learn Disabil Q 1999; 22:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/21\">",
"      Blair T, Rupley W, Nichols W. The Effective teacher of reading: considering the &ldquo;what&rdquo; and &ldquo;how\" of instruction. The Reading Teacher 2007; 60:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/22\">",
"      Rosenshine B. Advances in research on Instruction. J Educ Res 1995; 88:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/23\">",
"      Slavin R, Lake C, Chambers B, et al. Effective Reading programs for the elementary grads: a best-evidence synthesis. Review Educ Res 2009; 79:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/24\">",
"      Scruggs TE, Mastropieri MA, Okolo CM. Science and social studies for students with Disabilities. Focus on Exceptional Children 2008; 41:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/25\">",
"      Stenhoff DM, Lignagaris B. A Review of the Effects of Peer Tutoring on Students with Mild Disabilities in Secondary Settings. Exceptional Children 2007; 74:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/26\">",
"      Fletcher J, Francis D, O'Malley K. Effects of bundled accommodations package on high stakes testing for middle school students with learning disabilities. Except Child 2009; 75:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/27\">",
"      Fuchs L, Fuchs D, Capizzi A. Identifying appropriate test accommodations for students with learning disabilities. Focus on Exceptional Children 2005; 37.",
"     </a>",
"    </li>",
"    <li>",
"     National Center on Universal Design for Learning. file://www.udlcenter.org/aboutudl/whatisudl (Accessed on December 06, 2010).",
"    </li>",
"    <li>",
"     CAST. file://www.cast.org/about (Accessed on December 06, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/30\">",
"      Pisha B, Stahl S. The promise of new learning environments for students with learning disabilities. Intervention in School and Clinic 2005; 41:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/31\">",
"      Hitchcock C, Meyer A, Rose D, Jackson R. Providing new access to the general curriculum. Universal Design for Learning. Teaching Exceptional Children 2002; 35:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/32\">",
"      Troia G, Graham S. Effective writing instruction across the grades: what every educational consultant should know. J Educ Psychol Consult 2003; 14:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/33\">",
"      Asher AV. Handwriting instruction in elementary schools. Am J Occup Ther 2006; 60:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/34\">",
"      Ritchey K. The building blocks of writing: Learning to write letters and spell words. Read Writ 2008; 21:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/35\">",
"      Graham S. Handwriting and spelling instruction for students with LD: A Review. Learn Disabil Q 1999; 22:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/36\">",
"      Wanzek J, Vaughn S, Wexler J, et al. A synthesis of spelling and reading interventions and their effects on spelling outcomes of students with LD. J Learn Dis 2006; 39:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/37\">",
"      Scott CM. Principles and Methods of spelling instruction: Applications for Poor spellers. Topics in Language Disorders 2000; 20:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/38\">",
"      Gersten R, Chard D, Jaynathi M, et al. Mathematics Instruction for Students with Learning Disabilities: A meta-analysis of instructional components. Rev Educ Res 2009; 79:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/39\">",
"      Troia G, Graham S, Harris K. Teaching students with Learning disabilities to mindfully plan when writing. Exceptional Children 1999; 65:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/40\">",
"      Gibson SA. An Effective Framework for primary-grade guided writing instruction. The Reading Teacher 2008; 62:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/41\">",
"      MacArthur CA. Using technology to enhance the writing processes of students with learning disabilities. J Learn Disabil 1996; 29:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/42\">",
"      MacArthur C. New Tools for Writing: Assistive Technology for students with Writing Difficulties. Topics in Language Disorders 2000; 20:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/43\">",
"      Englert CS, Mariage TV. Shared understandings: structuring the writing experience through dialogue. J Learn Disabil 1991; 24:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/44\">",
"      Harris K, Graham S, Mason L. Self-regulated strategy development in the classroom: Part of a balanced approach to writing instruction for students with disabilities. Focus on Exceptional Children 2003; 35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/45\">",
"      Englert RS, Raphael TE, Anderson LM, et al. Making strategies and self-talk visible: Writing instruction in regular and special education classrooms. Am Educ Res J 1991; 28:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/46\">",
"      Gersten R, Baker S. Teaching expressive writing to students with Learning Disabilities: A meta-analysis. Elementary School J 2001; 97:475.",
"     </a>",
"    </li>",
"    <li>",
"     Harris, Learning Differences Conference, Harvard University Graduate School of Education, 2009, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/48\">",
"      Gersten R, Chard D. Rethinking mathematics instruction for students with Math Disabilities. J Spec Educ 1999; 33:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/49\">",
"      Gersten R, Jordan NC, Flojo JR. Early identification and interventions for students with mathematics difficulties. J Learn Disabil 2005; 38:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/50\">",
"      Geary DC. Consequences, characteristics, and causes of mathematical learning disabilities and persistent low achievement in mathematics. J Dev Behav Pediatr 2011; 32:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/51\">",
"      Dowker A. Early identification and intervention for students with mathematics difficulties. J Learn Disabil 2005; 38:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/52\">",
"      Bryant B, Bryant D, Kathley C, et al. Preventing mathematics difficulties in the primary grades: The critical features of instruction in textbooks as part of the equation. Learn Disabil Q 2008; 31:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/53\">",
"      Bryant B, Bryant D. Introduction to the special series. Mathematics Learning Disabilities. Learn Disabil Q 2008; 31:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/54\">",
"      Kroesbergen EH, Johannes EH, Van Luit C, Maas JM. Effectiveness of Explicit and Constructivist Mathematics Instruction for Low-Achieving Students in The Netherlands. Elementary School J 2004; 104:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/55\">",
"      Fuchs LS, Fuchs D, Powell SR, et al. Intensive Intervention for Students with Mathematics Disabilities: Seven Principles of Effective Practice. Learn Disabil Q 2008; 31:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/56\">",
"      Confrey J. Comparing and Contrasting the National Research Council Report on &ldquo;evaluating curricular effectiveness&rdquo; with the What Works Clearinghouse approach. Educ Eval Policy Analysis 2006; 28:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/57\">",
"      Slavin R, Lake C. Effective programs in elementary mathematics: A best evidence synthesis. Rev Educ Res 2008; 78:427.",
"     </a>",
"    </li>",
"    <li>",
"     Assisting students struggling with reading: Response to intervention (RtI) and multi-tier intervention in the primary grades. US Department of Education NCEE 2009-4045. National Center for Educational Evaluation and Regional Assistance. file://ies.ed.gov/ncee/wwc/pdf/practice_guides/rti_reading_pg_021809.pdf (Accessed on October 04, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/59\">",
"      Jimerson S. Meta-analysis of grade retention research: Implications for practice in the 21st century. School Psychol Rev 2001; 30:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/60\">",
"      Jimerson SR, Fletcher SM, Graydon K. Beyond grade retention and social promotion: Promoting the social and academic competence of students. Psychol School 2006; 43:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/61\">",
"      Bonvin P, Bless G, Schuepback M. Grade retention: decision-making and effects on learning as well as social and emotional development. School Effectiveness and School Improvement 2008; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/62\">",
"      Corman H. The effects of state policies, individual characteristics, family characteristics, and neighborhood characteristics on grade repletion in the United States. Economics Educ Rev 2003; 22:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/63\">",
"      Silberglitt B, Jimeson S, Burns M, Appleton J. Does the timing of grade retention make a difference? Examining the effects of early versus later retention. School Psychology Review 2006; 35:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/64\">",
"      Frederick CB, Hauser RM. Have we put an end to social promotion? Changes in school progress among children aged 6 to 17 from 1972 to 2005. Demography 2008; 45:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/65\">",
"      Wu W, West SG, Hughes JN. Effect of Retention in First Grade on Children's Achievement Trajectories Over 4 Years: A Piecewise Growth Analysis Using Propensity Score Matching. J Educ Psychol 2008; 100:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/66\">",
"      Wu W, West SG, Hughes JN. Effect of Grade Retention in First Grade on Psychosocial Outcomes. J Educ Psychol 2010; 102:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/67\">",
"      Jimerson S, Anderson G, Whipple A. Winning the Battle and losing the war: Examining the relation between grade retention and dropping out of high school. Psychol School 2002; 39:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/68\">",
"      Stearns E, Moller S, Blau J, Potochnick S. Staying back and Dropping out: the relationship between grade retention and school dropout. Sociol Educ 2007; 80:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/69\">",
"      McCoy AR, Reynolds AJ. Grade retention and school performance: An extended investigation. J Sch Psychol 1999; 37:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/70\">",
"      Eide E, Showalter M. The effect of grade retention on educational and labor market outcomes. Economics Educ Rev 2001; 20:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/71\">",
"      Allen CS, Chen Q, Willson VL, Hughes JN. Quality of Research Design Moderates Effects of Grade Retention on Achievement: A Meta-analytic, Multi-level Analysis. Educ Eval Policy Anal 2009; 31:480.",
"     </a>",
"    </li>",
"    <li>",
"     Alexander K, Entwisle D, Dauber S. On the Success of Failure: A Reassessment of the Effects of Retention in the Primary School Grades, 2nd ed, Cambridge University Press, Cambridge, UK 2003.",
"    </li>",
"    <li>",
"     Jimerson S, Woehr S, Kaufman A, Anderson G. Grade Retention and Promotion: Information and strategies for Educators. Position paper: national Association of School Psychologists. Downloaded from www.nasponline.org (2004). (Accessed on July 29, 2010.).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/74\">",
"      David JL. What the research says about grade retention. Educational Leader 2008; 65:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/75\">",
"      Jimerson S, Kaufman A. Reading, writing, and retention: A primer on grade retention research. Reading Teacher 2003; 56:622.",
"     </a>",
"    </li>",
"    <li>",
"     US DOE practice guide: Dropout Prevention. NCEE 2008-4025. National Center for Education Evaluation and Regional Assistance. Institute of Education Sciences",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/77\">",
"      Picklo DM, Christenson SL. Alternatives to Retention and Social Promotion: The Availability of Instructional Options. Remedial Spec Educ 2005; 26:258.",
"     </a>",
"    </li>",
"    <li>",
"     Lerner J. Learning Disabilities: Theories, Diagnosis, and Teaching Strategies, Houghton Mifflin Company, Boston 2000.",
"    </li>",
"    <li>",
"     IDEA 2004. 34 CFR 300.115 (b) authority: 20 U.S.C. 1412(a)(5)) and 34 CFR 300.114 (a) (2) (i) and (ii) authority: 20 U.S.C. 1412(a)(5)). Downloaded from: file://idea.ed.gov. (Accessed on July 29, 2010.).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/80\">",
"      Lerner JW. Educational interventions in learning disabilities. J Am Acad Child Adolesc Psychiatry 1989; 28:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/81\">",
"      McInerny TK. Children who have difficulty in school: a primary pediatrician's approach. Pediatr Rev 1995; 16:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/82\">",
"      Baker JM, Zigmond N. The meaning and practice of inclusion for students with learning disabilities: Themes and implications from the five cases. J Spec Educ 1995; 29:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/83\">",
"      Zigmond N. Models for delivery of special education services to students with learning disabilities in public schools. J Child Neurol 1995; 10 Suppl 1:S86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/84\">",
"      Whinnery KW, King M. Perceptions of students with learning disabilities. Preventing School Failure 1995; 40:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/85\">",
"      Edgar E, Polloway E. Education for Adolescents with disabilities: Curriculum and placement issues. J Spec Educ 1994; 27:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/86\">",
"      Deshler DD, Schumaker JB, Lenz BK, et al. Ensuring content-area learning by secondary students with learning disabilities. Learning Disabilities Research and Practice 2001; 16:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/87\">",
"      Ellis ES, Deshler DD, Schumaker JB. Teaching adolescents with learning disabilities to generate and use task-specific strategies. J Learn Disabil 1989; 22:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/88\">",
"      Ellis ES. Watering up the curriculum for adolescents with learning disabilities - Goals of the knowledge dimension. Remedial and Special Education 1997; 18:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/89\">",
"      Casareno A, Ellis E. Ed Ellis: Working to improve education for adolescents with learning disabilities. Intervention in School and Clinic 2002; 37:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/90\">",
"      Lieberman LM. The LD adolescent.... When do you stop? J Learn Disabil 1981; 14:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/91\">",
"      Whinnery KW. College preparation for students with learning disabilities: A curriculum approach. Preventing School Failure 2003; 37:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/92\">",
"      Cawley JF, Kahn H, Tedesco A. Vocational education and students with learning disabilities. J Learn Disabil 1989; 22:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/93\">",
"      Janiga SJ, Costenbader V. The transition from high school to postsecondary education for students with learning disabilities: a survey of college service coordinators. J Learn Disabil 2002; 35:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/94\">",
"      Brinckerhoff LC. Making the transition to higher education: opportunities for student empowerment. J Learn Disabil 1996; 29:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/95\">",
"      Hock MF, Deshler DD, Schumaker JB. Learning strategy instruction for at-risk and learning-disabled adults: The development of strategic learners through apprenticeship. Preventing School Failure 1993; 38:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/96\">",
"      Skinner ME, Lindstrom BD. Bridging the gap between high school and college: Strategies for the successful transition of students with learning disabilities. Preventing School Failure 2003; 47:132.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Department of Education, Office of Special Education and Rehabilitative Services, Office of Special Education Programs. (2006, April). with Disabilities Education Act, Vol. 1. Washington, DC26th Annual (2004) Report to Congress on the Implementation of the Individuals",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/98\">",
"      Patton JR, Cronin ME, Jairrels V. Curricular implications of transition. Remedial Spec Educ 1997; 18:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/99\">",
"      Cummings R, Maddux C, Casey J. Individualized transition planning for students with Learning Disabilities. Career Development Quarterly 2000; 49:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/100\">",
"      DuFur S. IEP transition Planning- from compliance to quality. Exceptionality 2003; 11:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/101\">",
"      Kohler P, Field S. Transition-focused education: foundation for the future. J Spec Educ 2003; 37:174.",
"     </a>",
"    </li>",
"    <li>",
"     IDEA 2004. Definition of transition planning. 34 CFR 300.43 (a)] Authority: [20 U.S.C. 1401(34). Age requirement for start of transition planning 34 CFR 300.320(b) and (c)] Authority: [20 U.S.C. 1414 (d)(1)(A)(i)(VIII)]. Downloaded from file://idea.ed.gov.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/103\">",
"      Hildreth BL, Dixon ME. College readiness for students with learning disabilities: The role of the school counselor. School Counselor 1994; 41:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/104\">",
"      Sitlington PL. Transition to living: the neglected component of transition programming for individuals with learning disabilities. J Learn Disabil 1996; 29:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/105\">",
"      Bouck E. Functional Curriculum Models for Secondary students with mild mental impairment. Educ Training Devel Disabil 2009; 44:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/106\">",
"      Zhang D, Ivester J, Katsiyannis A. Teachers&rsquo; view of transition services: results from a statewide survey in South Carolina. Educ Training Devel Disabil 2005; 40:360.",
"     </a>",
"    </li>",
"    <li>",
"     National Center for Education Statistics. Post secondary students with disabilities: enrollment, services, and persistence. June 2000. Downloaded from: file://nces.ed.gov/pubsearch/pubsinfo.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/108\">",
"      Shaw S. Transition to postsecondary education. Focus on Exceptional Children 2009; 42:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/109\">",
"      National Joint Committee on Learning Disabilitites. The documentation disconnect for students with learning disabilities. Learn Disabil Q 2007; 30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/110\">",
"      Mull C, Sitlington P, Alper S. Postsecondary education for students with learning disabilities. Except Child 2001; 68:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/111\">",
"      Rath K, Royer J. The nature and effectiveness of learning disability services for college students. Educ Psychol Rev 2002; 14:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/112\">",
"      Undheim AM. A thirteen-year follow-up study of young Norwegian adults with dyslexia in childhood: reading development and educational levels. Dyslexia 2009; 15:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/113\">",
"      Morris MA, Schraufnagel CD, Chudnow RS, Weinberg WA. Learning disabilities do not go away: 20- to 25-year study of cognition, academic achievement, and affective illness. J Child Neurol 2009; 24:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/114\">",
"      Wagner MM, Blackorby J. Transition from high school to work or college: how special education students fare. Future Child 1996; 6:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/115\">",
"      Janus AL. Disability and the Transition to Adulthood. Social Forces 2009; 88:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/116\">",
"      Dickinson DL, Verbeek RL. Wage differentials between college graduates with and without learning disabilities. J Learn Disabil 2002; 35:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/117\">",
"      Kavale K, Forness S. Learning disability grows up: Rehabilitation issues for individuals with Learning disabilities. J Rehab 1996; 62:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/118\">",
"      Seo Y, Abbott RD, Hawkins JD. Outcome status of students with learning disabilities at ages 21 and 24. J Learn Disabil 2008; 41:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/119\">",
"      Madaus JW. Employment outcomes of university graduates with learning disabilities. Learn Disabil Q 2006; 29:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/27/37306/abstract/120\">",
"      Gerber PJ, Reiff HB, Ginsberg R. Reframing the learning disabilities experience. J Learn Disabil 1996; 29:98.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 614 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7ADB670DEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_27_37306=[""].join("\n");
var outline_f36_27_37306=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H45047427\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11284702\">",
"      PREVENTIVE MEASURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11284710\">",
"      Quality instruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11284717\">",
"      Response to intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11284724\">",
"      REFERRAL FOR EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11284731\">",
"      QUALITY INSTRUCTION FOR LD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11284747\">",
"      Types of instruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11284754\">",
"      - Explicit or direct instruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11284761\">",
"      - Strategy instruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11284768\">",
"      - Other methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7835933\">",
"      Accommodations and modifications for students with LD in the general education classroom",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11284775\">",
"      Reading disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11284862\">",
"      Writing disability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11284870\">",
"      - Instruction in writing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88270081\">",
"      - Accommodations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11284877\">",
"      - Effective writing programs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11284970\">",
"      Math disability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11284978\">",
"      - Components of instruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24764929\">",
"      - General teaching strategies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11284985\">",
"      - Effective math programs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11285093\">",
"      GRADE RETENTION AND SOCIAL PROMOTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H546789319\">",
"      Which students are retained?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H546789333\">",
"      Prevalence of grade retention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11285121\">",
"      Is grade retention beneficial?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1176035\">",
"      - Quality of grade-retention research",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11285128\">",
"      Alternatives to grade retention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11285135\">",
"      SPECIALIZED EDUCATION PLACEMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11285142\">",
"      MANAGEMENT OF LD IN HIGH SCHOOL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11285149\">",
"      Transition planning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11285156\">",
"      SERVICES FOR LD IN COLLEGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11285170\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45047427\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/614\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/614|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/41/4765\" title=\"table 1\">",
"      Instructional variables in learning disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/53/7005\" title=\"table 2\">",
"      Writing strategy instruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/16/28940\" title=\"table 3\">",
"      POW and TREE mnemonics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/19/19772\" title=\"table 4\">",
"      LD advocacy file contents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/20/42317\" title=\"table 5\">",
"      Postsecondary transition skills",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/21/1370?source=related_link\">",
"      Clinical features and evaluation of reading difficulty in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/38/37480?source=related_link\">",
"      Definitions of specific learning disability and laws pertaining to learning disabilities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/10/26793?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/8/5257?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40887?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Management; outcomes; and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17592?source=related_link\">",
"      Interventions for children with reading difficulty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/16/6409?source=related_link\">",
"      Normal reading development and etiology of reading difficulty in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/47/38641?source=related_link\">",
"      Patient information: Learning disabilities (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32665?source=related_link\">",
"      Specific learning disabilities in children: Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35944?source=related_link\">",
"      Specific learning disabilities in children: Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/18/44329?source=related_link\">",
"      Specific learning disabilities in children: Role of the primary care provider",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_27_37307="Accuracy of Manning criteria";
var content_f36_27_37307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56919&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56919&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Predicted probability of the irritable bowel syndrome as a function of age, sex, and the number of Manning criteria",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Number of Manning",
"       </td>",
"       <td class=\"subtitle1\">",
"        At age 20",
"       </td>",
"       <td class=\"subtitle1\">",
"        At age 40",
"       </td>",
"       <td class=\"subtitle1\">",
"        At age 60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Men",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Any 2",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Any 4",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        All 6",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Any 2",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Any 4",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        61",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        All 6",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Talley NJ, Phillips SF, Melton LJ, et al, Gut 1990; 31:77; includes all subgroups with irritable bowel syndrome.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_27_37307=[""].join("\n");
var outline_f36_27_37307=null;
var title_f36_27_37308="Lysosomal storage disorders";
var content_f36_27_37308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of hereditary peripheral neuropathies associated with lysosomal storage diseases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inheritance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fabry disease",
"       </td>",
"       <td>",
"        XLR",
"       </td>",
"       <td>",
"        GLA",
"       </td>",
"       <td>",
"        Onset by 10 years of age, angiokeratomas, peripheral neuropathy, burning of palms and soles, hypohidrosis or anhidrosis, asymptomatic corneal dystrophy, cardiac involvement with disease progression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Krabbe disease",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        GALC",
"       </td>",
"       <td>",
"        Usual onset in first six months of life, peripheral motor sensory neuropathy, developmental delay, hypotonia, limb stiffness, optic atrophy, microcephaly, irritability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Metachromatic leukodystrophy",
"       </td>",
"       <td rowspan=\"3\">",
"        AR",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         ARSA",
"        </p>",
"        <p>",
"         PSAP",
"        </p>",
"       </td>",
"       <td>",
"        Late infant onset: usual onset at age 6 to 24 months, regression of motor skills, gait difficulty, ataxia, hypotonia, optic atrophy, peripheral neuropathy, absent or diminished deep tendon reflexes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Juvenile onset: onset between 4 to 8 years, gait disturbance, intellectual impairment, ataxia, upper motor neuron signs, peripheral neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adult onset: dementia between age 16 and late adulthood, slow progressive motor dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Niemann-Pick Disease",
"       </td>",
"       <td class=\"sublist_other_start\">",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Type A",
"       </td>",
"       <td class=\"sublist_other\">",
"        AR",
"       </td>",
"       <td class=\"sublist_other\">",
"        SMPD1",
"       </td>",
"       <td class=\"sublist_other\">",
"        Hepatosplenomegaly, feeding difficulties, loss of early motor skills, rapidly progressive loss of neurologic function, peripheral neuropathy, macular cherry red spots",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Type B",
"       </td>",
"       <td class=\"sublist_other\">",
"        AR",
"       </td>",
"       <td class=\"sublist_other\">",
"        SMPD1",
"       </td>",
"       <td class=\"sublist_other\">",
"        Onset of hepatomegaly in infancy or childhood, thrombocytopenia, interstitial lung disease, lipid abnormalities, rare peripheral neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Type C",
"       </td>",
"       <td class=\"sublist_other\">",
"        AR",
"       </td>",
"       <td class=\"sublist_other\">",
"        <p>",
"         NPC1",
"        </p>",
"        <p>",
"         NPC2",
"        </p>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Can present from the perinatal period until late adulthood (most often in middle to late childhood), typically with cerebellar symptoms, slow cognitive deterioration, vertical supranuclear gaze palsy, and progressive dystonia, dysarthria, and dysphagia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AR: autosomal recessive; ARSA: arylsulfatase A gene; GALC: galactocerebrosidase gene; GLA: alpha galactosidase A gene; NPC1: Niemann-Pick C1 gene; NPC2: Niemann-Pick C2 gene; PSAP: prosaposin gene; SMPD1: sphingomyelin phosphodiesterase 1 gene; XLR: X-linked recessive.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_27_37308=[""].join("\n");
var outline_f36_27_37308=null;
var title_f36_27_37309="Distal tubule transport";
var content_f36_27_37309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F64975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F64975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 490px\">",
"   <div class=\"ttl\">",
"    Ion transport in the distal tubule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 470px; height: 253px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the transport mechanisms in the distal tubule. The Na-K-ATPase pump in the basolateral (peritubular) membrane pumps sodium (Na) out of, and potassium (K) into, the cell. This creates a low intracellular Na concentration which drives many of the cell's reabsorptive processes. The entry of filtered Na and chloride (Cl) into the cell is mediated by a neutral Na-Cl cotransporter NCCT in the apical (luminal) membrane. This cotransporter is inhibited by thiazide diuretics. The energy for this process is provided by the favorable inward electrochemical gradient for Na (the intracellular Na concentration is very low and the cell interior is electronegative). The reabsorbed Na which has entered the cell is pumped out by the Na-K-ATPase pump. The reabsorbed Cl exits via a chloride channel. This is the ClC-Kb channel which requires interaction with a small protein called barttin to function normally. The distal tubule is also a major site of active calcium (Ca) reabsorption. Ca enters the cell via a Ca transporter that is probably a Ca channel. Reabsorbed Ca combines with a vitamin D-induced Ca binding protein (Ca-BP), moves across the cell, and is then extruded at the basolateral membrane by a Ca-ATPase (not shown) and a 3Na:1Ca exchanger that also uses the energy provided by the favorable inward electrochemical gradient for Na.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_27_37309=[""].join("\n");
var outline_f36_27_37309=null;
var title_f36_27_37310="Dyspareunia differential dx1";
var content_f36_27_37310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59848%7EOBGYN%2F70497%7EOBGYN%2F50537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59848%7EOBGYN%2F70497%7EOBGYN%2F50537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnoses for physical causes of dyspareunia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Location affected",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Important history",
"       </td>",
"       <td class=\"subtitle1\">",
"        Source of dyspareunia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments and Caveats",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"8\">",
"        Vulva and Vestibule",
"       </td>",
"       <td>",
"        Dermatitis (eczema)",
"       </td>",
"       <td>",
"        Atopic history, other eczema",
"       </td>",
"       <td>",
"        Erythema, scaling, fissuring",
"       </td>",
"       <td>",
"        Look for Candida also",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatosis: lichen sclerosus",
"       </td>",
"       <td>",
"        Itching, recent or lifelong, soreness, possibly no symptoms",
"       </td>",
"       <td>",
"        Fissures, ulceration, scarring",
"       </td>",
"       <td>",
"        Look for Candida also",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatosis: lichen planus",
"       </td>",
"       <td>",
"        Itching, irritation, burning",
"       </td>",
"       <td>",
"        Erosions, ulcers, scarring",
"       </td>",
"       <td>",
"        Many drugs exacerbate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulcerative disease: herpes simplex or zoster, chancroid, Crohn's, aphthae, Behcet's",
"       </td>",
"       <td>",
"        Episodic outbreaks",
"       </td>",
"       <td>",
"        Ulceration varying in size, tenderness",
"       </td>",
"       <td>",
"        Behcet's very rare, involves oral ulcers, uveitis, other systems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Labial hypertrophy",
"       </td>",
"       <td>",
"        Irritation w/physical activity",
"       </td>",
"       <td>",
"        Elongation of labia",
"       </td>",
"       <td>",
"        Look for vestibulitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Female circumcision",
"       </td>",
"       <td>",
"        Ethnicity and country of origin",
"       </td>",
"       <td>",
"        Absence of clitoris and prepuce, labial fusion",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Generalized dyesthesia (Vulvodynia)",
"       </td>",
"       <td>",
"        Episodic or virtually constant burning, stinging, soreness irritation, rawness",
"       </td>",
"       <td>",
"        Often no findings; or erythema and edema, areas of hyper or hypoesthesia",
"       </td>",
"       <td>",
"        Long history of unsuccessful urinary tract, yeast, bacterial vaginosis treatments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiation",
"       </td>",
"       <td>",
"        History of gyn or urinary tumor",
"       </td>",
"       <td>",
"        Pallor, alopecia, loss of elasticity",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Urethra and bladder",
"       </td>",
"       <td>",
"        Urinary tract infection",
"       </td>",
"       <td>",
"        Dysuria, frequency, urgency",
"       </td>",
"       <td>",
"        Tenderness over bladder",
"       </td>",
"       <td>",
"        Negative cultures suggests vulvodynia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urethral diverticulum",
"       </td>",
"       <td>",
"        Dysuria, dribbling, pain with penetration",
"       </td>",
"       <td>",
"        Urethral tenderness, mass",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interstitial cystitis",
"       </td>",
"       <td>",
"        Pelvic pain, dysuria, urgency, frequency, nocturia",
"       </td>",
"       <td>",
"        Tenderness over bladder, along anterior vaginal wall",
"       </td>",
"       <td>",
"        Look for vestibulodynia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Elizabeth Gunther Stewart, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnoses for physical causes of dyspareunia (cont.)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Location affected",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Important history",
"       </td>",
"       <td class=\"subtitle1\">",
"        Source of dyspareunia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments and Caveats",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"10\">",
"        Vestibule and vagina",
"       </td>",
"       <td>",
"        Atrophy: low or absent estrogen",
"       </td>",
"       <td>",
"        Dryness, irritation, hx breast feeding, oligo/amenorrhea, low",
"estrogen/high androgenic OCP, Depo-Provera, anorexia, exercise,",
"premenopausal tamoxifen, chemotherapy, radiation, BSO, aromatase",
"inhibitors",
"       </td>",
"       <td>",
"        Reduction in labial size, mucosal color and textural change, fissures; elevated vaginal pH, atrophic wet prep",
"       </td>",
"       <td>",
"        Can occur at any age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vulvovaginitis: Candida albicans",
"       </td>",
"       <td>",
"        Antibiotics, steroids, estrogen, immunosuppression",
"       </td>",
"       <td>",
"        Itching, erythema, edema, discharge, fissures; or few sx",
"       </td>",
"       <td>",
"        Look for superimposed vestibulitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Desquamative inflammatory",
"       </td>",
"       <td>",
"        Irritative sx, profuse discharge",
"       </td>",
"       <td>",
"        Erythema, sheets of wbc, parabasals, no lactobacilli",
"       </td>",
"       <td>",
"        Atypical pap. Look for vestibulodynia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vulvovaginitis: Trichomonas",
"       </td>",
"       <td>",
"        Itching, discharge, or few sx",
"       </td>",
"       <td>",
"        Mobile trichomonads; positive culture",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bartholin cyst or abscess",
"       </td>",
"       <td>",
"        Swelling and pain",
"       </td>",
"       <td>",
"        Cystic mass at base of vestibule",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seminal plasma allergy",
"       </td>",
"       <td>",
"        Itching on entry or ejaculation",
"       </td>",
"       <td>",
"        Edema and erythema post coitus",
"       </td>",
"       <td>",
"        Trial of condom helps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatosis: lichen sclerosus",
"       </td>",
"       <td>",
"        Itching or no symptoms",
"       </td>",
"       <td>",
"        Fissures, scaring around introitus",
"       </td>",
"       <td>",
"        Candida, vulvodynia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatosis: lichen planus",
"       </td>",
"       <td>",
"        Itching, burning, discharge",
"       </td>",
"       <td>",
"        Erosions, ulceration, scarring",
"       </td>",
"       <td>",
"        As above, atypical Pap smear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inadequate lubrication, dryness",
"       </td>",
"       <td>",
"        Poor sexual technique, sexual dysfunction, Sjogren's, OCP, medications, vestibulodynia",
"       </td>",
"       <td>",
"        Dryness, tenderness",
"       </td>",
"       <td>",
"        No good test; hard to judge on exam; history important",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiation",
"       </td>",
"       <td>",
"        History of gyn or urinary tumor",
"       </td>",
"       <td>",
"        Pallor, loss of elasticity, scarring",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     OCP: oral contraceptive pills; BSO: bilateral salpingo-oophorectomy; hx: history; sx: symptoms.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Elizabeth Gunther Stewart, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnoses for physical causes of dyspareunia (cont.)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Location affected",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Important history",
"       </td>",
"       <td class=\"subtitle1\">",
"        Source of dyspareunia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments and Caveats",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vestibule only",
"       </td>",
"       <td>",
"        Vestibulodynia",
"       </td>",
"       <td>",
"        Pain mainly with penetration, tampon or speculum",
"       </td>",
"       <td>",
"        Tenderness on touch or pressure, erythema",
"       </td>",
"       <td>",
"        No cause for the pain is found",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Perineum and anus",
"       </td>",
"       <td>",
"        Episiotomy",
"       </td>",
"       <td>",
"        Vaginal delivery with episiotomy",
"       </td>",
"       <td>",
"        Non-healing, tenderness",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatitis (eczema)",
"       </td>",
"       <td>",
"        Itching, irritation",
"       </td>",
"       <td>",
"        Erythema, edema, fissuring",
"       </td>",
"       <td>",
"        Look for Candida",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory bowel: Crohn's",
"       </td>",
"       <td>",
"        Diarrhea, bleeding, pain",
"       </td>",
"       <td>",
"        Edema, tags, fissures, sinuses",
"       </td>",
"       <td>",
"        May precede bowel symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rectum",
"       </td>",
"       <td>",
"        Rectocele",
"       </td>",
"       <td>",
"        Sensation of vaginal obstruction",
"       </td>",
"       <td>",
"        Protrusion of stool filled rectum",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Vagina&nbsp;",
"       </td>",
"       <td>",
"        Pelvic floor hypertonus",
"       </td>",
"       <td>",
"        Aching pain, vaginismus",
"       </td>",
"       <td>",
"        Levator spasm on palpation",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital anomaly: vaginal agenesis, imperforate hymen",
"       </td>",
"       <td>",
"        Inability to be penetrated",
"       </td>",
"       <td>",
"        Absent vagina, abn hymen",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Pelvis",
"       </td>",
"       <td>",
"        Retroverted or prolapsed uterus",
"       </td>",
"       <td>",
"        Pain with thrusting",
"       </td>",
"       <td>",
"        Uterine retroversion or descent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leiomyomata",
"       </td>",
"       <td>",
"        Pain with thrusting",
"       </td>",
"       <td>",
"        Tender uterine masses",
"       </td>",
"       <td>",
"        Uncommon cause of pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endometriosis, adenomyosis",
"       </td>",
"       <td>",
"        Cramping, deep dyspareunia; history of menorrhagia, dysmenorrhea",
"       </td>",
"       <td>",
"        Tender uterus, fixed uterus, nodules cul de sac rectovaginal septum, adnexal tenderness or masses",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adnexal pathology",
"       </td>",
"       <td>",
"        Deep dyspareunia, cyclical",
"       </td>",
"       <td>",
"        Tenderness in adnexa",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pelvic inflammatory disease",
"       </td>",
"       <td>",
"        Chronic pelvic pain, deep dyspareunia",
"       </td>",
"       <td>",
"        Uterine, cervical, adnexal tenderness",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irritable bowel syndrome",
"       </td>",
"       <td>",
"        Deep dyspareunia",
"       </td>",
"       <td>",
"        None; or pelvic tenderness",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Elizabeth Gunther Stewart, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_27_37310=[""].join("\n");
var outline_f36_27_37310=null;
var title_f36_27_37311="Gomco bell applied to glans";
var content_f36_27_37311=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The Gomco bell is applied to the glans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David G Weismiller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_27_37311=[""].join("\n");
var outline_f36_27_37311=null;
